Document:

Exhibit 10.1

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 15, 2017, is by and among Icagen, Inc.,
a Delaware corporation with its executive offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC,
27703 (the “Parent”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary (as defined below)
of the Parent with offices located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“ICA-T” or
the “Company”) and GPB Debt Holdings II, LLC (the “Buyer”).

 

RECITALS

 

A.       ICA-T,
the Parent and the Buyer are each executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and/or Rule 506(b)
of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the
“SEC”) under the 1933 Act.

 

B.       Upon
the terms and subject to the conditions set forth in this Agreement, the Buyer desires to purchase and (i) ICA-T desires to issue
and sell to the Buyer, a senior secured convertible note of ICA-T, in the aggregate original principal amount of $8,000,000, substantially
in the form attached hereto as Exhibit A (the “ICA-T Note”), which ICA-T Note shall be convertible
into shares of Parent Common Stock (as defined below), (the shares of Parent Common Stock issuable pursuant to the terms of the
ICA-T Note and the Parent Note (as defined below), including without limitation, upon conversion or otherwise, collectively, the
“Parent Conversion Shares”) in accordance with ICA-T Note and the Parent Note (as the case may be), and (ii)
the Parent desires to issue and sell to the Buyer a (a) senior secured convertible note of the Parent in the aggregate principal
amount of $2,000,000, substantially in the form attached hereto as Exhibit B (the “Parent Note,”
and together with ICA-T Note, collectively the “Notes”), which Parent Note shall be convertible into Parent
Conversion Shares in accordance with the terms of the Parent Note, and (b) warrant to purchase initially up to 857,143 shares
of Parent Common Stock substantially in the form attached hereto as Exhibit C (the “Parent Warrant”)
(the shares of Parent Common Stock issuable pursuant to the terms of the Parent Warrant, including, without limitation, upon exercise
or otherwise, collectively, the “Parent Warrant Shares,” and together with the Parent Conversion Shares, collectively,
the “Parent Underlying Shares”) in accordance with the terms of the Parent Warrant.

 

C.       ICA-T
Note, the Parent Note, the Parent Conversion Shares, the Parent Warrant and the Parent Warrant Shares collectively are referred
to herein as the “Securities”.

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

D.       The
Parent Note shall rank with respect to all present and future Parent Indebtedness as provided in the Parent Note; and the ICA-T
Note shall rank with respect to all present and future Indebtedness of ICA-T as provided in the ICA-T Note, however, as provided
in the ICA-T Note, the ICA-T Note shall rank senior to all Indebtedness of ICA-T (other than Indebtedness of ICA-T owed by ICA-T
to Sanofi (as defined below) set forth in the Sanofi Documents to the extent that the Sanofi Documents expressly require such
Indebtedness of ICA-T to Sanofi to be senior in right of payment to other Indebtedness of ICA-T and the payment and/or repayment
of which is secured by a senior security interest on the assets of ICA-T expressly identified in and pursuant to the S/I Deed
of Trust (as defined below) (the “Sanofi Indebtedness”), which under the ICA-T Note shall constitute Permitted
Indebtedness (as defined in the ICA-T Note) secured by Permitted Liens (as defined in the ICA-T Note), and which (A) the ICA-T
Note will be secured by a security interest in all of the existing and future assets of the Parent, ICA-T and the other Subsidiaries
(as defined in the ICA-T Security Documents), including a pledge of all of the capital stock of each of the Subsidiaries (other
than ICA-T), as evidenced by (i) a security and pledge agreement in the form attached hereto as Exhibit D (the “ICA-T
Security Agreement”) and (ii) a guaranty executed by the Parent and each Subsidiary (other than ICA-T), in the form
attached hereto as Exhibit E (the “ICA-T Guaranty”, and together with the ICA-T Security Agreement,
the Perfection Certificate (as defined below) and the other security documents and agreements (including, but not limited to,
a Deed of Trust and Assignment of Rents between ICA-T, as trustor, the trustee named therein and the Buyer as beneficiary, securing
all of ICA-T’s obligations to the Buyer by a senior priority security interest in the Property/Facilities (as defined below),
subordinated only to the S/I Deed of Trust, the S/I Warranty and Reverter Deed the form of which is annexed hereto as Exhibit
F (the “Buyer Deed of Trust Documents,” as each may be amended or modified from time to time and together
with all schedules and exhibits to each and all other instruments, filings, documents, agreements and related items securing,
establishing, perfecting, protecting and/or maintaining a security interest in and a perfected Lien on the assets of ICA-T in
favor of the Collateral Agent and/or the Buyer, collectively, the “ICA-T Security Documents”) pursuant to which
the Parent and the Subsidiaries (other than ICA-T) shall guarantee all of the Indebtedness and other obligations of ICA-T under
the Transaction Documents (as defined below), and (B) the Parent Note will be secured by a security interest in all of the existing
and future assets of the Parent and the Subsidiaries (other than ICA-T), including a pledge of all of the capital stock of each
of the Subsidiaries (other than ICA-T), as evidenced by (i) a security and pledge agreement in the form attached hereto as Exhibit
G (the “Parent Security Agreement” and together with the ICA-T Security Agreement, collectively, the
“Security Agreements”) and (ii) a guaranty executed by each Subsidiary (other than ICA-T), in the form attached
hereto as Exhibit H (the “Parent Guaranty”, and together with the ICA-T Guaranty, collectively,
the “Guaranty Agreements” and together with the Parent Security Agreement, the Perfection Certificate and the
other Parent security documents and agreements entered into in connection with this Agreement and each of such other documents
and agreements, as each may be amended or modified from time to time, and together will all schedules and exhibits to each of
such items and together with will all schedules and exhibits to each and all other instruments, filings, documents, agreements
and related items securing, establishing, perfecting, protecting and/or maintaining a security interest in and a perfected Lien
on the assets of the Parent and the Subsidiaries in favor of the Collateral Agent and/or the Buyer, collectively, the “Parent
Security Documents” and together with the ICA-T Security Documents, collectively, the “Security Documents”)
pursuant to which the Subsidiaries (other than ICA-T) shall guarantee the Indebtedness and all obligations of the Parent under
the Transaction Documents.

 

    	 	2	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, ICA-T, the Parent and the Buyer hereby agrees as follows:

 

		1.	PURCHASE
                                         AND SALE OF NOTES AND WARRANTS.

 

(a)       Purchase
of Notes and Parent Warrants. Subject to the satisfaction (or waiver) of the conditions set forth in Section 6 and
Section 7, at the Closing (as defined below), on the Closing Date (as defined below), (i) ICA-T shall issue and sell to
the Buyer, and the Buyer agrees to purchase from ICA-T, the ICA-T Note in the original aggregate principal amount of $8,000,000,
and (ii) the Parent shall issue and sell to the Buyer, and the Buyer agrees to purchase from the Parent (A) the Parent Note in
the original aggregate principal amount of $2,000,000, and (B) the Parent Warrant to initially acquire up to 857,143 Parent Warrant
Shares. The purchase and sales set forth in this Section 1(a)(i) and (ii) shall be contingent upon and deemed to occur
simultaneously with each other.

 

(b)       Closing.
The closing (the “Closing”) of the purchase of the Notes and the Parent Warrant by the Buyer shall occur at
the offices of Gusrae Kaplan Nusbaum PLLC, 120 Wall Street, New York, NY 10005. The date and time of the Closing (the “Closing
Date”) shall be 10:00 a.m., New York time, on the first (1st) Business Day on which the conditions to the Closing set
forth in Section 6 and Section 7 below are satisfied or waived (or such other date as is mutually agreed to by the
Parent, ICA-T and the Buyer). As used herein “Business Day” means any day other than a Saturday, Sunday or
other day on which commercial banks in New York, New York are authorized or required by law to remain closed.

 

(c)       Purchase
Price. The aggregate purchase price to be paid by the Buyer for (i) the ICA-T Note shall be $7,680,000 (the “ICA-T
Purchase Price”), and (ii) the Parent Note and the Parent Warrant shall be $1,920,000 (the “Parent Purchase
Price” and together with the ICA-T Purchase Price, collectively, the “Purchase Price”). The Buyer
and the Parent agree that the Parent Note and the Parent Warrant constitute an “investment unit” for purposes of Section
1273(c)(2) of the Internal Revenue Code of 1986, as amended (the “Code”). The Buyer, the Parent and ICA-T shall
prior to Closing mutually agree in writing to the allocation of the issue price of such investment unit between the Parent Note
and the Parent Warrant in accordance with Section 1273(c)(2) of the Code and Treasury Regulation Section 1.1273-2(h) and neither
the Buyer, the Parent nor ICA-T shall take any position inconsistent with such allocation in any tax return or in any judicial
or administrative proceeding in respect of taxes. For avoidance of doubt, the Buyer shall pay approximately (i) $960.00 for each
$1,000 aggregate principal amount of ICA-T Note, and (ii) $960.00 for each $1,000 of aggregate principal amount of the Parent
and corresponding portion of the Parent Warrant.

 

    	 	3	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(d)       Form
of Payment. On the Closing Date (i) the Buyer shall pay (A) to the Parent, the Parent Purchase Price for the Parent Note and
Parent Warrant to be issued and sold to the Buyer by the Parent at Closing, and (B) to ICA-T, the ICA-T Purchase Price for ICA-T
Note to be issued and sold to the Buyer by ICA-T at the Closing (less, in both cases, all amounts withheld and paid for by and
on behalf of the Parent and/or ICA-T by the Buyer pursuant to Section 4(g)), in cash by wire transfer of immediately available
funds in accordance with the Flow of Funds Letter (as defined below), and (ii) (A) the Parent shall deliver to the Buyer, the
Parent Note in the aggregate principal amount of $2,000,000 and the Parent Warrant to initially acquire 857,143 Warrant Shares,
and (B) ICA-T shall deliver to the Buyer, the ICA-T Note in the aggregate principal amount of $8,000,000, in each case duly executed
on behalf of the Parent and ICA-T, as applicable, and registered in the name of the Buyer or its designee.

 

(e)       Residency.
The Buyer is a resident of that jurisdiction specified below its address in Section 9(f).

 

2.    BUYER’S
REPRESENTATIONS AND WARRANTIES. 

 

The
Buyer represents and warrants to ICA-T and the Parent, as of the date hereof and as of the Closing Date:

 

(a)       Organization;
Authority. Buyer is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of
its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by the Transaction
Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder.

 

(b)       No
Public Sale or Distribution. Buyer (i) is acquiring the Notes and the Parent Warrant, and (ii) upon conversion and exercise
of the Notes and the Parent Warrant, respectively, will acquire the Parent Underlying Shares, respectively, in each case for its
own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation
of applicable securities laws, except pursuant to sales registered or exempted under the 1933 Act; provided, however,
by making the representations herein, the Buyer does not agree, or make any representation or warranty, to hold any of the Securities
for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant
to a registration statement or an exemption from registration under the 1933 Act. The Buyer does not presently have any agreement
or understanding, directly or indirectly, with any Person to distribute any of the Securities in violation of applicable securities
laws. For purposes of this Agreement, “Person” means an individual, a limited liability company, a partnership,
a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental Entity or any department
or agency thereof.

 

(c)       Accredited
Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D.

 

(d)       Reliance
on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that ICA-T and the Parent are relying
in part upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility
of the Buyer to acquire the Securities. None of the managers or directors or executive officers of the Buyer is subject to any
of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act.

 

    	 	4	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(e)       Information.
The Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of
ICA-T and the Parent and materials relating to the offer and sale of the Securities that have been requested by the Buyer. The
Buyer and its advisors, if any, have been afforded the opportunity to ask questions of ICA-T and the Parent. Neither such inquiries
nor any other due diligence investigations conducted by the Buyer or its advisors, if any, or its representatives shall modify,
amend or affect the Buyer’s right to rely on ICA-T’s and the Parent’s representations and warranties contained
herein. The Buyer understands that its investment in the Securities involves a high degree of risk. The Buyer has sought such
accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition
of the Securities.

 

(f)       No
Governmental Review. The Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(g)       Transfer
or Resale. The Buyer understands that except for the registration rights provided in this Agreement (i) the Securities have
not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold,
assigned or transferred unless (A) subsequently registered thereunder, (B) the Buyer shall have delivered to the Parent (if requested
by the Parent), an opinion of counsel, in a form reasonably acceptable to the Parent, to the effect that such Securities to be
sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, (C) the Buyer
provides the Parent with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or
Rule 144A promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule 144”), or (D) the
Parent’s counsel shall have provided the opinion required pursuant to Section 4(a)(xxi) of the ICA-T Note or otherwise,
(ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further,
if Rule 144 is not applicable, any resale of the Securities under circumstances in which the Buyer (or the Person through whom
the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some
other exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder; (iii) although the Parent Common
Stock is registered under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “1934 Act”),
none of the Securities including the Parent Common Stock currently are listed for trading on any Eligible Market (as defined in
the Notes), and (iv) neither the Parent, ICA-T, nor any other Person is under any obligation to register the Securities under
the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding
the foregoing, the Securities may be pledged by the Buyer or its assignee in connection with a bona fide margin account or other
loan or financing arrangement secured by the Securities and such pledge of Securities shall not be deemed to be a transfer, sale
or assignment of the Securities hereunder, and the Buyer or such other Person shall not be required to provide the Parent with
any notice thereof or otherwise make any delivery to the Parent pursuant to this Agreement or any other Transaction Document (including,
without limitation, this Section 2(g)).

 

    	 	5	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(h)       Validity;
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Buyer and shall
constitute the legal, valid and binding obligations of the Buyer enforceable against the Buyer in accordance with their respective
terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’
rights and remedies.

 

(i)       No
Conflicts. The execution, delivery and performance by the Buyer of this Agreement and the consummation by the Buyer of the
transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Buyer,
or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
federal and state securities laws) applicable to the Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts,
defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse
effect on the ability of the Buyer to perform its obligations hereunder.

 

		3.	REPRESENTATIONS
                                         AND WARRANTIES OF ICA-T AND THE PARENT.

 

ICA-T
and the Parent each severally represent and warrant to the Buyer that, as of the date hereof and as of the Closing Date:

 

(a)       Organization
and Qualification. Each of the Parent, ICA-T and the Subsidiaries are entities duly organized and validly existing and in
good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authority to own their
properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each of the Parent,
ICA-T and the Subsidiaries are duly qualified as a foreign entity to do business and is in good standing in every jurisdiction
in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to
the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse
Effect. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business,
properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the
Parent, ICA-T and the Subsidiaries individually or taken as a whole, (ii) the transactions contemplated hereby or in any of the
other Transaction Documents or any other agreements or instruments to be entered into in connection herewith or therewith or (iii)
the authority or ability of the Parent, ICA-T and/or the Subsidiaries to perform any of their respective obligations under any
of the Transaction Documents. Other than the Persons (as defined below) set forth on Schedule 3(a), the Parent nor
ICA-T has any Subsidiaries including, but not limited to, any Foreign Subsidiaries. “Foreign Subsidiary” means
at any time of determination any Subsidiary of ICA-T or the Parent organized under the laws of a jurisdiction other than the United
States, any of the states thereof, Puerto Rico or the District of Columbia. “Subsidiaries” means at any time
of determination any Person in which ICA-T or the Parent, directly or indirectly (A) owns any of the outstanding capital stock
or holds any equity or similar interest of such Person or (B) controls or operates all or any part of the business, operations
or administration of such Person, and each of the foregoing, is individually referred to herein as a “Subsidiary.”

 

    	 	6	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(b)       Authorization;
Enforcement; Validity. The Parent, ICA-T and the Subsidiaries have the requisite power and authority to enter into and perform
its obligations under this Agreement and the other Transaction Documents and to issue their respective Securities in accordance
with the terms hereof and thereof. Each Subsidiary has the requisite power and authority to enter into and perform its obligations
under the Transaction Documents to which it is a party. The execution and delivery of this Agreement and the other Transaction
Documents by the Parent, ICA-T and the Subsidiaries, and the consummation by the Parent, ICA-T and the Subsidiaries of the transactions
contemplated hereby and thereby (including, without limitation, the issuance and sale of the Parent Note, the Parent Warrant and
the ICA-T Note the SPA Share Reservation, the reservation for issuance and the issuance of the Parent Underlying Shares upon conversion
of the ICA-T and the Parent Note and exercise of the Parent Warrant and the Security Documents) have been duly authorized by the
Parent’s and ICA-T’s board of directors and the Subsidiaries’ board of directors or other governing body, as
applicable (and to the extent necessary, the stockholders of the Parent, ICA-T and the Subsidiaries), and other than (i) the filing
with the SEC of one or more Registration Statements in accordance with the requirements set forth in this Agreement, (ii) the
filing of a Form D with the SEC, (iii) all other filing(s) required by applicable state securities agencies, (iv) the Form 8-K
filing (as defined below), and (v) the filings of such documents, instruments and/or items required to effectuate and perfect
all Liens and security interests of the Buyer under the Transaction Documents including the Security Documents (the items set
forth in (i)-(v), collectively, the “Required Filings”) no further filing, consent or authorization is required
by the Parent, ICA-T or any of their respective Subsidiaries, their respective boards of directors or their stockholders or other
governing body in connection with the execution and performance of this Agreement and the other Transaction Documents and the
performance of their respective obligations hereunder and thereunder. This Agreement and the other Transaction Documents to which
it is a party will be prior to the Closing, duly executed and delivered by the Parent, ICA-T and the Subsidiaries, and each constitutes
the legal, valid and binding obligations of ICA-T, the Parent and the Subsidiaries, enforceable against ICA-T, the Parent and
the Subsidiaries in accordance with their respective terms, except as such enforceability may be limited by general principles
of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution
may be limited by federal or state securities law. Prior to the Closing, the Transaction Documents to which each Subsidiary is
a party will be duly executed and delivered by each such Subsidiary, and shall constitute the legal, valid and binding obligations
of each such Subsidiary, enforceable against each such Subsidiary in accordance with their respective terms, except as such enforceability
may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except
as rights to indemnification and to contribution may be limited by federal or state securities law. “Transaction Documents”
means, collectively, this Agreement, the Parent Note, ICA-T Note, the Parent Warrant, the Parent Common Stock, the Parent Conversion
Shares, the Parent Warrant Shares, the Parent Underlying Shares, the Flow of Funds Letter, the Buyer Deed of Trust, the Irrevocable
Transfer Agent Instructions (as defined below), the Confession of Judgment (as defined below), the Guaranties, the IP Security
Agreement (as defined in the Security Agreements), the Security Agreements, the other Security Documents, all Closing documents
and each of the other agreements, certificates and instruments entered into or delivered by any of the parties hereto in connection
with the transactions contemplated hereby and thereby, as may be amended and/or modified from time to time and includes for each
all amendments, supplements and/or other modifications and all schedules, exhibits and/or annexes to each.

 

    	 	7	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(c)       Issuance
of Securities. The issuance of the Securities are duly authorized and upon issuance in accordance with the terms shall be
validly issued, fully paid and nonassessable, and free from all preemptive or similar rights, mortgages, defects, claims, liens,
pledges, charges, taxes, rights of first refusal, encumbrances, security interests and other encumbrances (collectively “Liens”)
with respect to the issuance thereof. As of the Closing, the Parent shall have reserved from its duly authorized capital stock
the SPA Required Reserve Amount (as defined below). Upon issuance and conversion in accordance with the Parent Note and ICA-T
Note and exercise of the Parent Warrant, respectively, the Parent Conversion Shares and Parent Warrant Shares, respectively, when
issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect
to the issue thereof, with the holder being entitled to all rights accorded to a holder of Parent Common Stock. Subject to the
accuracy of the representations and warranties of the Buyer in this Agreement, the offer, issuance and sale by the Parent and
ICA-T of their respective Securities is exempt from registration under the 1933 Act.

 

(d)       No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Parent, ICA-T and the Subsidiaries
and the consummation by the Parent, ICA-T and the Subsidiaries of the transactions contemplated hereby and thereby (including,
without limitation, the issuance of the Securities, the reservation of the SPA Required Reserve Amount, the offer, issuance and
sale of the Securities and the entering into of the Security Documents and the performance by the Parent, ICA-T and the Subsidiaries
thereof including, but not limited to, the creation of and perfection of the Lien on the Property/ Facility pursuant to the Buyer
Deed of Trust) will not (i) result in a violation of the Certificate of Incorporation (as defined below) (including, without limitation,
any certificate of designation contained therein), By-Laws (as defined below), certificate of formation, memorandum of association,
articles of association, certificate of incorporation, bylaws or other organizational documents of the Parent, ICA-T and the Subsidiaries,
or any capital stock or other securities of the Parent, ICA-T and the Subsidiaries, (ii) conflict with, or constitute a default
(or an event which with notice or lapse of time or both would become a default or an event of default) in any respect under or
pursuant to, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture
or instrument to which the Parent, ICA-T and the Subsidiaries are a party and/or any of their respective assets and/or property
are bound by including, but not limited to, any of the Sanofi Documents, or (iii) result in a violation of any law, rule, regulation,
order, judgment or decree (including, without limitation, foreign, federal and state securities laws and regulations) applicable
to the Parent, ICA-T and the Subsidiaries or by which any property or asset of the Parent, ICA-T and/o any of their respective
Subsidiaries is bound or affected. The “Sanofi Documents” mean, collectively, (A) the Asset Purchase Agreement
dated June 27, 2016 by and between Sanofi US Services, Inc. (“Sanofi”) and ICA-T (as amended, supplemented
and/or modified and together with all exhibits thereto, collectively, the “S/I APA”), (B) the Master Services
Agreement dated July 15, 2016 by and between Sanofi and ICA-T (as amended, supplemented and/or modified and together with all
exhibits thereto, collectively, the “S/I MSA”), (C) the Special Warranty Deed with Reverter dated July 13,
2016 with Sanofi as the Grantor and ICA-T as the Grantee, as filed with the Official Records of the Pima County, Arizona Recorder’s
Office on July 15, 2016 (as amended, supplemented and/or modified and together with all exhibits thereto, collectively, the “S/I
Warranty and Reverter Deed”), (D) the Deed of Trust and Assignment of Rents Agreement between ICA-T, as Trustor, Sanofi,
as Beneficiary and Patricia E. Nolan as Trustee relating to, among other items set forth herein, the real estate located at 2090
E. Innovation Park Drive, Oro Valley, Arizona 85755, Arizona and the building thereon (the “Property/ Facility”)
(as amended, supplemented and/or modified and including all exhibits thereto including, but not limited to, Exhibit A thereto,
collectively, the “S/I Deed of Trust”), (E) the Transition Services Agreement dated July 15 2016 between ICA-T,
Sanofi (as amended, supplemented and/or modified and including all exhibits thereto, collectively, the “S/I TSA”),
and (F) all other agreements, instruments, certificates, documents and related items between, among and/or involving Sanofi and/or
its affiliates and ICA-T including those set forth in Section 4.2 of the S/I APA.

 

    	 	8	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(e)       Consents.
Neither ICA-T, the Parent nor any Subsidiary is required by law, contract or otherwise to obtain any consent from, authorization
or order of, or make any filing or registration with (other than the Required Filings), any Governmental Entity (as defined below)
or any regulatory or self-regulatory agency or any other Person including, but not limited to, Sanofi and/or any of its respective
affiliates and/or related parties in order for the Parent, ICA-T and the Subsidiaries to enter into, execute and/or deliver the
Transaction Documents and/or perform all of their respective obligations under or contemplated by the Transaction Documents, in
each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which
the Parent, ICA-T and the Subsidiaries are required to obtain pursuant to the preceding sentence are set forth on Schedule
3(e) and have been or will be obtained or effected on or prior to the Closing Date, and neither the Parent, ICA-T nor the
Subsidiaries are aware of any facts or circumstances which might prevent the Parent, ICA-T and the Subsidiaries from obtaining
or effecting any of the same including any registrations, applications or filings contemplated by the Transaction Documents. “Governmental
Entity” means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature,
federal, state, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including
any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization
or body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory,
or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned
or controlled by a government or a public international organization or any of the foregoing.

 

(f)       Acknowledgment
Regarding Buyer’s Purchase of Securities. The Parent and ICA-T each acknowledges and agrees that the Buyer is acting
solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby and that the Buyer is not (i) an officer or director of the Parent, ICA-T and the Subsidiaries, (ii) an “affiliate”
(as defined in Rule 144) of the Parent, ICA-T and the Subsidiaries or (iii) a “beneficial owner” of more than 9.99%
of the shares of Parent Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Parent and ICA-T each further
acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Parent, ICA-T and the Subsidiaries (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any
advice given by the Buyer or any of its representatives or agents in connection with the Transaction Documents and the transactions
contemplated hereby and thereby is merely incidental to the Buyer’s purchase of the Securities. The Parent and ICA-T further
represents to the Buyer that ICA-T’s, the Parent’s and the Subsidiary’s decision to enter into the Transaction
Documents to which it is a party and perform all of its obligations under the Transaction Documents has been based solely on the
independent evaluation by ICA-T, the Parent and the Subsidiary and their respective representatives.

 

(g)       No
General Solicitation; Placement Agent Fees. Neither ICA-T, the Parent nor the Subsidiaries or affiliates, nor any Person acting
on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with the offer or sale of the Securities. Neither ICA-T, the Parent nor the Subsidiaries has any direct and/or
indirect obligations to pay any placement agent’s fees, financial advisory fees, brokers’ commissions and/or related
fees (whether in cash, services or other type of payment) relating to or arising out of the transactions contemplated hereby.
ICA-T, the Parent and the Subsidiaries shall jointly and severally pay, and hold the Buyer and its affiliates harmless against,
any liability, loss or expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection
with any such claim. The Parent and ICA-T acknowledge, represent, warrant and agree that neither has engaged any placement agent,
finder, other agent and/or any Person in connection with the offer or sale of the Securities.

 

(h)       No
Integrated Offering. None of ICA-T, the Parent, nor the Subsidiaries, Affiliates, nor any Person acting on any of their behalf
has, directly or indirectly, made any offers or sales of any securities (as defined in the 1933 Act) or solicited any offers to
buy any securities, under circumstances that would require registration of any of the Securities under the 1933 Act, whether through
integration with prior offerings or otherwise, or cause this offering of the Securities to require approval of stockholders of
ICA-T or the Parent for purposes of the 1933 Act or under any applicable stockholder approval provisions. None of the Parent,
ICA-T and/or any the Subsidiaries, Affiliates nor any Person acting on any of their behalf will take any action or steps that
would require registration of any of the Securities under the 1933 Act or cause the issuance and sale of any of the Securities
to be integrated with other offerings of securities of ICA-T or the Parent. Since its inception, ICA-T has not directly and/or
indirectly effectuated any issuance or sale of any of its Securities other than to the Parent. Since December 31, 2015, the only
offerings of its Securities made by the Parent is set forth on Schedule 3(h).

 

    	 	9	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(i)       Application
of Takeover Protections; Rights Agreement. Neither the Parent, ICA-T nor any of their respective board of directors have taken
any necessary action to implement a poison pill (including, without limitation, any distribution under a rights agreement), stockholder
rights plan or other similar anti-takeover provision under the Certificate of Incorporation, Bylaws or other organizational documents
or the laws of the jurisdiction of its incorporation.

 

(j)       SEC
Documents; Financial Statements. During the two (2) years prior to the date hereof, the Parent has filed all reports, schedules,
forms, proxy statements, information statements and other documents required to be filed by it with the SEC pursuant to the reporting
requirements of the 1934 Act (all of the foregoing filed prior to the date hereof including, without limitation, Current Reports
on Form 8-K by the Parent with the SEC whether required to be filed or not (but excluding Item 7.01 thereunder) and all exhibits
and appendices included therein other than Exhibits 99.1 to Form 8-K) and financial statements, notes and schedules thereto and
documents incorporated by reference therein being hereinafter referred to as the “SEC Documents”). The Parent
has delivered or has made available to the Buyer or their respective representatives true, correct and complete copies of each
of the SEC Documents not available on the EDGAR system (if any). As of their respective dates, the SEC Documents complied in all
material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable
to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial
statements (including, without limitation, any notes or any letter of the independent accountants of the Parent and ICA-T with
respect thereto) of the Parent and/or ICA-T included in the SEC Documents (the “Financial Statements”) complied
in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect
thereto as in effect as of the time of filing. Such Financial Statements have been prepared in accordance with generally accepted
accounting principles (“GAAP”), consistently applied, during the periods involved (except (i) as may be otherwise
indicated in such Financial Statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent
they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial
position of the Parent as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject,
in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in
the aggregate). The reserves, if any, established by ICA-T and the Parent or the lack of reserves, if applicable, are reasonable
based upon facts and circumstances known by ICA-T and the Parent on the date hereof and there are no loss contingencies that are
required to be accrued by the Statement of Financial Accounting Standard No. 5 of the Financial Accounting Standards Board which
are not provided for by the Parent in its Financial Statements or otherwise. No other information provided by or on behalf of
the Parent, ICA-T and the Subsidiaries to the Buyer which is not included in the SEC Documents (including, without limitation,
information referred to in Section 2(e) of this Agreement or in the disclosure schedules to this Agreement and/or any other
Transaction Document) contains any untrue statement of a material fact or omits to state any material fact necessary in order
to make the statements therein not misleading, in the light of the circumstance under which they are or were made. Neither the
Parent nor ICA-T is currently contemplating to amend or restate any of the Financial Statements nor is the Parent or ICA-T currently
aware of facts or circumstances which would require the Parent or ICA-T to amend or restate any of the Financial Statements, in
each case, in order for any of the Financials Statements to be in compliance with GAAP and the rules and regulations of the SEC.
Neither the Parent nor ICA-T has been informed by its independent accountants that they recommend that the Parent or ICA-T amend
or restate any of the Financial Statements or that there is any need for the Parent or ICA-T to amend or restate any of the Financial
Statements. The Parent Common Stock is registered as a class registered under Section 12(g) of the 1934 Act.

 

    	 	10	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(k)       Absence
of Certain Changes. Other than as set forth on Schedule 3(k), since the date of the Parent’s most recent audited
financial statements contained in a Form 10-K, there has been no material adverse change and no material adverse development in
the business, assets, liabilities, properties, operations (including results thereof), condition (financial or otherwise) or prospects
of the Parent, ICA-T and the Subsidiaries. Since the date of the Parent’s most recent audited financial statements contained
in a Form 10-K, neither the Parent, ICA-T nor the Subsidiaries has (i) declared or paid any dividends, (ii) sold any assets, individually
or in the aggregate, outside of the ordinary course of business or (iii) made any capital expenditures, individually or in the
aggregate, outside of the ordinary course of business. Neither the Parent, ICA-T nor the Subsidiaries has taken any steps to seek
protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding
up, nor does the Parent, ICA-T or their respective Subsidiaries have any knowledge or reason to believe that any of their respective
creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead
a creditor to do so. Neither the Parent, ICA-T and/or the Subsidiaries, individually and/or on a consolidated basis, are not as
of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent
(as defined below). For purposes of this Section 3(k), “Insolvent” means (i) with respect to the Parent,
ICA-T and the Subsidiaries, on a consolidated basis, (A) the present fair saleable value of the Parent’s, ICA-T’s
and the Subsidiaries’ assets is less than the amount required to pay the Parent’s, ICA-T’s and the Subsidiaries’
total Indebtedness, (B) the Parent, ICA-T and the Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent
or otherwise, as such debts and liabilities become absolute and matured or (C) the Parent, ICA-T and the Subsidiaries intend to
incur or believe that they will incur debts that would be beyond their ability to pay as such debts mature; and (ii) with respect
to the Parent, ICA-T and the following Subsidiaries individually (but with respect to the following Subsidiaries, Caldera Discover,
Inc., XrPro Sciences, Inc. and Icagen Corp, any such calculation shall exclude the obligations of each such particular Subsidiary
pursuant to the Guaranty such Subsidiary will enter into at the Closing) (A) the present fair saleable value of the Parent’s,
ICA-T’s or such Subsidiary’s (as the case may be) assets is less than the amount required to pay its respective total
Indebtedness, (B) the Parent, ICA-T or such Subsidiary (as the case may be) is unable to pay its respective debts and liabilities,
subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (C) the Parent, ICA-T or such
Subsidiary (as the case may be) intends to incur or believes that it will incur debts that would be beyond its respective ability
to pay as such debts mature. Neither the Parent, ICA-T nor the Subsidiaries has engaged in any business or in any transaction,
and is not about to engage in any business or in any transaction, for which the Parent’s, ICA-T’s or their respective
Subsidiary’s remaining assets constitute unreasonably small capital with which to conduct the business in which it is engaged
as such business is now conducted and is proposed to be conducted. ICA-T is in compliance in all material respects with the Sanofi
Documents and no event of default exists and/or will exist with the passage of time or the giving of notice, or both, under the
Sanofi Documents. ICA-T and the Parent have no reason to believe that Sanofi may seek to modify and/or terminate any of the Sanofi
Documents and/or seek to take any action under the Deed of Trust including, but not limited to, foreclosing and/or selling the
Property/Facilities and/or reduce the payments it has agreed to pay to ICA-T and/or the services it has contracted to receive
from ICA-T under the Sanofi Documents and/or an event of default may occur in the immediate future under any of the Sanofi Documents.
The Parent is in compliance in all material respects with its documents and agreements with Icagen, Inc., a subsidiary of Pfizer,
Inc. (“Pfizer”) including, but not limited to, the Asset Purchase and Collaboration Agreement dated as of June
26, 2015, as amended (the “Pfizer APA” and collectively, the “Pfizer Documents”) and no
event of default exists and/or will exist with the passage of time or the giving of notice, or both, under the Pfizer Documents.
The Parent has no reason to believe that Pfizer may seek to modify and/or terminate any of the Pfizer Documents and/or seek to
take any such action to reduce the amount of business/services it has contracted for from the Parent and/or not pay or modify
the $1,000,000 guaranteed payment owed by Pfizer to the Parent due on or about June 30, 2017. The Parent has no reason to believe
that any event has occurred that would or could result in a violation of any of the Pfizer Documents and/or could result in Pfizer
seeking to terminate and/or otherwise modify any of the Pfizer Documents and/or the scope of its business relationship with the
Parent.

 

    	 	11	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(l)       No
Undisclosed Events, Liabilities, Developments or Circumstances. Other than as set forth on Schedule 3(l) and the transactions
contemplated by this, no event, liability, development or circumstance has occurred or exists, or is reasonably expected to exist
or occur with respect to the Parent, ICA-T, any of their respective Subsidiaries or any of their respective businesses, properties,
liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required
to be disclosed by the Parent, ICA-T and the Subsidiaries under applicable securities laws on a registration statement on Form
S-1 filed with the SEC relating to an issuance and sale by the Parent of its Parent Common Stock to the public and which has not
been publicly announced, (ii) could have a material adverse effect on any Buyer’s investment hereunder or (iii) could have
a Material Adverse Effect.

 

(m)       Conduct
of Business; Regulatory Permits. Neither the Parent, ICA-T nor any of the Subsidiaries are in violation of any term of or
in default under its Certificate of Incorporation, any certificate of designation, preferences or rights of any other outstanding
series of preferred stock of the Parent, ICA-T or any of the Subsidiaries or Bylaws or their organizational charter, certificate
of formation, memorandum of association, articles of association, Certificate of Incorporation or certificate of incorporation
or bylaws, respectively. Neither the Parent, ICA-T nor the Subsidiaries are in violation of any judgment, decree or order or any
statute, ordinance, rule or regulation (each a “Legal Requirement”) applicable to the Parent, ICA-T and the
Subsidiaries, and neither the Parent, ICA-T nor the Subsidiaries will conduct its business in violation of any of the foregoing,
except in all cases for possible violations which could not, individually or in the aggregate, have a Material Adverse Effect.
The Parent, ICA-T and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory
authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations
or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither ICA-T, the Parent, nor the
Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization
or permit. There is no agreement, commitment, judgment, injunction, order or decree binding upon the Parent, ICA-T nor the Subsidiaries
or to which the Parent, ICA-T or any of their respective Subsidiaries is a party which has or would reasonably be expected to
have the effect of prohibiting or materially impairing any business practice of the Parent, ICA-T and the Subsidiaries, any acquisition
of property by the Parent, ICA-T and the Subsidiaries or the conduct of business by the Parent, ICA-T and the Subsidiaries as
currently conducted other than such effects, individually or in the aggregate, which have not had and would not reasonably be
expected to have a Material Adverse Effect on the Parent, ICA-T and the Subsidiaries. Neither the Parent Common Stock nor any
other securities of the Parent, ICA-T and the Subsidiaries are listed and/or quoted on any Eligible Market and/or any other trading
medium and the Parent has not taken any actions nor to the best of its knowledge has any Person taken any action for the purpose
of having any such securities become listed and/or eligible for quotation on any Eligible Market or other trading medium.

 

    	 	12	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(n)       Foreign
Corrupt Practices. Neither the Parent, ICA-T nor any of the Subsidiaries nor to the knowledge of the Parent and ICA-T, any
director, officer, agent, employee, affiliate or any other Person acting for or on behalf of the foregoing (individually and collectively,
an “Icagen Affiliate”) have violated the U.S. Foreign Corrupt Practices Act (the “FCPA”)
or any other applicable anti-bribery or anti-corruption laws, nor has any Icagen Affiliate offered, paid, promised to pay, or
authorized the payment of any money, or offered, given, promised to give, or authorized the giving of anything of value, to any
officer, employee or any other person acting in an official capacity for any Governmental Entity to any political party or official
thereof or to any candidate for political office (individually and collectively, a “Government Official”) or
to any person under circumstances where such Icagen Affiliate knew or was aware of a high probability that all or a portion of
such money or thing of value would be offered, given or promised, directly or indirectly, to any Government Official, for the
purpose of:

 

(i)       influencing
any act or decision of such Government Official in his/her official capacity, (B) inducing such Government Official to do or omit
to do any act in violation of his/her lawful duty, (C) securing any improper advantage, or (D) inducing such Government Official
to influence or affect any act or decision of any Governmental Entity, or

 

(ii)       assisting
the Parent, ICA-T and the Subsidiaries in obtaining or retaining business for or with, or directing business to, the Parent, ICA-T
and the Subsidiaries.

 

(o)       Sarbanes-Oxley
Act. The Parent, ICA-T and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002, as amended, and any and all applicable rules and regulations promulgated by the SEC thereunder.

 

(p)       Transactions
With Affiliates. Since December 31, 2015 and except as set forth in Schedule 3(p), no current employee, partner, director
officer or stockholder of the Parent, ICA-T or any of their respective Subsidiaries or, to the knowledge of the Parent or ICA-T,
the Parent, any affiliate of any thereof, or any relative with a relationship no more remote than first cousin of any of the foregoing,
is presently, or has been, (i) a party to any transaction with the Parent, ICA-T or any of their respective Subsidiaries (including
any contract, agreement or other arrangement providing for the furnishing of services by, or rental of real or personal property
from, or otherwise requiring payments to, any such director, officer or stockholder or such associate or affiliate or relative
Subsidiaries (other than for ordinary course services as employees, officers or directors of the Parent, ICA-T and the Subsidiaries))
or (ii) the direct or indirect owner of an interest in any corporation, firm, association or business organization which is a
competitor, supplier or customer of the Parent, ICA-T or any of their respective Subsidiaries (except for a passive investment
(direct or indirect) in less than 2% of the common stock of a company whose securities are traded on or quoted through an Eligible
Market (as defined in the Note)), nor does any such Person receive income from any source other than the Parent, ICA-T or any
of their respective Subsidiaries which relates to the business of the Parent, ICA-T or any of their respective Subsidiaries or
should properly accrue to the Parent, ICA-T or any of their respective Subsidiaries. Except as set forth in Schedule 3(p),
no employee, officer, stockholder or director of the Parent, ICA-T and the Subsidiaries or member of his or her immediate family
is indebted to the Parent, ICA-T or any of their respective Subsidiaries, as the case may be, nor is the Parent, ICA-T and the
Subsidiaries indebted (or committed to make loans or extend or guarantee credit) to any of them, other than (i) for payment of
salary for services rendered, (ii) reimbursement for reasonable expenses incurred on behalf of the Parent or ICA-T, and (iii)
for other standard employee benefits made generally available to all employees or executives (including stock option agreements
or restricted stock agreements outstanding under any stock option plan or other stock incentive plan approved by the Board of
Directors of ICA-T, the Parent and the Subsidiaries).

 

    	 	13	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(q)      Equity
Capitalization.

 

(i)       
Definitions:

 

A.       “Parent
Common Stock” or “Common Stock” means (x) the Parent’s shares of common stock, $0.001 par value
per share, and (y) any capital stock into which such common stock shall have been changed or any share capital resulting from
a reclassification of such common stock.

 

B.       
“Preferred Stock” means (x) the Parent’s blank check preferred stock, $0.001 par value per share, the
terms of which may be designated by the board of directors of the Parent in a certificate of designations and (y) any capital
stock into which such preferred stock shall have been changed or any share capital resulting from a reclassification of such preferred
stock (other than a conversion of such preferred stock into Parent Common Stock in accordance with the terms of such certificate
of designations).

 

(ii)       
Authorized and Outstanding Capital Stock. The authorized capital stock of the Parent consists of (A) 50,000,000 shares
of Parent Common Stock, of which, 6,720, 017shares are issued and 6,393,107 outstanding and 3,850,932 shares are reserved for
issuance pursuant to Options (as defined in the Note) and/or Convertible Securities (as defined in the Note) (other than the Notes
and the Parent Warrant) exercisable or exchangeable for, or convertible into, shares of Parent Common Stock and (B) 10,000,000
shares of Preferred Stock of which (1) 400,000 shares are designated Series A Cumulative Convertible Preferred Stock (the “A
Shares”), (2) 3,000,000 are designated Series B Cumulative Convertible Preferred Stock (the “B Shares”),
and (3) 6,600,000 are undesignated. No Preferred Stock including A Shares or B Shares are issued and outstanding. As of the date
hereof, the authorized capital of ICA-T consists of 100 Shares, all of which are owned by the Parent.

 

(iii)       Valid
Issuance; Available Shares; Affiliates. All of such outstanding shares are duly authorized and have been, or upon issuance
will be, validly issued and are fully paid and nonassessable. Schedule 3(q)(iii) sets forth the number of shares of Parent
Common Stock that are as of the date hereof (A) reserved for issuance pursuant to Options and/or Convertible Securities (other
than the Notes and the Parent Warrant) and (B) are owned by Persons who are “affiliates” (as defined in Rule 405 of
the 1933 Act and calculated based on the assumption that only officers, directors and holders of at least 10% of the Parent’s
issued and outstanding Parent Common Stock are “affiliates” without conceding that any such Persons are “affiliates”
for purposes of federal securities laws) of the Parent, ICA-T and the Subsidiaries. To the Parent’s and ICA-T’s knowledge,
other than as set forth on Schedule 3(q)(iii), no Person owns (beneficially or otherwise) 10% or more of the issued and
outstanding shares of Parent Common Stock (calculated based on the assumption that all Convertible Securities, whether or not
presently exercisable or convertible, have been fully exercised or converted (as the case may be) taking account of any limitations
on exercise or conversion (including “blockers”) contained therein without conceding that such identified Person is
a 10% stockholder for purposes of federal securities laws).

 

    	 	14	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iv)       
Existing Securities; Obligations; Transfer Agent. Except as disclosed on Schedule 3(q)(iv): (A) none of the Parent’s,
ICA-T’s or the Subsidiary’s capital stock including, but not limited to, the Parent Common Stock, Preferred Stock
or interests, capital stock or other securities (as defined in the 1933 Act) is subject to preemptive rights or any other similar
rights or Liens suffered or permitted by the Parent, ICA-T and the Subsidiaries; (B) there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, or exercisable or exchangeable for, any shares, interests or capital stock of the Parent, ICA-T and the Subsidiaries, or
contracts, commitments, understandings or arrangements by which the Parent, ICA-T and the Subsidiaries are or may become bound
to issue additional shares, interests or capital stock of the Parent, ICA-T and the Subsidiaries or options, warrants, scrip,
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into,
or exercisable or exchangeable for, any shares, interests or capital stock of the Parent, ICA-T and the Subsidiaries; (C) there
are no agreements or arrangements under which the Parent, ICA-T and the Subsidiaries are obligated to register the sale of any
of their securities under the 1933 Act; (D) there are no outstanding securities, agreements, arrangements or instruments of the
Parent, ICA-T and the Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Parent, ICA-T and the Subsidiaries are or may become bound to redeem a security of
the Parent, ICA-T and the Subsidiaries; (E) there are no securities or instruments containing anti-dilution or similar provisions
that will be triggered by the issuance of the Securities; (F) there are no outstanding securities, arrangements, agreements and/or
instruments providing any Person with any pre-emptive rights, rights of first refusal and/or similar rights relating to any securities
of the Parent, ICA-T and the Subsidiaries including any that would be triggered by the transactions contemplated herein, and (G)
neither the Parent, ICA-T nor the Subsidiaries has any stock appreciation rights or “phantom stock” plans or agreements
or any similar plan or agreement. All prior issuances and/or any sale of securities by the Parent, ICA-T and the Subsidiaries
complied in all respects with all state “blue sky” laws and no Person has any rescission rights (whether mature or
unmatured, contingent and/or matured) with respect to any securities purchased from the Parent, ICA-T and the Subsidiaries.

 

(v)       Organizational
Documents. Attached hereto as Exhibit I are true, correct and complete copies of (I) (x) each of (A) ICA-T’s
and (B) the Parent’s Certificate of Incorporation (or similar document), as amended and as in effect on the date hereof
and on the Closing Date (the “Certificate of Incorporation”), and (II) (x) each of (A) ICA-T’s
and (B) the Parent’s bylaws, as amended and as in effect on the date hereof and on the Closing Date (the “Bylaws”),
and the terms of all Convertible Securities and the material rights of the holders thereof in respect thereto.

 

(vi)       Transfer
Agent. American Stock Transfer and Trust Company (the “Transfer Agent”) is the Parent’s stock transfer
company and the Transfer Agent participates in the DTC Fast Automated Securities Transfer Program.

 

(r)       Indebtedness
and Other Contracts. Except as disclosed on Schedule 3(r) hereto, neither the Parent, ICA-T nor the Subsidiaries, (i)
has any outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments
evidencing Indebtedness of the Parent, ICA-T and the Subsidiaries or by which the Parent, ICA-T and the Subsidiaries and/or any
of their respective properties is and/or may become bound, (ii) is a party to any contract, agreement or instrument, the violation
of which, or default under which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected
to result in a Material Adverse Effect, (iii) has any financing statements and/or other filings or recordings or its and/or any
of their real property and/or other assets are subject to securing obligations in any amounts filed and/or recorded in connection
with the Parent, ICA-T and the Subsidiaries; (iv) is in violation of any representation, warranty, covenant, agreement, provision
and/or term of, or in default under, any contract, agreement or instrument relating to any Indebtedness including, but not limited
to, any Indebtedness and/or other obligations owed to Sanofi and/or any of its affiliates and/or related pursuant to the Sanofi
Documents or otherwise, or (v) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance
of which, in the judgment of the Parent and/or ICA-T, has or is expected to have a Material Adverse Effect. Neither the Parent,
ICA-T nor the Subsidiaries have any liabilities, obligations and/or Indebtedness required to be disclosed in the Financial Statements
which are not so disclosed. For purposes of this Agreement: (x) “Indebtedness” of any Person means, without
duplication, (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase
price of property or services (including, without limitation, “capital leases” in accordance with GAAP) (other than
trade payables entered into in the ordinary course of business consistent with past practice), (C) all reimbursement or payment
obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes,
bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property,
assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or
incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even
though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession
or sale of such property), (F) all monetary obligations under any leasing or similar arrangement which, in connection with GAAP,
consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses
(A) through (F) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise,
to be secured by) any Lien upon or in any property or assets (including accounts and contract rights) owned by any Person, even
though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and
(H) all Contingent Obligations (as defined below) in respect of indebtedness or obligations of others of the kinds referred to
in clauses (A) through (G) above; and (y) “Contingent Obligation” means, as to any Person, any direct or indirect
liability, contingent or otherwise, of that Person with respect to any Indebtedness, lease, dividend or other obligation of another
Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance
to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will
be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto.

 

    	 	15	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(s)       Litigation.
Except as set forth in Schedule 3(s), there is no material action, suit, arbitration, proceeding, inquiry or investigation
before or by any court, public board, other Governmental Entity, self-regulatory organization or body pending or, to the knowledge
of the Parent or ICA-T, threatened against or affecting the Parent, ICA-T and the Subsidiaries, the Parent Common Stock or any
of the Parent’s, ICA-T’s or the Subsidiaries’ officers or directors , whether of a civil or criminal nature
or otherwise, in their capacities as such. No director, officer or employee of the Parent, ICA-T or any of their respective Subsidiaries
has willfully violated 18 U.S.C. §1519 or engaged in spoliation in reasonable anticipation of litigation. Without limitation
of the foregoing, there has not been, and to the knowledge of the Parent or ICA-T, there is not pending or contemplated, any investigation
by the SEC involving the Parent or ICA-T, any of their respective Subsidiaries or any current or former director or officer of
the Parent, ICA-T or each of their respective Subsidiaries. The SEC has not issued any stop order or other order suspending the
effectiveness of any registration statement filed by the Parent or ICA-T under the 1933 Act or the 1934 Act with respect to Registrable
Securities. After reasonable inquiry of its employees, neither the Parent nor ICA-T is aware of any fact which might result in
or form the basis for any such action, suit, arbitration, investigation, inquiry or other proceeding. Neither the Parent, ICA-T
nor the Subsidiaries are subject to any order, writ, judgment, injunction, decree, determination or award of any Governmental
Entity. The Parent, ICA-T and each Subsidiary is current in all payment obligations with respect to all settlement and/or similar
agreements including, but not limited to, with Dentons US LLP (“Dentons”) and American Millings, LP.

 

(t)       Insurance.
The Parent, ICA-T and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Parent, ICA-T and the Subsidiaries believes to be prudent and customary in the
businesses in which the Parent, ICA-T and the Subsidiaries are engaged (and/or as required by an agreement, documents and/or instrument)
including, but not limited to, all insurance required to be obtained, maintained and in the amounts as provided and/or pursuant
to the Sanofi Documents including, but not limited to, the S/I APA, the S/I MSA and the S/I Deed of Trust including, but not limited
to, a $5,000,000, 10-year pollution legal liability insurance policy pursuant to the S/I APA in the name of ICA-T with Sanofi
being named an additional insured party under such policy (the “$5,000,000 Pollution Policy”). The Parent,
ICA-T and the Subsidiaries have timely paid and are current with respect to all premiums and other payment amounts due under such
all insurance policies including the $5,000,000 Pollution Policy. All insurance and related policies of the Parent, ICA-T and
the Subsidiaries including, but not limited to, the $5,000,000 Pollution Policy are set forth on Schedule 3(t). Neither
the Parent, ICA-T nor the Subsidiaries has been refused any insurance coverage sought or applied for, and neither the Parent,
ICA-T nor the Subsidiaries has any reason to believe that it will be unable to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost
that would not have a Material Adverse Effect.

 

(u)       Employee
Matters; Benefit Plans.

 

(i)       Except
as set forth on Schedule 3(u)(i), the employment of each officer and employee of the Parent, ICA-T and the Subsidiaries
are terminable at the will of the Parent, ICA-T and the Subsidiaries, respectively. The Parent, ICA-T and the Subsidiaries have
complied in all material respects with all applicable laws relating to wages, hours, equal opportunity, collective bargaining,
workers’ compensation insurance and the payment of social security and other taxes. Neither the Parent, ICA-T nor each of
their respective Subsidiaries is aware that any officer, key employee or group of employees intends to terminate his, her or their
employment with the Parent, ICA-T or any of their respective Subsidiaries, as the case may be, nor does the Parent, ICA-T or each
of their respective Subsidiaries have a present intention, or know of a present intention, to terminate the employment of any
officer, key employee or group of employees of either the Parent, ICA-T or any of their respective Subsidiaries. There are no
pending or, to the knowledge of the Parent, ICA-T and the Subsidiaries, threatened employment discrimination charges or complaints
against or involving the Parent, ICA-T or any of their respective Subsidiaries before any federal, state, or local board, department,
commission or agency, or unfair labor practice charges or complaints, disputes or grievances affecting the Parent, ICA-T or any
of their respective Subsidiaries.

 

    	 	16	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(ii)       Since
the Parent’s, ICA-T’s and the Subsidiaries’ inception, neither the Parent, ICA-T nor the Subsidiaries has experienced
any labor disputes, union organization attempts or work stoppage due to labor disagreements. There are no unfair labor practice
charges or complaints against the Parent, ICA-T or any of their respective Subsidiaries pending, or to the knowledge of the Parent,
ICA-T or any of their respective Subsidiaries, threatened before the National Labor Relations Board or any comparable state agency
or authority. There are no written or oral contracts, commitments, agreements, understandings or other arrangements with any labor
organization, nor work rules or practices agreed to with any labor organization or employee association, applicable to employees
of the Parent, ICA-T and the Subsidiaries, nor is the Parent, ICA-T or any of their respective Subsidiaries a party to, or bound
by, any collective bargaining or similar agreement; there is not, and since the Parent’s, ICA-T’s and the Subsidiaries’
inception there has not been, any representation of the employees of the Parent, ICA-T or any of their respective Subsidiaries
by any labor organization and, to the knowledge of the Parent, ICA-T and the Subsidiaries, there are no union organizing activities
among the employees of the Parent, ICA-T or any of their respective Subsidiaries, and to the knowledge of the Parent, ICA-T and
the Subsidiaries, no question concerning representation has been raised or is threatened respecting the employees of the Parent,
ICA-T or any of their respective Subsidiaries.

 

(iii)       Schedule
3(u)(iii) contains a true, correct and complete list of each pension, retirement, savings, deferred compensation and profit-sharing
plan and each stock option, stock appreciation, stock purchase, performance share, bonus or other incentive plan, severance plan,
health, group insurance or other welfare plan, or other similar plan (whether written or otherwise) and any “employee benefit
plan” within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
under which the Parent and ICA-T has any current or future obligation or liability (including any potential, contingent or secondary
liability under Title IV of ERISA) or under which any employee or former employee (or beneficiary of any employee or former employee)
of the Parent and ICA-T has or may have any current or future right to benefits (the term “plan” shall include any
contract, agreement (including an employment or independent contractor agreement), policy or understanding, each such plan being
hereinafter referred to in this Agreement individually as a “Benefit Plan”). The Parent and ICA-T have delivered
to the Buyer true, correct and complete copies of (i) each material Benefit Plan, including any amendments thereto, (ii) the summary
plan description, if any, for each Benefit Plan, including any summaries of material modifications made since the most recent
summary plan description, (iii) the latest annual report which has been filed with the Internal Revenue Service (the “IRS”)
for each Benefit Plan required to file an annual report, and (iv) the most recent IRS determination letter for each Benefit Plan
that is a pension plan (as defined in ERISA) intended to be qualified under Section 401(a) of the Code. Each Benefit Plan intended
to be tax qualified under Sections 401(a) and 501(a) of the Code is and has been determined by the IRS to be tax qualified under
Sections 401(a) and 501(a) of the Code and, since such determination, no amendment to or failure to amend any such Benefit Plan
and no other event or circumstance has occurred that could reasonably be expected to adversely affect its tax qualified status.

 

    	 	17	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iv)       There
are no actions, claims, audits, lawsuits or arbitrations pending, or, to the knowledge of the Parent, ICA-T and the Subsidiaries,
threatened, with respect to any Benefit Plan or the assets of any Benefit Plan. Except as set forth in Schedule 3(u)(iv),
each Benefit Plan has been administered in all material respects in accordance with its terms and with all applicable Legal Requirements
(including, without limitation, the Code and ERISA).

 

(v)       The
consummation of the transactions contemplated by this Agreement will not (1) entitle any employee or independent contractor of
the Parent, ICA-T or any of their respective Subsidiaries to severance pay or termination benefits, (2) accelerate the time of
payment or vesting, or increase the amount of compensation due to any current or former employee or independent contractor of
the Parent, ICA-T or any of their respective Subsidiaries, (3) obligate Parent, ICA-T or any of their respective Subsidiaries,
or any of their respective affiliates to pay or otherwise be liable for any compensation, vacation days, pension contribution
or other benefits to any current or former employee, consultant, agent or independent contractor of the Parent, ICA-T or any of
their respective Subsidiaries for periods before the applicable Closing Date, (4) require assets to be set aside or other forms
of security to be provided with respect to any liability under a Benefit Plan, or (5) result in any “parachute payment”
(within the meaning of Section 280G of the Code) under any Benefit Plan.

 

(vi)       No
Benefit Plan is subject to the provisions of Section 412 of the Code or Part 3 of Subtitle B of Title I of ERISA. No Benefit Plan
is subject to Title IV of ERISA and no Benefit Plan is a “multiemployer plan” (within the meaning of Section 3(37)
of ERISA). Since inception, neither the Parent, ICA-T, their respective Subsidiaries, nor any business or entity treated as a
single employer with the Parent, ICA-T or any of their respective Subsidiaries for purposes of Title IV of ERISA contributed to
or was obliged to contribute to a pension plan that was at any time subject to Title IV of ERISA.

 

(vii)       No
Benefit Plan has provided, been required to provide, provides or is required to provide, at any time in the past, present, or
future, health, medical, dental, accident, disability, death or survivor benefits to or in respect of any Person beyond one year
following termination of employment, except to the extent required under any state insurance law or under Part 6 of Subtitle B
of Title I of ERISA and under Section 4980B of the Code. No Benefit Plan covers any individual that is not an employee or advisor
of the Parent, ICA-T or any of their respective Subsidiaries, other than spouses and dependents of employees under health and
child care policies listed in Schedule 3(u)(vii), true and complete copies of which have been made available to the Buyer.
Except as set forth on Schedule 3(u)(vii) or except as otherwise permitted pursuant to employment agreements with the Parent
or ICA-T disclosed to the Buyer, each officer of the Parent and ICA-T is currently devoting all of such officer’s business
time to the conduct of the business of the Parent or ICA-T. Except as otherwise permitted pursuant to employment agreements with
the Parent or ICA-T disclosed to the Buyer, the Parent and ICA-T are not aware of any officer or key employee of the Parent, ICA-T
and the Subsidiaries planning to work less than full time at the Parent, ICA-T or any of their respective Subsidiaries in the
future.

 

    	 	18	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(viii)      
The Parent and ICA-T are in compliance with all federal, state, local and foreign laws and regulations respecting labor, employment
and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance
would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

		(v)	Title.

 

(i)       Real
Property. Each of the Parent, ICA-T and the Subsidiaries holds good title to all real property, leases in real property, facilities
or other interests in real property owned or held by the Parent, ICA-T and the Subsidiaries, all of which are set forth on Schedule
3(v)(i) (collectively, the “Real Property”). Schedule 3(v)(i) sets forth all Real Property of the
Parent, ICA-T and the Subsidiaries and other than as set forth on Schedule 3(v)(i), the Real Property is free and clear
of all Liens and is not subject to any rights of way, building use restrictions, exceptions, variances, reservations, or limitations
of any nature. Any Real Property held under lease by the Parent, ICA-T and the Subsidiaries are held by them under valid, subsisting
and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made
of such property and buildings by the Parent, ICA-T and the Subsidiaries.

 

(ii)       Fixtures
and Equipment. Except as set forth on Schedule 3(v)(ii), each of the Parent, ICA-T and the Subsidiaries (as applicable) has
good title to, or a valid leasehold interest in, the tangible personal property, equipment, improvements, fixtures, and other
personal property and appurtenances that are used by the Parent, ICA-T and the Subsidiaries in connection with the conduct of
its business (the “Fixtures and Equipment”). The Fixtures and Equipment are structurally sound, are in good
operating condition and repair, are adequate for the uses to which they are being put, are not in need of maintenance or repairs
except for ordinary, routine maintenance and repairs and are sufficient for the conduct of the Parent’s, ICA-T’s and
the Subsidiaries’ businesses (as applicable) in the manner as conducted prior to the Closing. Except as set forth on Schedule
3(v)(ii), each of the Parent, ICA-T and the Subsidiaries own all of their respective Fixtures and Equipment free and clear
of all Liens.

 

    	 	19	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		(w)	Intellectual
                                         Property.

 

(i)       Except
as set forth on Schedule 3(w)(i), the Parent, ICA-T and the Subsidiaries own all right, title and interest in and to, or
have a valid and enforceable license to use all the Intellectual Property used by them in connection with the their respective
businesses. Except as set forth on Schedule 3(w)(i), none of the Parent’s, ICA-T’s and the Subsidiaries’
Intellectual Property have expired or terminated or have been abandoned or expected to expire or terminate or are expected to
be abandoned within five (5) years from this Agreement. The Parent, ICA-T and the Subsidiaries are in compliance with all contractual
obligations relating to the protection of such of the Intellectual Property as they use pursuant to licenses or other agreements.
The conduct of the business of the Parent, ICA-T and the Subsidiaries, to the knowledge of the Parent, ICA-T and the Subsidiaries,
as currently conducted, or as reasonably be expected to be conducted, does not, and is not reasonably expected to, knowingly,
conflict with or infringe any proprietary right or Intellectual Property of any third party, including, without limitation, the
transmission, reproduction, use, display or modification of any content or material (including framing, and linking web site content)
on a web site, bulletin board or other like medium hosted by or on behalf of the Parent, ICA-T and the Subsidiaries, except for
such infringements and conflicts which would not reasonably be expected to have a Material Adverse Effect. Neither the Parent,
ICA-T not their respective Subsidiaries has any knowledge of any infringement by the Parent, ICA-T or any of their respective
Subsidiaries of Intellectual Property of others. There is no claim action or proceeding being made or brought, or to the knowledge
of the Parent, ICA-T and the Subsidiaries, being threatened, against the Parent, ICA-T and the Subsidiaries regarding its Intellectual
Property. Neither the Parent, ICA-T nor the Subsidiaries are aware of any facts or circumstances that could reasonably be expected
to give rise to any of the foregoing infringements or claims, actions or proceedings. The Parent, ICA-T and the Subsidiaries have
taken reasonable security measures to protect the secrecy, confidentiality and value of their Intellectual Property.

 

(ii)       Schedule
3(w)(ii) sets forth a complete and current list of registered trademarks or copyrights, issued patents, applications therefor,
or other forms of Intellectual Property registration anywhere in the world that is owned by the Parent, ICA-T or their respective
Subsidiaries (“Listed Intellectual Property”) and the owner of record, date of application or issuance and
relevant jurisdiction as to each. Except as set forth on Schedule 3(w)(ii), all Listed Intellectual Property is owned by
the Parent, ICA-T or their respective Subsidiaries, free and clear of security interests, liens, encumbrances or claims of any
nature. All Listed Intellectual Property is subsisting, unexpired, in proper form and all renewal fees and other maintenance fees
that have fallen due on or prior to the effective date of this Agreement have been paid. No Listed Intellectual Property is the
subject of any proceeding before any governmental, registration or other authority in any jurisdiction, except as set forth on
Schedule 3(v)(ii). The consummation of the transactions contemplated hereby will not alter or impair any Intellectual Property
that is owned or licensed by the Parent, ICA-T or their respective Subsidiaries.

 

(iii)       Schedule
3(w)(iii) sets forth a complete list of all agreements relating to Intellectual Property to which the Parent, ICA-T or their
respective Subsidiaries is a party, subject or bound (the “Intellectual Property Contracts”) (other than agreements
involving (A) the license of the Parent, ICA-T or their respective Subsidiaries of standard, generally commercially available
“off-the-shelf” third party products that are not and will not to any extent be part of any product, service or intellectual
property offering of the Parent, ICA-T or their respective Subsidiaries or (B) non-disclosure or non-use of information). Each
Intellectual Property Contract: (i) is valid and binding on the Parent, ICA-T or their respective Subsidiaries, as the case may
be, and, the counterparties thereto, and is in full force and effect and (ii) upon consummation of the transactions contemplated
hereby shall continue in full force and effect without penalty or other adverse consequence.

 

    	 	20	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iv)       Except
as set forth on Schedule 3(w)(iv), the Parent, ICA-T and the Subsidiaries are not under any obligation to pay royalties
or other payments in connection with any agreement, nor restricted from assigning their rights respecting Intellectual Property
nor will the Parent, ICA-T or their respective Subsidiaries otherwise be, as a result of the execution and delivery of this Agreement
or the performance of the Parent’s or ICA-T’s obligations under this Agreement, in breach of any agreement relating
to the Intellectual Property.

  

(v)       Except
as set forth on Schedule 3(w)(v), no present or former employee, officer or director of the Parent, ICA-T or their respective
Subsidiaries, or agent or outside contractor of the Parent, ICA-T or any of their respective Subsidiaries, holds any right, title
or interest, directly or indirectly, in whole or in part, in or to any Intellectual Property that is owned or licensed by the
Parent, ICA-T or their respective Subsidiaries.

 

(vi)       To
the Parent’s and ICA-T’s knowledge: (i) none of the Listed Intellectual Property has been used, disclosed or appropriated
to the detriment of the Parent, ICA-T or their respective Subsidiaries for the benefit of any Person other than the Parent, ICA-T
or their respective Subsidiaries; and (ii) no employee, independent contractor or agent of the Parent, ICA-T or their respective
Subsidiaries has misappropriated any trade secrets or other confidential information of any other Person in the course of the
performance of his or her duties as an employee, independent contractor or agent of the Parent, ICA-T or their respective Subsidiaries.

 

(vii)       Except
as set forth on Schedule 3(w)(vii), any programs, modifications, enhancements or other inventions, improvements, discoveries,
methods or works of authorship (“Works”) that were created by employees of the Parent, ICA-T or their respective
Subsidiaries were made in the regular course of such employees’ employment or service relationships with the Parent, ICA-T
or their respective Subsidiaries using the Parent’s, ICA-T’s or their respective Subsidiaries’ facilities and
resources and, as such, constitute either works made for hire or all rights and title to and in such Works have been fully assigned
to the Parent, ICA-T or their respective Subsidiaries. Each such employee who has created Works or any employee who in the regular
course of his employment may create Works and all consultants have signed an assignment or similar agreement with the Parent,
ICA-T or their respective Subsidiaries confirming the Parent’s, ICA-T’s or their respective Subsidiaries’ ownership
or, in the alternate, transferring and assigning to the Parent, ICA-T or their respective Subsidiaries all right, title and interest
in and to such programs, modifications, enhancements or other inventions including copyright and other intellectual property rights
therein.

 

    	 	21	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(viii)       For
the purpose of this Agreement, “Intellectual Property” shall mean all of the following: (A) trademarks, service
marks, service mark registrations, service names, trade dress, product configurations, trade names and other indications of origin,
applications or registrations in any jurisdiction pertaining to the foregoing and all goodwill associated therewith; (B) inventions,
discoveries, improvements, ideas, know-how, formula methodology, processes, technology, software (including password unprotected
interpretive code or source code, object code, development documentation, programming tools, drawings, specifications and data)
and applications and patents in any jurisdiction pertaining to the foregoing, including re-issues, continuations, divisions, continuations-in-part,
renewals or extensions; (C) trade secrets, including confidential information and the right in any jurisdiction to limit the use
or disclosure thereof; (D) copyrights in writings, designs software, mask works or other works, applications or registrations
in any jurisdiction for the foregoing and all moral rights related thereto; (E) database rights; (F) Internet Web sites, domain
names and applications and registrations pertaining thereto and all intellectual property used in connection with or contained
in all versions of the Parent’s, ICA-T’s or their respective Subsidiaries’ Web sites; (G) rights under all agreements
(including a license agreement) relating to the foregoing; (H) books and records pertaining to the foregoing; (I) governmental
authorizations, and (J) claims or causes of action arising out of or related to past, present or future infringement or misappropriation
of the foregoing.

 

(x)       Environmental
Laws.

 

(i)       The
Parent, ICA-T and the Subsidiaries (A) are in compliance with any and all Environmental Laws (as defined below), (B) have received
all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses
and (C) are in compliance with all terms and conditions of any such permit, license or approval where, in each of the foregoing
clauses (A), (B) and (C), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material
Adverse Effect. The term “Environmental Laws” means all federal, state, local or foreign laws relating to pollution
or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land
surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases
of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

    	 	22	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

 

		(ii)	No
                                         Hazardous Materials:

 

		a.	have
                                         been disposed of or otherwise released from any Interest of the Parent, ICA-T and the
                                         Subsidiaries in violation of any Environmental Laws; or

 

		b.	are
                                         present on, over, beneath, in or upon an Interest or any portion thereof in quantities
                                         that would constitute a violation of any Environmental Laws. No prior use by the Parent,
                                         ICA-T and the Subsidiaries of any Interest has occurred that violates any Environmental
                                         Laws, which violation would have a material adverse effect on the business of the Parent,
                                         ICA-T and the Subsidiaries.

 

(iii)       
Neither the Parent, ICA-T nor the Subsidiaries knows of any other person who or entity which has stored, treated, recycled, disposed
of or otherwise located on any Interest any Hazardous Materials, including, without limitation, such substances as asbestos and
polychlorinated biphenyls.

 

(iv)       None
of the Real Property is on any federal or state “Superfund” list or Liability Information System (“CERCLIS”)
list or any state environmental agency list of sites under consideration for CERCLIS, nor subject to any environmental related
Liens.

 

(y)       Subsidiary
Rights. Except with respect to ICA-T but if and only to the extent ICA-T is so restricted at a time in question pursuant to
the S/I MSA, the Parent has the unrestricted right to vote in all respects, and (subject to limitations imposed by applicable
law) to receive dividends and distributions on, all capital securities of ICA-T and each of the Subsidiaries. Except with respect
to the stock of ICA-T, all outstanding securities of each Subsidiary of the Parent and ICA-T is owned free and clear of all Liens
by the Parent.

 

(z)       Tax
Status.

 

(i)       Each
of the Parent, ICA-T and the Subsidiaries has filed or caused to be filed in a timely manner (within any applicable extension
periods) and in the appropriate jurisdictions all material returns, reports, information statements and other documentation (including
any additional or supporting materials) filed or maintained, or required to be filed or maintained, in connection with the calculation,
determination, assessment or collection of any and all federal, state, local, foreign and other taxes, levies, fees, imposts,
duties, governmental fees and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection
therewith or with respect thereto), including, without limitation, taxes imposed on, or measured by, income, franchise, profits,
gross income or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital
stock, stock transfer, license, payroll, withholding, employment, social security, workers’ compensation, unemployment compensation,
utility, severance, production, excise, stamp, occupation, premium, windfall profits, environmental, transfer and gains taxes
and customs duties (each a “Tax”) and shall include amended returns required as a result of examination adjustments
made by the IRS or other Governmental Entity responsible for the imposition of any Tax (collectively, the “Returns”)
and such Returns are true, correct and complete in all material respects.

 

    	 	23	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(ii)       Each
of the Parent, ICA-T and the Subsidiaries has paid all material Taxes and other assessments due from and payable by the Parent,
ICA-T and the Subsidiaries on or prior to the date hereof on a timely basis except as to those set forth in Schedule 3(z)(ii).
The charges, accruals, and reserves for Taxes with respect to the Parent, ICA-T and the Subsidiaries are adequate to cover Tax
liabilities of the Parent, ICA-T and the Subsidiaries accruing throughout the date thereof. Except as set forth in Schedule
3(z)(ii), each of the Parent, ICA-T and the Subsidiaries has complied in all material respects with all applicable Legal Requirements
relating to the payment and withholding of Taxes (including withholding and reporting requirements under Sections 1441 through
1464, 3401 through 3406, and 6041 and 6049 of the Code and similar provisions under any other applicable Legal Requirements) and,
within the time and in the manner prescribed by law, has withheld from wages, fees and other payments and paid over to the proper
governmental or regulatory authorities all amounts required. Except as set forth in Schedule 3(z)(ii), neither the Parent,
ICA-T nor the Subsidiaries has received notice of assessment or proposed assessment of any Taxes claimed to be owed by it or any
other Person on its behalf. Except as set forth in Schedule 3(z)(ii), no Returns filed by or on behalf of the Parent, ICA-T
and the Subsidiaries with respect to Taxes are currently being audited or examined. Except as set forth in Schedule 3(z)(ii),
neither the Parent, ICA-T nor the Subsidiaries has received notice of any such audit or examination. Except as set forth in Schedule
3(z)(ii), no issue has been raised by any taxing authority with respect to the Parent, ICA-T and the Subsidiaries in any audit
or examination which, by application of similar principles, could reasonably be expected to result in a proposed material adjustment
to the liability for Taxes for any period not so examined.

 

(iii)       Except
as set forth in Schedule 3(z)(iii), no known Liens have been filed and no claims are being asserted by or against the Parent,
ICA-T and the Subsidiaries with respect to any Taxes (other than Liens for Taxes not yet due and payable). Neither the Parent,
ICA-T nor the Subsidiaries has currently elected pursuant to the Code to be treated as an S corporation or any comparable provision
of local, state or foreign law, or has made any other elections pursuant to the Code (other than elections that relate solely
to entity classification, methods of accounting, depreciation, or amortization) that would have a material effect on the business,
properties, prospects, or financial condition of the Parent, ICA-T and the Subsidiaries, individually or in the aggregate.

 

    	 	24	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iv)       No
claim has ever been made, or, to the knowledge of the Parent or ICA-T, is threatened or pending, by any authority in a jurisdiction
where the Parent, ICA-T and the Subsidiaries, respectively, does not file Returns that the Parent, ICA-T and the Subsidiaries
are or may be subject to taxation by that jurisdiction, and neither the Parent, ICA-T nor the Subsidiaries has received any notice
or request for information from any such authority. Neither the Parent, ICA-T nor the Subsidiaries has been a member of an affiliated
group (as defined in Section 1504(a) of the Code) or filed or been included in a combined, consolidated or unitary income tax
return other than the affiliated group of which ICA-T is currently the common parent. Neither the Parent, ICA-T nor the Subsidiaries
are required to include in income any adjustment pursuant to Section 481(a) of the Code by reason of a voluntary change in accounting
methods initiated by the Parent, ICA-T and the Subsidiaries, and no Governmental Entity has proposed an adjustment or change in
accounting method. All transactions or methods of accounting that could give rise to a substantial understatement of federal income
tax as described in Section 6662(d)(2)(B)(i) of the Code have been adequately disclosed on the Parent’s, ICA-T’s and
the Subsidiaries’ federal income tax returns in accordance with Section 6662(d)(2)(B) of the Code. Neither the Parent, ICA-T
nor the Subsidiaries are a party to any Tax sharing or Tax indemnity agreement or any other agreement of a similar nature that
remains in effect. Neither the Parent, ICA-T nor the Subsidiaries has consented to any waiver of the statute of limitations for
the assessment of any Taxes or has requested any extension of time for the payment of any Taxes. Neither the Parent, ICA-T nor
the Subsidiaries has ever held a material beneficial interest in any other Person, other than those listed in Schedule 3(z)(iv).
Neither the Parent, ICA-T nor the Subsidiaries are obligated to make, nor as a result of any event connected with the transactions
contemplated by this Agreement will become obligated to make, any payment that would not be deductible under Section 280G of the
Code. Neither the Parent, ICA-T nor the Subsidiaries are a “passive foreign investment company” within the meaning
of Section 1296 of the Code (a “PFIC”), and neither the Parent nor ICA-T anticipates that the Parent or ICA-T
or any additional foreign Subsidiaries will become a PFIC in the foreseeable future.

  

(v)       The
net operating loss carryforwards (“NOLs”) for United States federal income tax purposes of the consolidated
group of which the Parent or ICA-T is the common parent, if any, shall not be adversely effected by the transactions contemplated
hereby. The transactions contemplated hereby do not constitute an “ownership change” within the meaning of Section
382 of the Code, thereby preserving the Parent’s or ICA-T’s ability to utilize such NOLs.

 

(aa)     Internal
Accounting and Disclosure Controls. Except as disclosed in Schedule 3(aa), the Parent, ICA-T and the Subsidiaries maintains
internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the 1934 Act) that is effective to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles, including that (i) transactions are executed in
accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP and to maintain asset and liability accountability, (iii) access to assets or
incurrence of liabilities is permitted only in accordance with management’s general or specific authorization and (iv) the
recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals
and appropriate action is taken with respect to any difference. Except as disclosed in Schedule 3(aa), the Parent maintains
disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the 1934 Act) that are effective in ensuring
that information required to be disclosed by the Parent in the reports that it files or submits under the 1934 Act is recorded,
processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, including, without limitation,
controls and procedures designed to ensure that information required to be disclosed by the Parent in the reports that it files
or submits under the 1934 Act is accumulated and communicated to the Parent’s management, including its principal executive
officer or officers and its principal financial officer or officers, as appropriate, to allow timely decisions regarding required
disclosure. Neither the Parent, ICA-T nor the Subsidiaries has received any notice or correspondence from any accountant, Governmental
Entity or other Person relating to any potential material weakness or significant deficiency in any part of the internal controls
over financial reporting of the Parent, ICA-T and the Subsidiaries.

 

    	 	25	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(bb)    Off
Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Parent, ICA-T and the
Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Parent in its 1934
Act filings and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

(cc)     Investment
Company Status. Neither the Parent, ICA-T nor the Subsidiaries are and upon consummation of the sale of the Securities will
not be, an “investment company,” an affiliate of an “investment company,” a company controlled by an “investment
company” or an “affiliated person” of, or “promoter” or “principal underwriter” for,
an “investment company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

(dd)    U.S.
Real Property Holding Corporation. Neither the Parent, ICA-T nor the Subsidiaries are, or has ever been, and so long as any
of the Securities are held by the Buyer, shall become a U.S. real property holding corporation within the meaning of Section 897
of the Code, and the Parent, ICA-T and each Subsidiary shall so certify upon the Buyer’s request.

 

(ee)    Transfer
Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be
paid in connection with the issuance, sale and transfer of the Securities to be sold to the Buyer hereunder will be, or will have
been, fully paid or provided for by the Parent and/or ICA-T, and all laws imposing such taxes will be or will have been complied
with.

 

(ff)      Bank
Holding Company Act. Neither the Parent, ICA-T nor the Subsidiaries are subject to the Bank Holding Company Act of 1956, as
amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the “Federal
Reserve”). Neither the Parent, ICA-T nor the Subsidiaries or affiliates owns or controls, directly or indirectly, five
percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total
equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Parent, ICA-T
nor the Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any entity that
is subject to the BHCA and to regulation by the Federal Reserve.

 

    	 	26	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(gg)    Illegal
or Unauthorized Payments; Political Contributions. Neither the Parent, ICA-T nor the Subsidiaries nor, to the best of ICA-T’s
knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents or other
representatives of the Parent, ICA-T and the Subsidiaries or any other business entity or enterprise with which the Parent, ICA-T
or their respective Subsidiaries is or has been affiliated or associated, has, directly or indirectly, made or authorized any
payment, contribution or gift of money, property, or services, whether or not in contravention of applicable law, (i) as a kickback
or bribe to any Person or (ii) to any political organization, or the holder of or any aspirant to any elective or appointive public
office except for personal political contributions not involving the direct or indirect use of funds of the Parent, ICA-T and
the Subsidiaries.

 

(hh)    Money
Laundering. The Parent, ICA-T and the Subsidiaries are in compliance with, and have not previously violated, the USA Patriot
Act of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without limitation,
the laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including,
but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions
With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations
contained in 31 CFR, Subtitle B, Chapter V.

 

(ii)       Books
and Records. The books of account, ledgers, order books, records and documents of the Parent, ICA-T and the Subsidiaries accurately
and completely reflect all information relating to the respective businesses of the Parent, ICA-T and the Subsidiaries, the nature,
acquisition, maintenance, location and collection of each of their respective assets, and the nature of all transactions giving
rise to material obligations or accounts receivable of the Parent, ICA-T or any of their respective Subsidiaries, as the case
may be, except where the failure to so reflect such information would not have a Material Adverse Effect. The minute books of
the Parent, ICA-T and the Subsidiaries contain accurate records of all material meetings and accurately reflect all other material
actions taken by the stockholders, boards of directors and all committees of the boards of directors, and other governing Persons
of the Parent, ICA-T and the Subsidiaries, respectively.

 

(jj)      Management.
Except as set forth in Schedule 3(jj) hereto, during the past five year period, no current or former officer or director
or, to the knowledge of the Parent and ICA-T, no current ten percent (10%) or greater stockholder of the Parent, ICA-T and the
Subsidiaries has been the subject of:

 

(i)       a
petition under bankruptcy laws or any other insolvency or moratorium law or the appointment by a court of a receiver, fiscal agent
or similar officer for such Person, or any partnership in which such person was a general partner at or within two years before
the filing of such petition or such appointment, or any corporation or business association of which such person was an executive
officer at or within two years before the time of the filing of such petition or such appointment;

 

(ii)       a
conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations that do
not relate to driving while intoxicated or driving under the influence);

 

    	 	27	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iii)       any
order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently
or temporarily enjoining any such person from, or otherwise limiting, the following activities:

 

		1.	Acting
                                         as a futures commission merchant, introducing broker, commodity trading advisor, commodity
                                         pool operator, floor broker, leverage transaction merchant, any other person regulated
                                         by the United States Commodity Futures Trading Commission or an associated person of
                                         any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities,
                                         or as an affiliated person, director or employee of any investment company, bank, savings
                                         and loan association or insurance company, or engaging in or continuing any conduct or
                                         practice in connection with such activity;

 

		2.	Engaging
                                         in any particular type of business practice; or

 

		3.	Engaging
                                         in any activity in connection with the purchase or sale of any security or commodity
                                         or in connection with any violation of securities laws or commodities laws;

 

(iv)       
any order, judgment or decree, not subsequently reversed, suspended or vacated, of any authority barring, suspending or otherwise
limiting for more than sixty (60) days the right of any such person to engage in any activity described in the preceding sub paragraph,
or to be associated with persons engaged in any such activity;

 

(v)       a
finding by a court of competent jurisdiction in a civil action or by the SEC or other authority to have violated any securities
law, regulation or decree and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently
reversed, suspended or vacated; or

 

(vi)       a
finding by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated
any federal commodities law, and the judgment in such civil action or finding has not been subsequently reversed, suspended or
vacated.

 

(kk)    Stock
Option Plans. Neither the Parent, ICA-T nor the Subsidiaries has any stock option, equity incentive and/or other related or
similar plans except as set forth in the SEC Documents (collectively, the “SOP’s”). Schedule 3(kk)
sets forth for each SOP the type of and aggregate amount of securities eligible to be issued under each SOP, the categories
of eligible participants thereunder and the aggregate number of equity incentive or other securities issued thereunder. Each stock
option, other securities or equity incentives under the SOPs granted by the Parent, ICA-T and the Subsidiaries (as the case may
be), was granted and/or issued (i) in accordance with the terms of the applicable SOP and (ii) with an exercise price at least
equal to the fair market value of the Parent Common Stock or common stock or other securities on the date such would be considered
granted and/or issued under GAAP and applicable law. No stock option, other securities or equity incentives granted under the
SOP’s has been backdated.

 

    	 	28	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(ll)     No
Disagreements with Accountants and Lawyers. Except as disclosed in the SEC Documents, there are no material disagreements
of any kind presently existing, or reasonably anticipated by the Parent, ICA-T and the Subsidiaries to arise, between the Parent,
ICA-T and the Subsidiaries and the accountants and lawyers formerly or presently employed by the Parent, ICA-T and the Subsidiaries
and the Parent, ICA-T and the Subsidiaries are current with respect to any fees owed to its accountants and lawyers which could
affect ICA-T’s and the Subsidiary’s ability to perform any of its obligations under any of the Transaction Documents.
In addition, on or prior to the date hereof, the Parent, ICA-T and the Subsidiaries had discussions with its accountants about
its Financial Statements previously filed with the SEC. Based on those discussions and/or otherwise, neither the Parent nor ICA-T
has no reason to believe that it will need to restate any Financial Statements or any part thereof.

 

(mm)  No
Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the
1933 Act (“Regulation D Securities”), none of the Parent, ICA-T, any of their respective predecessors, any
affiliated issuer, any director, executive officer, other officer of the Parent or ICA-T participating in the purchase and sale
of any of the Securities (or other transactions) contemplated hereby and in the Transaction Documents, any beneficial owner of
20% or more of the Parent’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the 1933 Act) connected with the Parent or ICA-T in any capacity at the time of sale
(each, an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject to
any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Parent and ICA-T have exercised
reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Parent and ICA-T have
complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Buyer a copy of
any disclosures provided thereunder.

 

(nn)  Other
Covered Persons and Related Matters. Except as disclosed in Schedule 3(nn), the Parent and ICA-T are not aware of any
Person that has been or will be paid (directly or indirectly) remuneration for solicitation of the Buyer or potential purchasers
in connection with the sale of any Regulation D Securities. To the best knowledge of the Parent and/or ICA-T, no holder of any
securities of the Parent, ICA-T nor any employee, officer, director and/or consultant or advisor to or of the Parent, ICA-T and
the Subsidiaries are a Bad Actor subject to a Disqualification Event.

 

(oo)   No
Additional Agreements. Neither the Parent nor ICA-T have any agreement or understanding with the Buyer with respect to the
transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents.

 

    	 	29	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(pp)  Public
Utility Holding Act. None of the Parent, ICA-T nor the Subsidiaries are a “holding company,” or an “affiliate”
of a “holding company,” as such terms are defined in the Public Utility Holding Act of 2005.

 

(qq)  Federal
Power Act. None of the Parent, ICA-T nor the Subsidiaries are subject to regulation as a “public utility” under
the Federal Power Act, as amended.

 

(rr)    Ranking
of Notes. Other than as set forth on Schedule 3(rr), no Indebtedness of the Parent, ICA-T and/or any Subsidiaries,
at the Closing will be in any manner and/or for any reason (i) senior to the Notes and/or any other liabilities and/or obligations
of the Parent, ICA-T and/or any Subsidiaries to the Buyer in right of payment or otherwise, and/or (ii) pari passu with
the Notes and/or any other liabilities and/or obligations of the Parent, ICA-T and/or any Subsidiaries to the Buyer in right of
payment and/or in otherwise, whether with respect to payment, redemptions, principal, interest, Late Charges (as defined in the
Note), damages, upon liquidation, dissolution or otherwise.

 

(ss)   Customers;
Suppliers.

 

(i)       Schedule
3(ss)(i) attached hereto sets forth a true and correct list of (a) all customers of the Parent, ICA-T and the Subsidiaries
with annual gross sales (as calculated pursuant to GAAP, consistently applied in accordance with past practices) in excess of
$250,000 in terms of gross sales during the fiscal year ended December 31, 2016 and for the twelve month period ended as of the
date hereof (collectively, the “Major Customers”).

 

(ii)       Schedule
3(ss)(ii) attached hereto lists, and the Parent and ICA-T have previously provided to the Buyer a copy of, all written contracts,
commitments, agreements and other arrangements with Major Customers, including all amendments, modifications and supplements thereto.
Except as set forth on Schedule 3(ss)(ii), there are no material oral contracts, commitments, agreements and other arrangements
between the Parent, ICA-T or each of their respective Subsidiaries, on the one hand, and any Major Customer, on the other hand.

 

(iii)       Except
as disclosed Schedule 3(ss)(iii), neither the Parent, ICA-T nor the Subsidiaries has received any written or oral notice,
and neither the Parent, ICA-T nor the Subsidiaries has any reason to believe, that any Major Customer (i) has ceased, or in the
reasonably foreseeable future may cease, to use the services of the Parent, ICA-T and the Subsidiaries, (ii) has substantially
reduced, or in the reasonably foreseeable future may substantially reduce, the use of the services of the Parent, ICA-T and the
Subsidiaries or (iii) has terminated or materially altered, or in the reasonably foreseeable future would reasonably be expected
to terminate or materially alter its business relations with the Parent, ICA-T and the Subsidiaries, in each case as a result
of the consummation of the transactions contemplated hereby or otherwise.

 

    	 	30	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iv)       Neither
the Parent, ICA-T nor the Subsidiaries has received any written or oral notice, and neither the Parent, ICA-T nor the Subsidiaries
has any reason to believe, that any material partner, supplier or vendor to the Parent, ICA-T and the Subsidiaries has terminated
or materially altered, or in the reasonably foreseeable future would reasonably be likely to terminate or materially alter, its
business relations with the Parent, ICA-T and the Subsidiaries, in each case as a result of the transactions contemplated hereby
or otherwise.

 

(tt)    Dilutive
Effect. The Parent and ICA-T each understands and acknowledges that the number of Parent Underlying Shares will increase in certain
circumstances. The Parent and ICA-T each further acknowledges that the Parent’s obligation to issue the Parent Conversion
Shares pursuant to the terms of the Notes and Parent Warrant Shares pursuant to the terms of the Parent Warrant in accordance
with this Agreement, the Notes and the Parent Warrant is, in each case, absolute and unconditional regardless of the dilutive
effect that such issuance may have on the ownership interests of other stockholders of the Parent.

 

(uu)   Disclosure.
No statement made by the Parent or ICA-T in this Agreement, any other Transaction Document or the exhibits and schedules attached
hereto or in any certificate or schedule furnished or to be furnished by or on behalf of the Parent and/or ICA-T to the Buyer
or any of their representatives in connection with the transactions contemplated hereby and/or thereby and/or in any other Transaction
Document contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements
contained herein or therein not misleading. The Parent and ICA-T each confirms that neither it nor any other Person acting on
its behalf has provided the Buyer or its agents or counsel with any information that constitutes or could reasonably be expected
to constitute material, non-public information concerning the Parent, ICA-T and the Subsidiaries, other than the existence of
the transactions contemplated by this Agreement and the other Transaction Documents. The Parent and ICA-T each understands and
confirms that the Buyer will rely on the foregoing representations in effecting transactions in securities of the Parent and ICA-T
each. Each press release issued by the Parent, ICA-T and the Subsidiaries during the twelve (12) months preceding the date of
this Agreement did not at the time of release contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they are made, not misleading. To each of the Parent’s and ICA-T’s knowledge, no event or circumstance has occurred
or information exists with respect to the Parent, ICA-T and the Subsidiaries or its or their business, properties, liabilities,
prospects, operations (including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or
regulation, requires public disclosure at or before the date hereof or announcement by the Parent or ICA-T but which has not been
so publicly disclosed. The due diligence materials previously provided by or on behalf of the Parent and ICA-T to the Buyer (the
“Due Diligence Materials”), have been prepared in a good faith effort by the Parent and ICA-T to describe the
Parent and ICA-T’s present and proposed products, and projected growth of the Parent and ICA-T and do not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading, except
that with respect to assumptions, projections and expressions of opinion or predictions contained in the Due Diligence Materials.
The Parent and ICA-T each acknowledge and agree that the Buyer does not make nor has made any representations or warranties with
respect to the transactions contemplated hereby and/or in the other Transaction Documents other than those specifically set forth
in Section 2.

 

    	 	31	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(vv)
Acknowledgement Regarding Buyer’s Trading Activity. It is understood and acknowledged by the Parent and ICA-T that
(i) following the public disclosure of the transactions contemplated by the Transaction Documents, in accordance with the terms
thereof, the Buyer has not been asked by the Parent, ICA-T and the Subsidiaries to agree, nor has any Buyer agreed with the Parent,
ICA-T and the Subsidiaries, to desist from effecting any transactions in or with respect to (including, without limitation, purchasing
or selling, long and/or short) any securities of the Parent and/or ICA-T, or “derivative” securities based on securities
issued by the Parent and/or ICA-T or to hold any of the Securities for any specified term; (ii) the Buyer, and counterparties
in “derivative” transactions to which the Buyer is a party, directly or indirectly, presently may have a “short”
position in the Parent Common Stock which was established prior to the Buyer’s knowledge of the transactions contemplated
by the Transaction Documents; and (iii) the Buyer shall not be deemed to have any affiliation with or control over any arm’s
length counterparty in any “derivative” transaction. The Parent and ICA-T each further understands and acknowledges
that following the public disclosure of the transactions contemplated by the Transaction Documents pursuant to the Press Release
(as defined below) the Buyer may engage in hedging and/or trading activities at various times during the period that the Securities
are outstanding, including, without limitation, during the periods that the value and/or number of the Parent Warrant Shares or
Parent Conversion Shares, as applicable, deliverable with respect to the Securities are being determined and such hedging and/or
trading activities, if any, can reduce the value of the existing stockholders’ equity interest in the Parent and ICA-T both
at and after the time the hedging and/or trading activities are being conducted. The Parent and ICA-T each acknowledges that such
aforementioned hedging and/or trading activities do not constitute a breach of this Agreement, the Notes, the Parent Warrant or
any other Transaction Document or any of the documents executed in connection herewith or therewith.

 

(ww) Liens.
Other than as set forth on Schedule 3(ww), there are no Liens on any of the assets of the Parent, ICA-T and/or the Subsidiaries.

 

(xx)     Shell
Company Status. The Parent is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

(yy)  Material
Contracts. All Material Contracts of the Parent and the Subsidiaries are set forth on Schedule 3(yy) and each has been
filed with the SEC (as defined below). An accurate, current and complete copy of each of the Material Contracts has been furnished
to Buyers and each of the Material Contracts constitutes the entire agreement of the respective parties thereto relating to the
subject matter thereof. Each of the Material Contracts is in full force and effect and is a valid and binding obligation of the
parties thereto in accordance with the terms and conditions thereof. To the knowledge of the Parent and ICA-T and each of their
respective officers, all obligations required to be performed under the terms of each of the Material Contracts by any party thereto
have been fully performed by all parties thereto, and no party to any Material Contracts is in default with respect to any term
or condition thereof, nor has any event occurred which, through the passage of time or the giving of notice, or both, would constitute
a default thereunder or would cause the acceleration or modification of any obligation of any party thereto or the creation of
any encumbrance upon any of the assets of the Parent and ICA-T. Further, the neither the Parent nor ICA-T has received notice,
nor does ICA-T or the Parent have any knowledge, of any pending or contemplated termination of any of the Material Contracts and,
no such termination is proposed or has been threatened, whether in writing or orally. “Material Contract” means
any contract to which the Parent, ICA-T and the Subsidiaries are a party or by which it is bound which has been filed or is required
to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K promulgated
by the SEC. Notwithstanding anything to the contrary provided herein or elsewhere, for purposes of the Transaction Documents,
the term Material Contracts includes the Sanofi Documents.

 

(zz)    Registration
Eligibility. The Parent is eligible to register the Registrable Securities (as defined below) for sale or resale on a Registration
Statement on Form S-1.

 

    	 	32	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		4.	COVENANTS.

 

(a)       Best
Efforts. The Buyer shall use its best efforts to timely satisfy each of the covenants under this Section 4 and conditions
to be satisfied by it as provided in Section 6 of this Agreement. The Parent and ICA-T shall each use its best efforts
to timely satisfy each of the covenants hereunder and conditions to be satisfied by it as provided in Section 7 of this
Agreement.

 

(b)       Form
D and Blue Sky. The Parent and ICA-T shall each file a Form D with respect to the Securities issued and/or sold by each as
required under Regulation D and to provide a copy thereof to the Buyer promptly after such filing. The Parent and ICA-T shall,
on or before the Closing Date, take such action as the Parent and ICA-T shall reasonably determine is necessary in order to obtain
an exemption for, or to, qualify the Securities for sale to the Buyer at the Closing pursuant to this Agreement under applicable
securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification),
and shall provide evidence of any such action so taken to the Buyer on or prior to the Closing Date. Without limiting any other
obligation of the Parent and ICA-T under this Agreement, the Parent and ICA-T shall timely make all filings and reports relating
to the offer and sale of the Securities required under all applicable securities laws (including, without limitation, all applicable
federal securities laws and all applicable “Blue Sky” laws), and the Parent and ICA-T shall comply with all applicable
foreign, federal, state and local laws, statutes, rules, regulations and the like relating to the offering and sale of the Securities
to the Buyer.

 

(c)       Reporting
Status. Until the Business Day immediately following to the day on which the Buyer or any transferee or assignee thereof to
which the Buyer assigns its rights as a holder of Securities (each an “Investor”, and collectively, the “Investors”)
shall have sold all of the Parent Underlying Shares (the “Reporting Period”), the Parent (or its Successor
Entity (as defined in the Notes)), shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and
the Parent (or its Successor Entity (as defined in the Notes)) shall not terminate the registration of the Parent Common Stock
under Section 12 of the 1934 Act and/or the Parent’s status as an issuer required to file reports under the 1934 Act even
if the 1934 Act or the rules and regulations thereunder would no longer require or otherwise permit such termination. The Parent
shall maintain its eligibility to register the Registrable Securities on Form S-1.

 

    	 	33	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(d)       Use
of Proceeds. (i) the Parent shall use the net proceeds from the Parent Purchase Price to (A) repay the $1,500,000 aggregate
principal amount of the 8% notes sold by the Parent in April 2017 (the “Parent Bridge Notes”) and all accrued
but unpaid interest thereon, and (B) the balance for general corporate and working capital purposes including payments made against
the $1,400,000 amount owed by the Parent to Dentons pursuant to the Settlement and Release Agreement dated May 11, 2017 by and
between Dentons and the Parent (the “Denton Settlement Agreement”), and (ii) ICA-T shall use the net proceeds
from the ICA-T Purchase Price for general corporate and working capital purposes of ICA-T; provided, however, notwithstanding
anything to the contrary provided herein or elsewhere, except as expressly provided in this “d,” neither the Parent
nor ICA-T shall use any of the net proceeds of the Parent Purchase Price or ICA-T Purchase Price, respectively, for (A) as to
ICA-T, the repayment of any Indebtedness of ICA-T other than Permitted Indebtedness (as defined in the ICA-T Note), as to the
Parent, other than Permitted Indebtedness (as defined in the Parent Note), (B) the redemption or repurchase of any securities
of the Parent, ICA-T and the Subsidiaries, or (C) except for the payments pursuant to the Denton Settlement Agreement, the settlement
of any outstanding litigation; provided, further, ICA-T will not use any of such proceeds in violation of the Sanofi
Documents.

 

(e)       Financial
and Other Information. The Parent agrees to send the following to each Investor during the Reporting Period (i) unless the
following are filed with the SEC through EDGAR and are available to the public through the EDGAR system, within one (1) Business
Day after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, any interim
reports or any consolidated balance sheets, income, statements, stockholder’s equity statements and/or cash flow statements
for any period other than annually, any Current Reports on Form 8-K, any registration statements (other than on Form S-8) or amendments
filed pursuant to the 1933 Act, (ii) unless the following are either filed with the SEC through EDGAR or are otherwise widely
disseminated via a recognized news release service (such as PR Newswire), on the same day as the release thereof, facsimile copies
of all press releases issued by the Parent, ICA-T and the Subsidiaries and (iii) unless the following are filed with the SEC through
EDGAR or made permanently available on the Parent or ICA-T’s website, copies of any notices and other information made available
or given to the stockholders of the Parent generally, contemporaneously with the making available or giving thereof to the stockholders.

 

(f)       Inspection.
In addition to the inspection and related rights of the Buyer as set forth in the Notes, the Parent and ICA-T shall permit any
representative that the Buyer or the Collateral Agent authorizes, including attorneys and accountants, to inspect the Collateral
and examine and make copies and abstracts of the books of account and records of the Parent, ICA-T and the Subsidiaries at reasonable
times and upon reasonable notice during normal business hours but no more than once per quarter; provided that they execute the
Parent’s and/or ICA-T’s standard confidentiality agreement. In addition, any such representative shall have the right
to meet with management and officers of the Parent, ICA-T and the Subsidiaries and/or their representatives to discuss such books
of account and records including, but not limited to, the accountants and legal counsels of the Parent, ICA-T and the Subsidiaries.
In addition, the Collateral Agent and the Buyer shall be entitled at reasonable times and intervals to consult with and advise
the management and officers of the Parent, ICA-T and the Subsidiaries concerning significant business issues affecting the Parent,
ICA-T and the Subsidiaries.

 

    	 	34	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(g)       Listing.
In the event the Parent becomes a Trading Issuer (as defined in the Note) or the Parent Common Stock otherwise becomes listed
or designated for quotation (as the case may be) on an Eligible Market or otherwise, the Parent shall take any and all action
to ensure all Parent Underlying Shares are listed or designated for quotation (as the case may be) on such Eligible Market and
shall maintain the listing or designation for quotation (as the case may be) of all Parent Underlying Shares from time to time
issuable under the terms of the Transaction Documents on the Eligible Market upon which the Parent Common Stock is then listed
or designated for quotation (as the case may be) or any other Eligible Market. The Parent shall pay all fees and expenses in connection
with satisfying its obligations under this Section 4(g). No event has occurred and to the best knowledge of the Parent,
there is no reason why the Parent Common Stock cannot be listed and trade on any Eligible Market, subject to meet the specific
shareholder and financial requirements thereof.

 

(h)       Fees,
Etc. At and as a condition to the Closing, the Parent and ICA-T shall reimburse the Buyer for all costs and expenses incurred
by it or its affiliates in connection with its due diligence up to $20,000 of which $6,000 was previously paid, structuring, documentation,
negotiation and closing of the transactions contemplated by the Transaction Documents. Notwithstanding and in addition to the
above, the Parent and ICA-T shall also pay (i) the legal fees incurred by the Buyer to Gusrae Kaplan Nusbaum PLLC, legal counsel
to the Buyer, and local real estate counsel to the Buyer in the State where any Real Property of the Parent, ICA-T and the Subsidiaries
are located, up to $75,000 in the aggregate less $10,000 previously paid, and (ii) all documented costs and expenses incurred
by such legal counsels including, but not limited to Lien, judgment, tax, and UCC and related searches, and all filing fees including,
but not limited to, all UCC-1 Financing Statements, UCC-3 Termination Statements, if any, USPTO filings and all recordation fees
and related costs and expenses (collectively, the “Transaction Expenses”). Such Transaction Expenses shall
be withheld by the Buyer from the Purchase Price paid to the Parent and ICA-T at the Closing, less $10,000 previously paid by
the Parent to the Buyer; provided, that ICA-T shall promptly reimburse Buyer and Gusrae Kaplan Nusbaum PLLC on demand for
all Transaction Expenses not so invoiced and/or reimbursed through such withholding at the Closing or otherwise upon the provision
of reasonable satisfactory evidence of such expense including, but not limited to, all Lien (UCC, USPTO, Etc.), judgment, bankruptcy
searches, which will be paid upon delivery of each invoice from the service provider or other Person. The Parent and ICA-T shall
be responsible for the payment of any placement agent’s fees, financial advisory fees, Controlled Account Bank fees, DTC
fees, transfer agent fees, listing fees, if any, fees or broker’s commissions, filing and/or recordation fees, blue sky
fees relating to or arising out of the transactions contemplated hereby and in the other Transaction Documents. The Parent and
ICA-T shall pay, and hold the Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable
attorneys’ fees and out-of-pocket expenses as and when incurred) arising in connection with any claim relating to any such
payment. Except as otherwise set forth in the Transaction Documents, each party to this Agreement and/or any other Transaction
Document shall bear its own expenses in connection with the sale of the Securities to the Buyer. The Parent and ICA-T, however,
shall be jointly and severally responsible and pay any and all reasonable attorneys’ and other professionals’ fees
and expenses incurred by the Collateral Agent and/or the Buyer (as and when incurred) after the Closing in connection with or
related to: (a) the Transaction Documents and/or any of the transactions contemplated and/or arising therefrom; (b) the administration,
collection, or enforcement of the Transaction Documents; (c) the amendment or modification of the Transaction Documents; (d) any
waiver, consent, release, or termination under the Transaction Documents; (e) the perfection of Liens on, the protection, preservation,
sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal,
litigation, regulatory, administrative, arbitration, or out of court proceeding in connection with or related to the Parent, ICA-T,
each of their respective Subsidiaries, Collateral, any of the Transaction Documents and/or any transaction contemplated hereby
and/or thereby or otherwise, related to and/or arising therefrom and from any appeal or review thereof; and (g) any bankruptcy,
restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to the Parent,
ICA-T, each of their respective Subsidiaries, the Collateral, the Transaction Documents, including representing the Collateral
Agent and the Buyer in any adversary proceeding or contested matter commenced or continued by or on behalf of the Parent, ICA-T
and the Subsidiaries’ estate, property and/or any appeal or review thereof.

 

    	 	35	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(i)       Pledge
of Securities. Notwithstanding anything to the contrary contained in this Agreement, the Parent and ICA-T each acknowledge
and agree that the Securities may be pledged by an Investor in connection with a bona fide margin agreement or other loan or financing
arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment
of the Securities hereunder, and no Investor effecting a pledge of Securities shall be required to provide the Parent or ICA-T,
as the case may be, with any notice thereof or otherwise make any delivery to the Parent or ICA-T, as the case may be pursuant
to this Agreement or any other Transaction Document, including, without limitation, Section 2(g) hereof; provided that
an Investor and its pledgee shall be required to comply with the provisions of Section 2(g) hereof in order to effect a
sale, transfer or assignment of Securities to such pledgee. The Parent and ICA-T each hereby agrees to execute and deliver such
documentation as a pledgee of the Securities as the Buyer may reasonably request in connection with a pledge of the Securities
to such pledgee by the Buyer.

 

(j)       Disclosure
of Transaction, Etc.

 

(i)       Disclosure
of Transaction. The Parent shall, on or before 9:30 a.m., New York time, no later than the fourth (4th) Business
Day after the date of this Agreement, issue a press release (the “Press Release”) reasonably acceptable to
the Buyer disclosing all the material terms of the transactions contemplated by the Transaction Documents. On or before 9:30 a.m.,
New York time, no later than the fourth (4th) Business Day after the date of this Agreement, the Parent shall file
a Current Report on Form 8-K describing all the material terms of the transactions contemplated by the Transaction Documents in
the form required by the 1934 Act and attaching all the material Transaction Documents (including, without limitation, this Agreement
(and all schedules to this Agreement), the form of Note, the form of the Parent Warrant, the form of Guaranties and the form of
Security Documents) (including all attachments, the “8-K Filing”).

 

(ii)       Limitations
on Disclosure. The Parent and ICA-T shall not, and the Parent and ICA-T shall cause each of the Subsidiaries and each of its
and their respective officers, directors, employees and agents not to, provide any Buyer with any material, non-public information
regarding the Parent, ICA-T and/or any of the Subsidiaries from and after the date hereof without the express prior written consent
of the Buyer (which may be granted or withheld in the Buyer’s sole discretion). In the event of a breach of any of the foregoing
covenants, including, without limitation, Section 4(m) of this Agreement, or any of the covenants or agreements contained
in any other Transaction Document, by the Parent, ICA-T and/or any of the Subsidiaries, or any of its or their respective officers,
directors, employees and agents (as determined in the reasonable good faith judgment of the Buyer), in addition to any other remedy
provided herein or in the Transaction Documents, the Buyer shall have the right to make a public disclosure, in the form of a
press release, public advertisement or otherwise, of such breach or such material, non-public information, as applicable, without
the prior approval by the Parent, ICA-T, any of their respective Subsidiaries, or any of its or their respective officers, directors,
employees or agents. The Buyer shall not have any liability to the Parent, ICA-T, any of the Subsidiaries, or any of its or their
respective officers, directors, employees, affiliates, stockholders or agents, for any such disclosure. To the extent that the
Parent, ICA-T or any of the Subsidiaries delivers any material, non-public information to the Buyer without the Buyer’s
prior written consent, the Parent and ICA-T hereby covenant and agree that the Buyer shall not have any duty of confidentiality
with respect to, or a duty not to trade on the basis of, such material, non-public information. Subject to the foregoing, neither
the Parent, ICA-T nor the Subsidiaries nor any Buyer shall issue any press releases or any other public statements (other than
the filing of a Current Report on Form 8-K) with respect to the transactions contemplated hereby; provided, however, the Parent
shall be entitled, without the prior approval of any Buyer, to make the Press Release and any press release or other public disclosure
with respect to such transactions (i) in substantial conformity with the 8-K Filing and (ii) as is required by applicable law
and regulations (provided that in the case of clause (i) the Buyer shall be notified by the Parent of any such press release or
other public disclosure prior to its release). Notwithstanding anything contained in this Agreement to the contrary and without
implication that the contrary would otherwise be true, the Parent expressly acknowledges and agrees that the Buyer shall not have
any duty of confidentiality with respect to, or a duty not to trade on the basis of, any material, non-public information regarding
the Parent, the Parent and/or any of their respective Subsidiaries.

 

    	 	36	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iii)       Other
Confidential Information. In addition to other remedies set forth in this Section 4(j), and without limiting anything
set forth in any other Transaction Document, at any time after the Closing Date if the Parent, ICA-T, any of their respective
Subsidiaries, or any of their respective officers, directors, employees or agents, provides the Buyer with material non-public
information relating to the Parent, ICA-T and/or any of the Subsidiaries (each, the “Confidential Information”),
and such disclosure is without the consent of the Buyer, the Parent shall on the Required Disclosure Date (as defined below),
publicly disclose such Confidential Information on a Current Report on Form 8-K or otherwise (each, a “Disclosure”).
From and after such Disclosure, the Parent shall have disclosed all Confidential Information provided to the Buyer and/or any
of its affiliates by the Parent, ICA-T and the Subsidiaries or any of their respective officers, directors, employees or agents
in connection with the transactions contemplated by the Transaction Documents other than material non-public information relating
to the Parent, ICA-T and/or any of the Subsidiaries provided to the Buyer prior written consent of the Buyer. In addition, effective
upon such Disclosure, the Parent and ICA-T acknowledge and agree that any and all confidentiality or similar obligations under
any agreement, whether written or oral, between the Parent, ICA-T, any of the Subsidiaries or any of their respective officers,
directors, affiliates, employees or agents, on the one hand, and the Buyer or any of their affiliates, on the other hand, shall
terminate with respect to material non-public information relating to the Parent, ICA-T and/or any of the Subsidiaries provided
to the Buyer without the Buyer’s prior written consent . For purposes of this Agreement, the term “Required Disclosure
Date” means (x) if the Buyer authorized the delivery of such Confidential Information, either (I) if the Parent and
the Buyer have mutually agreed upon a date (as evidenced by an e-mail or other writing) of Disclosure of such Confidential Information,
such agreed upon date or (II) otherwise, the fifth (5th) calendar day after the date the Buyer first received any Confidential
Information or (y) if the Buyer did not authorize the delivery of such Confidential Information, the first (1st) Business
Day after the Buyer’s receipt of such Confidential Information. Notwithstanding anything to the contrary contained in this
Agreement, the Parent and ICA-T shall not be required to publicly disclose any material, non-public information relating to ICA-T,
the Parent and/or any of the Subsidiaries that is provided to the Buyer if the Buyer consents in writing to the receipt of such
information.

 

(k)       Conduct
of Business. The business of the Parent, ICA-T and the Subsidiaries shall not be conducted in violation of any law, ordinance
or regulation of any Governmental Entity.

 

(l)       Other
Notes; Variable Securities. So long as the Buyer and/or any of its transferees, affiliates and/or related persons own (beneficially
or otherwise) any Securities, neither the Parent, ICA-T or any of the Subsidiaries shall issue, sell and/or enter into an agreement
to effect any sale of Notes and/or any Variable Rate Transaction. “Variable Rate Transaction” means a transaction
in which the Parent, ICA-T or any of the Subsidiaries (i) issues or sells any Common Stock Equivalents (as defined in the Notes),
Convertible Securities (as defined in the Notes) either (A) at a conversion, exercise or exchange rate or other price that is
based upon and/or varies with the trading prices of or quotations for the shares of Parent Common Stock at any time after the
initial issuance of such Convertible Securities, or (B) with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such Convertible Securities or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Parent, ICA-T and/or any Subsidiary or the market for the Parent
Common Stock, or (ii) enters into any agreement (including, without limitation, an equity line of credit) whereby the Parent,
ICA-T and the Subsidiaries may sell securities at a future determined price (other than standard and customary “preemptive”
or “participation” rights). The Buyer shall be entitled to obtain injunctive relief against the Parent, ICA-T and/or
any of the Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages. Notwithstanding
anything to the contrary provided herein or elsewhere, neither ICA-T nor any other Subsidiary shall directly and/or indirectly
issue any capital stock (other than the 100 shares of ICA-T capital stock and the capital stock of each Subsidiary) issued and
outstanding as of the date hereof, all of which and all of whose voting stock is owned solely and exclusively by the Parent. Notwithstanding
anything to the contrary contained herein, a Variable Rate Transaction shall not include an “at the market” offering.

 

    	 	37	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(m)       Participation
Right. Until the two (2) year anniversary of the Closing Date, the Buyer shall have the right (the “Participation
Right”), but not the obligation to participate in all Subsequent Placements, up to the aggregate initial original principal
amount of the Notes at Closing, other than Exempt Issuances, on the terms and conditions so negotiated between the Parent and/or
ICA-T on the one hand and the Buyer on the other. For the purpose of this Agreement, the following definitions shall apply:

 

a.       “Exempt
Issuance” means the issuance of (a) shares of Parent Common Stock or options to purchase shares of Parent Common Stock
issued pursuant to any stock or option plan duly adopted for such purpose, by the Parent’s board of directors and a majority
of the non-employee members of the board of directors or a majority of the members of a committee of non-employee directors established
for such purpose, (b) shares of Parent Common Stock issuable upon the exercise or exchange of or conversion of any of the Notes,
the Parent Warrant issued hereunder and/or any Common Stock Equivalents issued and outstanding on the date of this Agreement,
provided that such securities have not been amended since their original issue, (c) securities issued in lieu of cash pursuant
to merger, consolidation, acquisition or strategic transactions approved by a majority of the disinterested directors of the Parent,
provided that any such issuance shall only be to a Person which is, itself or through its subsidiaries, an operating company in
a business synergistic with the business of the Parent and in which the Parent receives benefits in addition to any investment
of funds, but shall not include a transaction in which the Parent is issuing securities primarily for the purpose of raising capital
or to an entity whose primary business is investing in securities and/or being issued to affiliates, employees and/or related
persons of the Parent and/or any of its affiliates, (d) securities issued pursuant to any equipment loan or leasing arrangement,
real property leasing arrangement or debt financing having such terms and on such terms and conditions and from a bank or similar
financial institution, all as approved by a majority of the disinterested directors of the Parent, (e) securities to an entity
as a component of any business relationship with such entity primarily for the purpose of a joint venture or licensing activity
or another arrangement involving a corporate partner primarily for purposes other than raising capital, and (f) issuance of securities
pursuant to a stock dividend or stock split except as otherwise prohibited and/or limited in this Note and/or any other Transaction
Document.

 

b.       
“Subsequent Placement” means any issuance, offer, sale, grant for capital raising purposes of any option or
right to purchase, or other disposal by the Parent or any of its affiliates and/or Subsidiaries, directly or indirectly, of any
debt securities including, but not limited to, convertible debt, debt issued with equity components or debt not considered a “security”
under the 1933 Act and any short term instruments (as defined in the 1933 Act) of the Parent, ICA-T and the Subsidiaries.

 

    	 	38	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(n)       
Passive Foreign Investment Company. ICA-T and the Parent shall conduct its business, and shall each cause each of its Subsidiaries
to conduct their respective businesses, in such a manner as will ensure that ICA-T and the Parent will not be deemed to constitute
a passive foreign investment company within the meaning of Section 1297 of the Code.

 

(o)       Restriction
on Redemption and Cash Dividends. So long as any Securities are outstanding and except as expressly provided herein, neither
the Parent nor ICA-T shall, and the Parent and ICA-T shall cause each Subsidiary not to, directly or indirectly, redeem, or declare
or pay any cash dividend or distribution on, any securities (other than Securities) of the Parent, ICA-T or any Subsidiary without
the prior express written consent of the Buyer, other than intercompany dividends (“Intercompany Dividends”)
from any Subsidiary to the Parent provided all of such Subsidiary’s operations are in the United States and it does not
have any foreign bank or similar account; provided, however, that notwithstanding anything to the contrary provided
herein or elsewhere, all Intercompany Dividends shall be prohibited commencing on the date an Event of Default occurs and continuing
through and including the tenth (10th) Business Day following the date the Collateral Agent receives written notice
from ICA-T and the Parent signed by the CFO of ICA-T and the Parent that such Event of Default has been cured and no longer exists.

 

(p)       Corporate
Existence. So long as the Buyer beneficially owns the Notes and the Parent Warrant, the Parent shall not and shall cause each
Subsidiary not to be a party to any Fundamental Transaction (as defined in the Note) unless the Parent is in compliance with the
applicable provisions governing Fundamental Transactions set forth in the Notes, this Agreement and the Parent Warrant.

 

(q)       
Stock Splits. Until the Notes are no longer outstanding, the Parent shall not effect any stock combination, reverse stock
split or other similar transaction submitted for stockholder approval at a meeting of the shareholders of the Parent or via written
consent of stockholders (or make any public announcement or disclosure with respect to any of the foregoing) without the prior
written consent of the Buyer, which consent shall not be unreasonably withheld.

 

(r)       Collateral
Agent. The Buyer is the collateral agent hereunder, under the other Security Documents and the other Transaction Documents
(in such capacity, the “Collateral Agent”), and (ii) as the Collateral Agent (as well as its officers, directors,
employees and agents) is and shall be entitled to take such action on the Buyer’s and any of its assignees’ and/or
transferees’ behalf in accordance with the terms hereof and thereof. The Collateral Agent shall not have, by reason hereof,
the other Transaction Documents including the Security Documents, a fiduciary relationship in respect of any assignee and/or transferee
of the Buyer. Neither the Collateral Agent nor any of its officers, directors, employees or agents shall have any liability to
any assignee and/or transferee of the Buyer for any action taken or omitted to be taken in connection hereof or any other Security
Document except to the extent caused by its own gross negligence or willful misconduct, any assignee and/or transferee of the
Buyer agrees to defend, protect, indemnify and hold harmless the Collateral Agent and all of its officers, directors, employees,
affiliates and agents (collectively, the “Collateral Agent Indemnitees”) from and against any losses, damages,
liabilities, obligations, penalties, actions, judgments, suits, fees, costs and expenses (including, without limitation, reasonable
attorneys’ fees, costs and expenses) incurred by such Collateral Agent Indemnitee, whether direct, indirect or consequential,
arising from or in connection with the performance by such Collateral Agent Indemnitee of the duties and obligations of Collateral
Agent pursuant hereto or any of the Security Documents. The Collateral Agent shall be entitled to rely upon any written notices,
statements, certificates, orders or other documents or any telephone message believed by it in good faith to be genuine and correct
and to have been signed, sent or made by the proper Person, and with respect to all matters pertaining to this Agreement or any
of the other Transaction Documents and its duties hereunder or thereunder, upon advice of counsel selected by it.

 

    	 	39	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(s)       Successor
Collateral Agent.

 

(i)       The
Collateral Agent may resign from the performance of all its functions and duties hereunder and under the other Transaction Documents
at any time by giving at least ten (10) Business Days’ prior written notice to the Parent and ICA-T and each holder of the
Notes. Such resignation shall take effect upon the acceptance by a successor Collateral Agent of appointment pursuant to clauses
(ii) and (iii) below or as otherwise provided below.

 

(ii)       Upon
any such notice of resignation or removal, the Buyer shall appoint a successor collateral agent. Upon the acceptance of any appointment
as Collateral Agent hereunder by a successor agent, such successor collateral agent shall thereupon succeed to and become vested
with all the rights, powers, privileges and duties of the collateral agent, and the Collateral Agent shall be discharged from
its duties and obligations under this Agreement and the other Transaction Documents. After the Collateral Agent’s resignation
or removal hereunder as the collateral agent, the provisions of this Section 4(s) shall inure to its benefit as to any
actions taken or omitted to be taken by it while it was the Collateral Agent under this Agreement and the other Transaction Documents.

 

(iii)       If
a successor collateral agent shall not have been so appointed within ten (10) Business Days of receipt of a written notice of
resignation or removal, the Collateral Agent shall then appoint a successor collateral agent who shall serve as the Collateral
Agent until such time, if any, as the Buyer appoints a successor collateral agent as provided above.

 

(iv)       In
the event that a successor Collateral Agent is appointed pursuant to the provisions of this Section 4(s) that is not the
Buyer or an affiliate of the Buyer (or the Buyer or the Collateral Agent (or its successor), as applicable, notify the Parent
and ICA-T that they or it wants to appoint such a successor Collateral Agent pursuant to the terms of this Section 4(s)),
the Parent, ICA-T and each Subsidiary thereof covenants and agrees to promptly take all actions reasonably requested by the Buyer
or the Collateral Agent (or its successor), as applicable, from time to time, to secure a successor Collateral Agent satisfactory
to the requesting part(y)(ies), in their sole discretion, including, without limitation, by paying all reasonable and customary
fees and expenses of such successor Collateral Agent, by having the Parent, ICA-T and each Subsidiary thereof agree to indemnify
any successor Collateral Agent pursuant to reasonable and customary terms and by each of the Parent, ICA-T and each Subsidiary
thereof executing a collateral agency agreement or similar agreement and/or any amendment to the Security Documents reasonably
requested or required by the successor Collateral Agent.

 

    	 	40	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(t)       New
Subsidiaries. Neither the Parent, ICA-T nor the Subsidiaries shall form or acquire any Foreign Subsidiaries without the express
prior written consent of the Collateral Agent and the Buyer, which written consent shall, among other conditions, be conditioned
upon, among other items, compliance by the Parent, ICA-T and each Subsidiary of Section 4(x).

 

(u)       General
Solicitation. None of the Parent, ICA-T, any of their respective affiliates or any Person acting on behalf of the Parent,
ICA-T or any such affiliate will solicit any offer to buy or offer or sell the Securities by means of any form of general solicitation
or general advertising within the meaning of Regulation D, including: any advertisement, article, notice or other communication
published in any newspaper, magazine or similar medium or broadcast over television or radio; and any seminar or meeting whose
attendees have been invited by any general solicitation or general advertising.

 

(v)       Integration.
None of the Parent, ICA-T, any of their respective affiliates or any Person acting on behalf of the Parent, ICA-T or any such
affiliates will sell, offer for sale, or solicit offers to buy or otherwise negotiate in respect of any security which will be
integrated with the sale of the Securities in a manner which would require the registration of any of the Securities under the
1933 Act or result in rescission rights.

 

(w)       Notice
of Disqualification Events. The Parent and ICA-T will notify the Buyer in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification
Event relating to any Issuer Covered Person.

 

(x)       Subsidiary
Guarantees, Etc. For so long as any of the Notes remain outstanding, upon any entity becoming a Subsidiary, the Parent and
ICA-T shall cause each such Subsidiary to become party to all of the Security Documents, to the extent required in the Security
Documents and take all actions required by the Security Documents in form and substance satisfactory to the Collateral Agent and
the Buyer.

 

(y)       Public
Information. At any time during the period commencing on Closing Date and ending at such time that all of the Parent Conversion
Shares and Parent Warrant Shares may be sold without restriction or limitation pursuant to Rule 144 and without the requirement
to be in compliance with Rule 144(c)(1), if the Parent shall (i) fail for any reason to satisfy the requirements of Rule 144(c)(1),
including, without limitation, the failure to satisfy the current public information requirement under Rule 144(c) or (ii) if
the Parent becomes an issuer described in Rule 144(i)(1)(i), and the Parent shall fail to satisfy any condition set forth in Rule
144(i)(2) (a “Public Information Failure”), then, as partial relief for the damages to any holder of the Notes,
the Parent Warrant and/or the Parent Conversion Shares by reason of any such delay in or reduction of its ability to sell these
securities (which remedy shall not be exclusive of any other remedies available at law or in equity), the Parent shall pay to
each such holder an amount in cash equal to two percent (2.0%) of the aggregate Purchase Price of such holder’s Notes and
Parent Conversion Shares and Parent Warrant Shares on the day of a Public Information Failure and on every thirtieth day (pro-rated
for periods totaling less than thirty days) thereafter until the earlier of (i) the date such Public Information Failure is cured
and (ii) such time that such Public Information Failure no longer prevents a holder of Notes, the Parent Warrant, the Parent Warrant
Shares and/or Parent Conversion Shares from selling such securities pursuant to Rule 144 without any restrictions or limitations.
The payments to which a holder shall be entitled pursuant to this Section 4(y) are referred to herein as “Public
Information Failure Payments.” Public Information Failure Payments shall be paid in cash, by wire transfer to the Buyer
on the earlier of (I) the last day of the calendar month during which such Public Information Failure Payments are incurred and
(II) the third Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the
event the Parent fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments
shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full.

 

    	 	41	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(z)       Books
and Records. The Parent and ICA-T will keep proper books of record and account, in which full and correct entries shall be
made of all financial transactions and the asset and business of the Parent, ICA-T and the Subsidiaries in accordance with GAAP.

 

(aa)   Closing
Documents. On or prior to ten (10) calendar days after the Closing Date, the Parent and ICA-T each agree to deliver, or cause
to be delivered, to the Buyer and Gusrae Kaplan Nusbaum PLLC a complete closing set of the executed Transaction Documents, Securities,
Parent Underlying Shares and any other document required to be delivered to any party pursuant to Section 7 hereof or otherwise.

 

(bb)  Information
Related to Sanofi. Notwithstanding anything to the contrary provided herein or elsewhere including, but not limited to, any
of the other Transaction Documents, and in addition to all other requirements of the Parent, ICA-T and each Subsidiary to provide
to the Buyer and the Buyer’s rights to obtain from the Parent, ICA-T and each Subsidiary, whether provided in this Agreement
and/or any other Transaction Document, the Parent and ICA-T shall immediately but no later than two (2) business days or three
(3) calendar days following (i) ICA-T and/or the Parent becoming aware of and/or receipt by any such party from Sanofi, the Trustee
(as defined in the S/I Deed of Trust) and/or any of their respective affiliates, officers, directors, agents and/or representatives
of notice (whether oral, in writing or otherwise) of any event of default (or any event that with the passage of time or the giving
of notice (or both) would constitute an event of default), a default and/or a breach by the ICA-T and/or the Parent under any
of the Sanofi Documents (including, but not limited to, any sale and/or notice of any intended sale of the Property/Facilities
and/or any foreclosure or notice of foreclosure relating to the Property/Facilities including under the S/I Deed of Trust, any
intended or actual termination of any Sanofi Documents and/or any claim made against ICA-T and/or the Parent including a claim
for indemnification under any S/I Document (even if contemplated in any such of the following documents) to the S/I MSA, the S/I
Deed of Trust and/or the S/I APA.

 

(cc)  
Conversion/Exercise Procedures. The form of Conversion Notice (as defined in the Note) and Notice of Exercise (as defined
in the Parent Warrant) set forth the totality of the procedures required of the Buyer in order to convert the Notes and/or exercise
the Parent Warrant. Except as provided in Section 5(c), no additional legal opinion, other information or instructions
shall be required of the Buyer to convert their Notes or exercise their Parent Warrant. The Parent shall honor conversions of
the Notes and exercises of the Parent Warrant and shall deliver the Parent Underlying Shares in accordance with the terms, conditions
and time periods set forth in the Notes and the Parent Warrant.

 

    	 	42	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(dd)   [INTENTIONALLY
LEFT BLANK]

 

(ee)   No
Foreign Subsidiaries. None of the Parent, ICA-T and/or any Subsidiary shall directly and/or indirectly make any direct and/or
indirect payment in any form and/or manner (including, but not limited to, dividends and/or distributions and/or otherwise to
or for the benefit of any Foreign Subsidiary without the express prior written consent of the Buyer so long as any Securities
remain outstanding.

 

(ff)    Information
Rights. For so long any of the Notes remain outstanding, but prior to the closing date of the earliest to occur of a (i) Qualified
PO, (ii) the sale of all of substantially all of the assets of the Parent, ICA-T and the Subsidiaries, and (iii) the sale of all
of the issued and outstanding securities of the Parent, ICA-T and the Subsidiaries, and regardless of whether or not the Parent
is required to file any forms, reports or documents with the SEC, the Parent and ICA-T shall deliver to the Buyer, the following
financial statements and/or information of the Parent, ICA-T and the Subsidiaries and the Buyer hereby consents to the delivery
of the information set forth below in accordance with the terms hereof despite the fact that such information may constitute Confidential
Information, provided that the Parent, the Company and/or each Subsidiary who is providing any such information to the Buyer,
shall inform the Buyer in writing at least three (3) Business Days prior to the date any such information is actually delivered
to the Buyer (“Information Delivery Date”), and the Buyer shall have the right until 11:59pm on the date 2
Business Days from the date the Buyer received written notice that such information was being delivered to it, to inform the Parent
that the Buyer does not want to receive such information and as a result thereof, such information shall not be delivered to the
Buyer:

 

(I)       Within
twenty one (21) calendar days after the end of each calendar month (with May 2017 being the first month) (A) unaudited interim
and year-to-date financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable),
including balance sheet and related statements of income and cash flows, (B) monthly accounts receivable and accounts payable
statements as of the last day of each month, and which items set forth in (A)–(B) shall be accompanied by a report detailing
any material contingencies (including the commencement of any material litigation by or against the Parent, ICA-T and the Subsidiaries)
or any other occurrence that would reasonably be expected to have a Material Adverse Effect on the Parent, ICA-T and the Subsidiaries,
all certified in writing by the Parent’s and ICA-T’s Chief Executive Officer and Chief Financial Officer stating that
they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal
year-end adjustments;

 

(II)       Within
forty five (45) calendar days (or 50 calendar days if the Parent files a Notification of Late filing on Form 12b-25 with the SEC
(a “12b-25”) for such period) after the end of each calendar quarter (A) unaudited interim and year-to-date
financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable),
including balance sheet and related statements of income and cash flows, and (B) monthly accounts receivable and accounts payable
statements as of the last day of each month accompanied by a report detailing any material contingencies (including the commencement
of any material litigation by or against the Parent, ICA-T and the Subsidiaries) or any other occurrence that would reasonably
be expected to have a Material Adverse Effect on the Parent, ICA-T and the Subsidiaries, certified by the Parent’s and ICA-T’s
Chief Executive Officer and Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except
(i) for the absence of footnotes, and (ii) that they are subject to normal year-end adjustments. The Parent and ICA-T shall provide
both such information, the most recent capitalization table for the Parent, ICA-T and the Subsidiary, including the exercise price
of all employee stock options and other securities issued during such period, as certified by the CEO and CFO of the Parent and
ICA-T;

 

    	 	43	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(III)       within
ninety (90) calendar days (or one hundred twenty (120) calendar days if the Parent files a 12b-25 for such period)) after the
end of each fiscal year audited financial statements as of the end of such year (prepared on a consolidated and consolidating
basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative
form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants
selected by the Parent and reasonably acceptable to the Collateral Agent, accompanied by any management report from such accountants,
and (B) monthly accounts receivable and accounts payable statements as of the last day of each month of the Parent, ICA-T and
the Subsidiaries. The Parent also shall provide to the Buyer with such information the most recent capitalization table for the
Parent, ICA-T and each of their respective Subsidiaries, including the exercise price of all employee stock options and other
securities issued during such period, as certified by the CEO and CFO of the Parent and ICA-T;

 

(IV)       Additionally,
no later than the twenty first (21st) Business Day from the last calendar day of each calendar month, the Parent and
ICA-T shall deliver to the Buyer (simultaneously with the information required in Section 4(ff)(I)) monthly account payable
and account receivable statements.

 

(V)       All
monthly, quarterly and annual information required to be provided by the Parent and ICA-T to the Buyer shall be in writing and
in form and substance reasonably satisfactory to the Buyer. All such information shall be certified in a writing signed by the
Parent’s and ICA-T’s Chief Executive Officer and Chief Financial Officer as being true and correct.

 

(VI)       In
addition to the above, upon request from the Buyer, the Parent and ICA-T shall provide the Buyer, no later than the third (3rd)
Business Day of any request, a status update on matters relating to the business and operations of the Parent, ICA-T and the Subsidiaries,
including, but not limited to, manufacturing and capital expenditures, shipment of products, sales pipeline, decisions of the
board of directors of the Parent, ICA-T and the Subsidiaries and regulatory and licensing issues, and such information and such
other information including, but not limited to, status updates, clarifications of previously provided information including supporting
documentation and written explanations.

 

(VII)       The
Parent and ICA-T may satisfy its obligations under clauses “II” and “III” of this Section 4(ff)(II)
and (III) (as applicable) by delivery (i) for each calendar quarter, a quarterly report on Form 10-Q for such quarter, if
timely filed with the SEC in accordance with SEC rules and regulations, and (ii) for each calendar year, an Annual Report on Form
10-K for such year, if timely filed with the SEC in accordance with SEC rules and regulations.

 

(gg)   Reservation
of Shares. So long as any of the Notes and/or the Parent Warrant remain outstanding, the Parent and ICA-T shall take all action
necessary to at all times have authorized, and reserved for the purpose of issuance, no less than the sum of (x) the sum of (A)
ICA-T’s Required Reserve Amount (as defined in and related to ICA-T Note), and (B) the Parent’s Required Reserve Amount
(as defined in and related to the Parent Note), plus (y) the Required Reserved Amount (as defined in and relating to the Parent
Warrant) (collectively, the “SPA Required Reserve Amount”); provided that at no time shall the number of shares
of Parent Common Stock reserved pursuant to this Section 4(gg) be reduced. If at any time the number of shares of Parent
Common Stock authorized and reserved for issuance is not sufficient to meet the SPA Required Reserve Amount (an “Authorized
Share Failure”), the Parent shall immediately take all action necessary to increase the Parent authorized shares of
Parent Common Stock to an amount sufficient to allow the Parent to reserve the SPA Required Reserve Amount. Without limiting the
generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure,
but in no event later than ninety (90) days after the occurrence of such Authorized Share Failure, the Parent shall either (i)
hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Parent Common Stock or
(ii) have rectified such Authorized Share Failure by increasing the required SPA Reserve Amount by obtaining approval by written
request of the required percentage of issued and outstanding shares of Parent Common Stock and having taken all other such actions
to effectuate the same. In connection with a meeting described in “(i)” above, the Parent shall provide each stockholder
with a proxy statement and shall use its best efforts to solicit its stockholders’ approval of such increase in authorized
shares of Parent Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal.
Nothing contained in this Section 4(gg) shall limit any obligations of the Parent and/or ICA-T under any provision of the
Transaction Documents.

 

    	 	44	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		5.	REGISTER;
                                         LEGEND.

 

(a)       Register.
(i) The Parent (and ICA-T as to the ICA-T Note) shall maintain at its principal executive offices (or such other office or agency
of the Parent (or ICA-T with regard to holders of any ICA-T Notes) as it may designate by notice to each holder of Securities),
a register for the Notes, the Parent Warrant and the Parent Underlying Shares in which the Parent shall record the name and address
of the Person in whose name the Notes, the Parent Warrant and the Parent Underlying Shares have been issued; provided that such
information is provided to the Parent by the Buyer (including the name and address of each transferee) and the principal amount
of the Notes held by such Person and number of shares issuable upon exercise of the Parent Warrant. The Parent shall keep the
register open and available at all times during business hours for inspection of the Buyer or its legal representatives.

 

(b)       Legends.
The Buyer understands that the Securities have been and will be issued pursuant to an exemption from registration or qualification
under the 1933 Act and applicable state securities laws, and except as set forth below, the Securities shall bear any legend as
required by the “blue sky” laws of any state and a restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of such stock certificates):

 

[NEITHER
THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR APPLICABLE STATE SECURITIES LAWS.][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR (B) AN OPINION OF COUNSEL TO THE HOLDER OR THE PARENT IN A FORM REASONABLY ACCEPTABLE TO THE PARENT, THAT REGISTRATION IS NOT
REQUIRED UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

[NEITHER
THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE ACCEPTABLE TO THE PARENT. THESE SECURITIES
AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED
BY SUCH SECURITIES.]

 

    	 	45	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(c)       
Transfer Agent Instructions. The Parent and ICA-T shall issue irrevocable instructions to the Transfer Agent and any subsequent
transfer agent (as applicable, the “Transfer Agent”) in the form annexed hereto as Exhibit J
(the “Irrevocable Transfer Agent Instructions”) to issue certificates or credit shares to the applicable balance
accounts at The Depository Trust Company (“DTC”), registered in the name of the Buyer or its respective nominee(s),
for the shares of Parent Common Stock issuable upon conversions of the Notes and exercise of the Parent Warrant in such amounts
as specified from time to time by the Buyer to the Parent and ICA-T upon conversions of the Notes and/or exercises of the Parent
Warrant. The Parent and ICA-T each represent and warrant that no instruction other than the Irrevocable Transfer Agent Instructions
referred to in this Section 5(c), and stop transfer instructions to give effect to Section 2(g) hereof, will be
given by the Parent and ICA-T to the Transfer Agent with respect to the Securities, and that the Securities (as the case may be)
and ending on the date of receipt by the Buyer of such shares without restrictive legend and the required payment. Such shares
shall be freely transferable on the books and records of the Parent and ICA-T, as applicable, to the extent provided in this Agreement
and the other Transaction Documents. If the Buyer effects a sale, assignment or transfer of the Securities in accordance with
Section 2(g), the Parent and ICA-T shall permit the transfer and shall promptly instruct the Transfer Agent to issue one
or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified
by the Buyer to effect such sale, transfer or assignment. In the event that such sale, assignment or transfer involves shares
of Parent Common Stock issuable upon conversions of the Notes or exercise of the Parent Warrant sold, assigned or transferred
pursuant to an effective registration statement or in compliance with Rule 144, the Transfer Agent shall issue such shares of
Parent Common Stock to the Buyer, assignee or transferee (as the case may be) without any restrictive legend in accordance with
Section 5(d) below. The Parent and ICA-T each acknowledge that a breach by it of its obligations hereunder will cause irreparable
harm to the Buyer and/or any of its assignees and/or transferees. Accordingly, the Parent and ICA-T acknowledge that the remedy
at law for a breach of its obligations under this Section 5(c) will be inadequate and agrees, in the event of a breach
or threatened breach by the Parent and ICA-T of the provisions of this Section 5(c), the Buyer and/or any of its assignees
and/or transferees shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any
breach and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other
security being required. The Parent shall cause its legal counsel to issue the legal opinion referred to in the Irrevocable Transfer
Agent Instructions to the Parent’s Transfer Agent on each Effective Date. Any fees (with respect to the Transfer Agent,
DTC, counsel to the Parent or otherwise) associated with the issuance of such opinion or the removal of any legends on any of
the Securities shall be borne by the Parent.

 

(d)       Removal
of Legends. Certificates evidencing the Securities shall not be required to contain the legend set forth in Section 5(b)
above or any other legend (i) while a registration statement (including a Registration Statement) covering the resale of such
Securities is effective under the 1933 Act, (ii) following any sale of such Securities (as the case may be), pursuant to Rule
144 (assuming the transferor is not an affiliate of the Parent or ICA-T), (iii) if such Securities (as the case may be), are eligible
to be sold, assigned or transferred under Rule 144 (provided that the Buyer provides the Parent with reasonable assurances that
such Securities are eligible for sale, assignment or transfer under Rule 144 which shall not include an opinion of Buyer’s
counsel), (iv) in connection with a sale, assignment or other transfer (other than under Rule 144), provided that the Buyer provides
the Parent with an opinion of counsel to the Buyer, in a form reasonably acceptable to the Parent, to the effect that such sale,
assignment or transfer of the Securities may be made without registration under the applicable requirements of the 1933 Act, (v)
if legal counsel to the Parent and/or ICA-T provides the legal opinion required pursuant to Section 4(a)(xxi) of the ICA-T Note
or otherwise, or (vi) if such legend is not required under applicable requirements of the 1933 Act (including, without limitation,
controlling judicial interpretations and pronouncements issued by the SEC). If a legend is not required pursuant to the foregoing,
the Parent shall no later than two (2) Trading Days (as defined in the Notes) (or such earlier date as required pursuant to the
1934 Act or other applicable law, rule or regulation for the settlement of a trade initiated on the date the Buyer delivers such
legended certificate representing such Securities to the Parent) following the delivery by the Buyer to the Parent or its Transfer
Agent (with notice to the Parent) of a legended certificate representing such Securities (endorsed or with stock powers attached,
signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer, if applicable), together with
any other deliveries from the Buyer as may be required above in this Section 5(d), as directed by the Buyer, either: (A)
provided that the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program and such Securities are
shares of Parent Common Stock credit the aggregate number of shares of Parent Common Stock to which the Buyer shall be entitled
to the Buyer’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system or (B)
if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via reputable
overnight courier) to the Buyer, a certificate representing such Securities that is free from all restrictive and other legends,
registered in the name of the Buyer or its designee (the date by which such credit is so required to be made to the balance account
of such Buyer’s or such Buyer’s designee with DTC or such certificate is required to be delivered to such Buyer pursuant
to the foregoing is referred to herein as the “Required Delivery Date”, and the date such shares of Parent
Common Stock are actually delivered without restrictive legend to such Buyer or such Buyer’s designee with DTC, as applicable,
the “Share Delivery Date”). The Parent shall be responsible for any transfer agent fees or DTC fees with respect
to any issuance of Securities or the removal of any legends with respect to any Securities in accordance herewith.

 

    	 	46	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(e)       Failure
to timely Deliver; Buy-In. If the Parent fails for any reason or no reason, to issue and deliver (or cause to be delivered)
to the Buyer (or its designee) by the Required Delivery Date, either (i) if the Transfer Agent is not participating in the DTC
Fast Automated Securities Transfer Program, a certificate for the number of shares of Parent Common Stock to which the Buyer is
entitled without any restrictive and/or other legend and register such shares of Parent Common Stock on the Parent 's share register,
or (ii) if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit the balance account
of the Buyer or the Buyer’s designee with DTC for the number of shares of Parent Common Stock to which the Buyer submitted
for legend removal by the Buyer pursuant to Section 5(d) above and if on or after such Trading Day the Buyer purchases
(in an open market transaction or otherwise) shares of Parent Common Stock corresponding to all or any portion of Parent Conversion
Shares or Parent Warrant Shares (as the case may be) submitted for legend removal by the Buyer pursuant to Section 5(d)
above that the Buyer is entitled to receive from the Parent (a “Buy-In”), then the Parent shall, within two
(2) Trading Days after the Buyer’s request and in the Buyer’s discretion, either (i) pay cash to the Buyer in an amount
equal to the Buyer’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any, for
the shares of Parent Common Stock so purchased) (the “Buy-In Price”), at which point the Parent’s obligation
to so deliver such certificate or credit the Buyer’s (or its designee’s account) balance account with the DTC through
its Deposit Withdrawal at Custodian System, shall terminate and such shares shall be cancelled, or (ii) promptly honor its obligation
to so deliver to the Buyer a certificate or certificates or credit the balance account of the Buyer or the Buyer’s designee
with the DTC through its Deposit Withdrawal at Custodian System representing such number of Parent Conversion Shares or Parent
Warrant Shares (as the case may be) that would have been so delivered if the Parent timely complied with its obligations hereunder
and pay cash to the Buyer in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of
shares of Parent Conversion Shares or Parent Warrant Shares (as the case may be) that the Parent was required to deliver to the
Buyer by the Required Delivery Date multiplied by (B) the lowest Closing Sale Price or Closing Bid Price (as the case may be and
as defined in the Note) of the Parent Common Stock on any Trading Day during the period commencing on the date of the applicable
Conversion Notice or Exercise Notice (as the case may be) and ending on the date of such delivery and payment under this clause
(ii). Nothing shall limit the Buyer’s right to pursue any other remedies available to it hereunder, at law or in equity,
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Parent’s failure
to timely deliver certificates representing shares of Parent Common Stock (or to electronically deliver such shares of Parent
Common Stock) as required pursuant to the terms hereof.

 

(f)       Transfer
Agent and FAST Compliance. While any Notes or Parent Warrants are outstanding, the Parent shall maintain a Transfer Agent
that participates in the DTC Fast Automated Securities Transfer Program.

 

		6.	CONDITIONS
                                         TO THE PARENT’S AND ICA-T’S OBLIGATION TO SELL.

 

(a)       The
obligation of (i) the Parent to issue and sell the Parent Note and the Parent Warrant, and (ii) ICA-T to issue and sell the ICA-T
Note to the Buyer at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions,
provided that these conditions are for the Parent’s and ICA-T’s sole benefit and may be waived by the Parent or ICA-T
at any time in its sole discretion by providing the Buyer with prior written notice thereof:

 

(A)       The
Buyer shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Parent or ICA-T
(as the case may be).

 

(B)       The
Buyer shall have executed and delivered to the Parent Lock Up Agreement in form and substance reasonably satisfactory to the Buyer
(the “Lock-Up Agreement”)

 

(C)       The
Buyer shall have delivered to (I) the Parent, the Parent Purchase Price and (II) ICA-T, the ICA-T Purchase Price (less the amounts
withheld pursuant to Section 4(h) hereof) for the Parent Note and the Parent Warrant; and the ICA-T Note, respectively,
being purchased by the Buyer at the Closing by wire transfer of immediately available funds in accordance with the Flow of Funds
Letter.

 

    	 	47	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(D)       The
representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and as
of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific
date, which shall be true and correct as of such specific date), and the Buyer shall have performed, satisfied and complied in
all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied
with by the Buyer at or prior to the Closing Date.

 

		7.	CONDITIONS
                                         TO THE BUYER’S OBLIGATION TO PURCHASE.

 

(a)       The
obligation of the Buyer hereunder to purchase the Notes and the Parent Warrant at the Closing is subject to the satisfaction,
at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Buyer’s sole
benefit and may be waived by the Buyer at any time in its sole discretion by providing the Parent and ICA-T with prior written
notice thereof:

 

(i)       (A)
The Parent, ICA-T and each Subsidiary shall have duly executed and delivered to the Buyer each of the Transaction Documents to
which it is a party, and (B (I) the Parent, with regard to the Parent Note and the Parent Warrant initially to purchase 857,143
shares of Parent Common Stock, and (II) ICA-T, with regard to the ICA-T Note, shall have duly executed and delivered to the Buyer
such instruments, respectively.

 

(ii)       The
Buyer shall have received the legal opinion of Gracin & Marlow, LLP, the Parent’s and ICA-T’s corporate securities
counsel, dated the Closing Date, in the form acceptable to the Buyer.

 

(iii)       The
Buyer shall have received the legal opinion of Morgan, Lewis and Bockius LLP, the Parent’s, ICA-T’s and the Subsidiaries’
intellectual property counsel, dated the Closing Date in form and substance acceptable to the Buyer.

 

(iv)       The
Parent and ICA-T shall have delivered to the Buyer a certificate evidencing the formation and good standing of the Parent, ICA-T
and each Subsidiary in each such entity’s jurisdiction of formation issued by the Secretary of State (or comparable office)
of such jurisdiction of formation as of a date within five (5) days of the Closing Date.

 

(v)       The
Parent and ICA-T shall have delivered to the Buyer a certificate evidencing the Parent, ICA-T’s and each Subsidiary’s
qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction
in which the Parent, ICA-T and each Subsidiary conducts business and is required to so qualify, as of a date within five (5) days
of the Closing Date.

 

    	 	48	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(vi)       The
Parent and ICA-T shall have delivered to the Buyer a certified copy of their respective certificate of incorporation as certified
by the Delaware Secretary of State within five (5) days of the Closing Date.

 

(vii)       The
Parent and ICA-T shall have delivered to the Buyer a certified copy of the certificate of incorporation (or such equivalent organizational
document) of each Subsidiary as certified by the Secretary of State (or comparable office) of each such Subsidiary’s jurisdiction
of incorporation within five (5) days of the Closing Date.

 

(viii)       The
Parent, ICA-T and each Subsidiary shall have delivered to the Buyer a certificate, in the form acceptable to the Buyer, executed
by the secretary of the Parent, ICA-T and each Subsidiary dated as of the Closing Date, as to (i) the resolutions consistent with
Section 3(b) as adopted by the Parent’s, ICA-T’s and each Subsidiary’s board of directors in a form acceptable
to the Buyer, (ii) Certificate of Incorporation of each of the Parent, ICA-T and each Subsidiary, and (iii) the Bylaws of the
Parent, ICA-T and each Subsidiary, each as in effect at the Closing.

 

(ix)       Each
and every representation and warranty of the Parent and ICA-T made herein and of the Parent, ICA-T and each Subsidiary in each
other Transaction Document shall be true and correct as of the date when made and as of the Closing Date as though originally
made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct
as of such specific date) and the Parent, ICA-T and each Subsidiary shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Parent, ICA-T
and each Subsidiary at or prior to the Closing Date. The Buyer shall have received a certificate, duly executed by the Chief Executive
Officer of the Parent, ICA-T and each Subsidiary, dated as of the Closing Date, to the foregoing effect and as to such other matters
as may be reasonably requested by the Buyer in the form acceptable to the Buyer.

 

(x)       The
Parent and ICA-T shall have obtained all governmental, regulatory and third party consents and approvals, if any, necessary for
the sale of the Securities.

 

(xi)       No
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or Governmental Entity of competent jurisdiction that prohibits the consummation of any of the transactions contemplated
by the Transaction Documents.

 

(xii)       No
event or series of events shall have occurred that reasonably could or result in a Material Adverse Effect.

 

    	 	49	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(xiii)       In
accordance with the terms of the Security Documents, the Parent and ICA-T shall have delivered to the Collateral Agent (A) original
certificates (I) representing 100% of outstanding capital stock of each Subsidiary (other than ICA-T) to the extent such Subsidiary
is a corporation or otherwise has certificated equity and (II) representing all other equity interests to be pledged thereunder,
in each case, accompanied by undated stock powers executed in blank and other proper instruments of transfer and (B) appropriate
financing statements on Form UCC-1 and such other financing or similar statement to be filed with the United States Patent and
Trademark Office and/or any other governmental body or agency to be duly filed in such office or offices as may be necessary or,
in the opinion of the Collateral Agent, desirable to perfect the security interests purported to be created by each Security Document
(the “Perfection Certificate”).

 

(xiv)       Within
two (2) Business Days prior to the Closing, the Parent and ICA-T shall have delivered or caused to be delivered to the Buyer and
the Collateral Agent a perfection certificate, duly completed and executed by the Parent, ICA-T and each Subsidiary, in form and
substance satisfactory to the Buyer.

 

(xv)       The
Collateral Agent shall have received the Security Agreements and the other Security Documents, duly executed by the Parent, ICA-T
and each Subsidiary (as applicable).

 

(xvi)       With
respect to the Intellectual Property of the Parent, ICA-T and each Subsidiary, the Parent, ICA-T and each Subsidiary shall have
duly executed and delivered to the Collateral Agent and the Buyer the Intellectual Property Security Agreements and Assignment
for Security for the Intellectual Property of the Parent, ICA-T and each Subsidiary, in the form attached as Exhibit A to the
Security Agreements.

 

(xvii)       Each
Control Account Bank (as defined in the Security Agreement), the Collateral Agent and each of the Parent, ICA-T and the Subsidiaries
(as applicable) shall have duly executed and delivered to the Buyer a Controlled Account Agreement (as defined in the Security
Agreement) with respect to each account of the Parent, ICA-T and each of the Subsidiaries held at each Control Account Bank; provided,
however, that notwithstanding anything to the contrary provided herein or elsewhere, the Closing conditions set forth in
this “(xvii)” shall if not satisfied at Closing, become a “post-Closing condition” and shall be satisfied
if all duly executed Collateral Account Agreements are delivered to the Collateral Agent with fourteen (14) calendar days from
the Closing Date.

 

(xviii)       The
Buyer shall have received a letter on the letterhead of the Parent and ICA-T, duly executed by the Chief Executive Officer of
the Parent and ICA-T, setting forth the wire amounts of the Buyer and the wire transfer instructions of the Parent and ICA-T (the
“Flow of Funds Letter”).

 

(xix)       The
Parent shall have delivered to the Buyer fully executed Pay-Off Letters from each holder of the Parent Bridge Notes demonstrating
that the $1,500,000 aggregate principal amount of and all accrued but unpaid interest thereon has been paid in full and such other
executed documents reasonably requested by the Buyer demonstrating that all Liens and security interests in any assets of the
Parent, ICA-T and/or any Subsidiary securing such Parent Bridge Notes have been terminated including, but not limited to, the
filing of any Lien termination and/or release documents with any Governmental Entity including a UCC-3 Termination Statement (whether
such is required to be signed or not).

 

    	 	50	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(xx)       The
Parent and ICA-T shall have delivered to the Buyer a copy of the Irrevocable Transfer Agent Instructions, in the form and substance
reasonably acceptable to the Buyer, fully executed by the Parent, ICA-T and the Buyer which instructions shall have been delivered
to and acknowledged by execution thereof by the Transfer Agent.

 

(xxi)       
The Parent and ICA-T shall have duly executed and delivered to the Buyer the Leak-Out Agreement.

 

(xxii)       The
Buyer shall have received the fully executed Buyer Deed of Trust with proof of filing with the appropriate Governmental Entity
and such other documents necessary and/or reasonably requested by the Buyer to satisfy itself it has a senior secured interest
in and a perfected Lien on the Property/Facilities securing all Indebtedness and other obligations of ICA-T to the Buyer.

 

(xxiii)       The
Parent shall have delivered to the Buyer a stockholder list dated within 2 days of the Closing Date from and certified by the
Transfer Agent showing (I) the number of shares of Parent Common Stock issued and outstanding, (II) the number of shares of Parent
Common Stock that (x) contain 1933 Act restrictive legends, (y) that are unlegended, and (II) the number of shares that are held
by “Cede & Co.”

 

(xxiv)       [INTENTIONALLY
LEFT BLANK.]

 

(xxv)       The
Buyer shall have received legal opinion of Ballard Spahr LLP, real property legal counsel to the Parent and ICA-T as to matters
relating to, among other related matters, the Property/Facilities, the Deed of Trust, the Buyer Deed of Trust, the security interests
created in the Collateral and the Liens evidencing a security interest in such Collateral and the perfection thereof including,
but not limited to, the Property/Facilities, dated the Closing Date in form and substance acceptable to the Buyer.

 

(xxvi)       The
Parent, ICA-T and the Subsidiaries shall have delivered to the Buyer such other documents, instruments, opinions or certificates
relating to the transactions contemplated by this Agreement as the Buyer or its counsel may reasonably request.

 

(xxvii)       The
Parent and ICA-T shall have delivered to the Buyer a fully executed Pay-off Letter in the form attached hereto as Exhibit
K.

 

    	 	51	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(xxviii)       
The Parent and ICA-T shall execute and deliver to the Collateral Agent separate Confession of Judgments in the form attached hereto
as Exhibit M (the “Confession of Judgments”), with such other documents, affidavits and related
items as are deemed necessary and/or advisable by counsel to the Buyer.

 

(xxix)       The
Parent and each Subsidiary (other than ICA-T) shall have delivered to the Collateral Agent the fully executed Guaranty Agreements.

 

		8.	MISCELLANEOUS.

 

(a)       Governing
Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of New York. The Parent and ICA-T hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder
or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that
the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address
for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by law. Nothing contained herein shall be deemed or operate to preclude the Buyer from bringing suit or taking other legal action
against the Parent and ICA-T in any other jurisdiction to collect on the Parent’s and ICA-T’s obligations to the Buyer
or to enforce a judgment or other court ruling in favor of the Buyer. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION
DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED
HEREBY OR THEREBY.

 

(b)       Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that
any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of
an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

    	 	52	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(c)       Headings;
Gender. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine,
feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include”
and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,”
“hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision
in which they are found.

 

(d)       Severability;
Maximum Payment Amounts. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or
unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable
shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability
of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so
modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof
and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred
upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s). Notwithstanding anything to the contrary contained in this Agreement or any other Transaction Document (and without
implication that the following is required or applicable), it is the intention of the parties that in no event shall amounts and
value paid by the Parent, ICA-T and/or any of the Subsidiaries (as the case may be), or payable to or received by the Buyer, under
the Transaction Documents (including without limitation, any amounts that would be characterized as “interest” under
applicable law) exceed amounts permitted under any applicable law. Accordingly, if any obligation to pay, payment made to the
Buyer, or collection by the Buyer pursuant the Transaction Documents is finally judicially determined to be contrary to any such
applicable law, such obligation to pay, payment or collection shall be deemed to have been made by mutual mistake of the Buyer,
the Parent, ICA-T and/or any of the Subsidiaries and such amount shall be deemed to have been adjusted with retroactive effect
to the maximum amount or rate of interest, as the case may be, as would not be so prohibited by the applicable law. Such adjustment
shall be effected, to the extent necessary, by reducing or refunding, at the option of the Buyer, the amount of interest or any
other amounts which would constitute unlawful amounts required to be paid or actually paid to the Buyer under the Transaction
Documents. For greater certainty, to the extent that any interest, charges, fees, expenses or other amounts required to be paid
to or received by the Buyer under any of the Transaction Documents or related thereto are held to be within the meaning of “interest”
or another applicable term to otherwise be violative of applicable law, such amounts shall be pro-rated over the period of time
to which they relate.

 

    	 	53	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(e)       Entire
Agreement; Amendments. This Agreement, the other Transaction Documents and the schedules and exhibits attached hereto and
thereto and the instruments referenced herein and therein supersede all other prior oral or written agreements between the Buyer,
the Parent, ICA-T and/or any of the Subsidiaries, their respective affiliates and Persons acting on their behalf, including, without
limitation, any transactions by the Buyer with respect to Parent Common Stock or the Securities, and the other matters contained
herein and therein. For clarification purposes, the Recitals are part of this Agreement. No provision of this Agreement may be
amended other than by an instrument in writing signed by the Parent and ICA-T and the Buyer, and any amendment to any provision
of this Agreement made in conformity with the provisions of this Section 9(e) shall be binding on the Buyer and holders
of Securities, as applicable. No waiver shall be effective unless it is in writing and signed by an authorized representative
of the waiving party. As a material inducement for the Buyer to enter into this Agreement, the Parent and ICA-T expressly acknowledges
and agrees that (x) no due diligence or other investigation or inquiry conducted by the Buyer, any of its advisors or any of its
representatives shall affect the Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to
any of, the Parent and ICA-T’s representations and warranties contained in this Agreement or any other Transaction Document
and (y) unless a provision of this Agreement or any other Transaction Document is expressly preceded by the phrase “except
as disclosed in the SEC Documents,” (or a substantially similar term) nothing contained in any of the SEC Documents shall
affect the Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Parent and
ICA-T’s representations and warranties contained in this Agreement or any other Transaction Document.

 

(f)       Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when
sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party) or electronic mail; or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery
specified, in each case, properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses
for such communications shall be:

 

If
to the Parent:

 

Icagen,
Inc.

4222
Emperor Blvd., Suite 350

Research
Triangle Park

Durham,
NC 27703

Telephone:
(919) 941-5206

Facsimile:
(919) 941-0813

Attention:
Richard Cunningham, Chief Executive Officer

Email:
rcunningham@icagen.com

 

with
a copy (for informational purpose only) to:

 

Gracin
& Marlow, LLP

The
Chrysler Building

405
Lexington Avenue, 26th Floor

New
York, NY 10174

Telephone:
(212) 907-6457

Facsimile:
(212) 208-4657

Attention:
Leslie Marlow, Esq.

Email:
lmarlow@gracinmarlow.com

 

If
to ICA-T:

 

Icagen-T,
Inc.

2090
E. Innovation Park Drive

Oro
Valley, Arizona 85755

Telephone:
(520) 544-6800

Facsimile:
(520) 544-6805

Attention:
Richie Cunningham

Email:
rcunningham@icagen.com

 

    	 	54	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

with
a copy (for informational purpose only) to:

 

Gracin
& Marlow, LLP

The
Chrysler Building

405
Lexington Avenue, 26th Floor

New
York, NY 10174

Telephone:
(212) 907-6457

Facsimile:
(212) 208-4657

Attention:
Leslie Marlow, Esq.

Email:
lmarlow@gracinmarlow.com

 

If
to the Buyer:

 

GPB
Debt Holdings II, LLC

535
West 24th Street, 4th Floor

New
York, NY 10011

Telephone:
(212) 558-9199

Facsimile:
(212) 235-2651

Attention:
Tim Creutz

Email:
tcreutz@gpb-cap.com

 

with
a copy (for informational purpose only) to:

 

Gusrae
Kaplan Nusbaum PLLC

120
Wall Street

New
York, NY 10005

Telephone
(212) 269-1400

Facsimile:
(212) 809-4147

Attention:
Lawrence G. Nusbaum, Esq.

Email:
lnusbaum@gusraekaplan.com

 

or
to such other address, e-mail address and/or facsimile number and/or to the attention of such other Person as the recipient party
has specified by written notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation
of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically
generated by the sender’s facsimile machine or e-mail containing the time, date, recipient facsimile number and, with respect
to each facsimile transmission, an image of the first page of such transmission or (C) provided by an overnight courier service
shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance
with clause (i), (ii) or (iii) above, respectively.

 

(g)       Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns, including any purchasers of any of the Notes, Parent Warrant and Parent Underlying Shares. Neither the Parent nor
ICA-T shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the Buyer, including,
without limitation, by way of a Fundamental Transaction (as defined in the Notes and Parent Warrant) (unless the Parent and ICA-T
are in compliance with the applicable provisions governing Fundamental Transactions set forth in the Notes and Parent Warrants).
The Buyer may assign some or all of its rights hereunder in connection with any transfer of any of its Securities to an Affiliate
of the Buyer without the consent of the Parent and ICA-T, in which event such assignee shall be deemed to be a “Buyer”
hereunder with respect to such assigned rights.

 

    	 	55	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(h)       No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, other than
the Indemnitees referred to in Section 8(k).

 

(i)       Survival.
The representations, warranties, agreements and covenants shall survive the Closing.

 

(j)       Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

(k)       Indemnification.

 

(i)       In
consideration of the Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities thereunder
and in addition to all of the Parent and ICA-T’s other obligations under the Transaction Documents, to the full extent required
by law, the Parent and ICA-T each will and hereby does, jointly and severally, defend, protect, indemnify and hold harmless the
Buyer and each other holder of any Securities and all of their predecessors, successors, advisors, stockholders, partners, members,
managers, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents or other
representatives including in-house and outside legal counsels (including, without limitation, those retained in connection with
the transactions contemplated by this Agreement) (collectively, the “Indemnitees”) from and against any and
all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection
therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought),
and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred
by any Indemnitee as a result of, or arising out of, or relating to (i) any misrepresentation or breach of any representation
or warranty made by the Parent, ICA-T and/or any of the Subsidiaries in any of the Transaction Documents, (ii) any breach of any
material covenant, agreement or obligation of the Parent, ICA-T and/or any of the Subsidiaries contained in any of the Transaction
Documents or (iii) any cause of action, suit, arbitration, proceeding or claim brought or made against such Indemnitee by a third
party (including for these purposes a derivative action brought on behalf of the Parent, ICA-T and/or any of the Subsidiaries)
or which otherwise involves such Indemnitee that arises out of or results from (A) the execution, delivery, performance or enforcement
of any of the Transaction Documents, (B) any of the transactions contemplated by any of the Transaction Documents including, but
not limited to, any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the
issuance of the Securities, (C) any disclosure properly made by the Buyer pursuant to Section 4(i), or (D) the status of
the Buyer or any other holder of the Securities either as an investor in the Parent and ICA-T pursuant to the transactions contemplated
by the Transaction Documents or as a party to this Agreement and/or any other Transaction Document (including, without limitation,
as a party in interest or otherwise in any action or proceeding for injunctive or other equitable relief). To the extent that
the foregoing undertaking by the Parent and ICA-T may be unenforceable for any reason, the Parent and ICA-T shall and shall cause
each Subsidiary to make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which
is permissible under applicable law. The rights and remedies of an Indemnitee and the obligations and responsibilities of the
Parent and ICA-T as set forth in this Section 8(k) are in addition and not in limitation to those set forth in Section
8(q) of this Agreement.

 

    	 	56	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(ii)       Promptly
after receipt by an Indemnitee under this Section 8(k) of notice of the commencement of any action or proceeding (including
any governmental or regulatory action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim in
respect thereof is to be made against the Parent and ICA-T under this Section 8(k), deliver to the Parent and ICA-T a written
notice of the commencement thereof, and the Parent and ICA-T shall have the right to participate in, and, to the extent the Parent
and ICA-T so desires, to assume control of the defense thereof with counsel mutually satisfactory to the Parent and ICA-T and
the Indemnitee; provided, however, that an Indemnitee shall have the right to retain its own counsel with the fees
and expenses of such counsel to be paid by the Parent and ICA-T if: (A) the Parent and ICA-T has agreed in writing to pay such
fees and expenses; (B) the Parent and ICA-T shall have failed promptly to assume the defense of such Indemnified Liability and
to employ counsel reasonably satisfactory to such Indemnitee in any such Indemnified Liability; or (C) the named parties to any
such Indemnified Liability (including any impleaded parties) include both such Indemnitee and the Parent and ICA-T, and such Indemnitee
shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnitee
and the Parent and ICA-T (in which case, if such Indemnitee notifies the Parent and ICA-T in writing that it elects to employ
separate counsel at the expense of the Parent and ICA-T, then the Parent and ICA-T shall not have the right to assume the defense
thereof and such counsel shall be at the expense of the Parent and ICA-T); provided, further, that in the case of
clause (C) above the Parent and ICA-T shall not be responsible for the reasonable fees and expenses of more than one (1) separate
legal counsel for the Indemnitees. The Indemnitee shall reasonably cooperate with the Parent and ICA-T in connection with any
negotiation or defense of any such action or Indemnified Liability by the Parent and ICA-T and shall furnish to the Parent and
ICA-T all information reasonably available to the Indemnitee which relates to such action or Indemnified Liability. The Parent
and ICA-T shall keep the Indemnitee reasonably apprised at all times as to the status of the defense or any settlement negotiations
with respect thereto. The Parent and ICA-T shall not be liable for any settlement of any action, claim or proceeding effected
without its prior written consent, provided, however, that the Parent and ICA-T shall not unreasonably withhold, delay or condition
its consent. The Parent and ICA-T shall not, without the prior written consent of the Indemnitee, consent to entry of any judgment
or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such Indemnitee of a release from all liability in respect to such Indemnified Liability or litigation, and such
settlement shall not include any admission as to fault on the part of the Indemnitee. Following indemnification as provided for
hereunder, the Parent and ICA-T shall be subrogated to all rights of the Indemnitee with respect to all third parties, firms or
corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the Parent
and ICA-T within a reasonable time of the commencement of any such action shall not relieve the Parent and ICA-T of any liability
to the Indemnitee under this Section 8(k), except to the extent that the Parent and ICA-T is materially and adversely prejudiced
in its ability to defend such action.

 

    	 	57	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iii)       All
representations and warranties contained in the Transaction Documents shall survive until the Notes are repaid in full are no
longer outstanding. The covenants and agreements which by their terms do not contemplate performance after the Closing Date shall
survive until the Notes are paid in full are no longer outstanding. The covenants and agreements which by their terms contemplate
performance after the Closing Date shall survive the Closing Date in accordance with their terms until 60 days following the expiration
of any applicable statute of limitations (after giving effect to any waivers and extensions thereof). The indemnification required
by this Section 8(k) shall be made by periodic wire payments of the amount thereof during the course of the investigation
or defense, within ten (10) days after bills are received or Indemnified Liabilities are incurred.

 

(iv)       The
indemnity agreement contained herein shall be in addition to (A) any cause of action or similar right of the Indemnitee against
the Parent and ICA-T or others, B) any liabilities the Parent and ICA-T may be subject to pursuant to the law, and (C) those provided
in Section 8(q)(xi).

 

(l)       Construction.
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and
no rules of strict construction will be applied against any party. No specific representation or warranty shall limit the generality
or applicability of a more general representation or warranty. Each and every reference to share prices, shares of Parent Common
Stock and any other numbers in this Agreement that relate to the Parent Common Stock shall be automatically adjusted for any stock
splits, stock dividends, stock combinations, recapitalizations or other similar transactions that occur with respect to the Parent
Common Stock after the date of this Agreement. It is expressly understood and agreed that for all purposes of this Agreement,
and without implication that the contrary would otherwise be true, neither transactions nor purchases nor sales shall include
the location and/or reservation of borrowable shares of Parent Common Stock.

 

    	 	58	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(m)       Remedies.
The Buyer and in the event of assignment by Buyer of its rights and obligations hereunder, each holder of Securities, shall have
all rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted
at any time under any other agreement or contract and all of the rights which such holders have under any law. Any Person having
any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond
or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights
granted by law. Furthermore, the Parent and ICA-T recognize that in the event that it or any Subsidiary fails to perform, observe,
or discharge any or all of its or such Subsidiary’s (as the case may be) obligations under the Transaction Documents, any
remedy at law may prove to be inadequate relief to the Buyer. The Parent and ICA-T therefore agrees that the Buyer shall be entitled
to seek specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief from any court of
competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security.
The remedies provided in this Agreement and the other Transaction Documents shall be cumulative and in addition to all other remedies
available under this Agreement and the other Transaction Documents, at law or in equity (including a decree of specific performance
and/or other injunctive relief).

 

(n)       Withdrawal
Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the Transaction
Documents, whenever the Buyer exercises a right, election, demand or option under a Transaction Document and the Parent, ICA-T
or their respective Subsidiaries does not timely perform its related obligations within the periods therein provided, then the
Buyer may rescind or withdraw, in its sole discretion from time to time upon written notice to the Parent and ICA-T or such Subsidiary
(as the case may be), any relevant notice, demand or election in whole or in part without prejudice to its future actions and
rights.

 

(o)       Payment
Set Aside; Currency. To the extent that the Parent and ICA-T makes a payment or payments to the Buyer hereunder or pursuant
to any of the other Transaction Documents or the Buyer enforce or exercise their rights hereunder or thereunder, and such payment
or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent
or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Parent
and ICA-T, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign,
state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part
thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred. Unless otherwise expressly indicated, all dollar amounts referred to
in this Agreement and the other Transaction Documents are in United States Dollars (“U.S. Dollars”), and all
amounts owing under this Agreement and all other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated
in other currencies (if any) shall be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on
the date of calculation. “Exchange Rate” means, in relation to any amount of currency to be converted into
U.S. Dollars pursuant to this Agreement, the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant
date of calculation.

 

    	 	59	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(p)       Judgment
Currency.

 

(i)       If
for the purpose of obtaining or enforcing judgment against the Parent and ICA-T in connection with this Agreement or any other
Transaction Document in any court in any jurisdiction it becomes necessary to convert into any other currency (such other currency
being hereinafter in this Section 9(p) referred to as the “Judgment Currency”) an amount due in US Dollars
under this Agreement, the conversion shall be made at the Exchange Rate prevailing on the Business Day immediately preceding:

 

		a.	the
                                         date actual payment of the amount due, in the case of any proceeding in the courts of
                                         New York or in the courts of any other jurisdiction that will give effect to such conversion
                                         being made on such date; or

 

		b.	the
                                         date on which the foreign court determines, in the case of any proceeding in the courts
                                         of any other jurisdiction (the date as of which such conversion is made pursuant to this
                                         Section 9(p)(i)(2) being hereinafter referred to as the “Judgment Conversion
                                         Date”).

 

(ii)       If
in the case of any proceeding in the court of any jurisdiction referred to in Section 9(p)(i)(2) above, there is a change
in the Exchange Rate prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable
party shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted
at the Exchange Rate prevailing on the date of payment, will produce the amount of US Dollars which could have been purchased
with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on the Judgment
Conversion Date.

 

(iii)       Any
amount due from the Parent and ICA-T under this provision shall be due as a separate debt and shall not be affected by judgment
being obtained for any other amounts due under or in respect of this Agreement or any other Transaction Document.

 

    	 	60	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(q)       Registration
Rights, Etc.

 

(i)       Filing;
Effectiveness, Etc. The Parent and ICA-T hereby agree that the Parent shall prepare and file with the SEC an initial Registration
Statement (as defined below) on Form S-3 covering the resale of all of the Registrable Securities (as defined below)subject to
the provisions of Section 8(q)(v) below; provided that such initial Registration Statement shall register for resale at least
the number of shares of Parent Common Stock equal to the Required Registration Amount (as defined below) as of the date such Registration
Statement is initially filed with the SEC; provided further that if Form S-3 is unavailable for such a registration, the
Parent shall use such other form as is required by Section 8(q)(iii). Such initial Registration Statement, and each other
Registration Statement required to be filed pursuant to the terms of this Agreement, shall contain (except if otherwise directed
by the Buyer in accordance with the rules and regulations of the 1933 Act) the “Selling Stockholders” and “Plan
of Distribution” sections in substantially the form provided to the Parent by the Holder within ten (10) days from such
request by the Parent. After the filing of the Registration Statement and each other Registration Statement required to be filed
by the Parent hereunder with the SEC, the Parent shall use its commercially reasonable efforts to cause such Registration Statement
to be declared effective by the SEC (the date the SEC declares the Registration Statement and/or any other Registration Statement
covering Registrable Securities effective shall be the “Effective Date”), as soon as possible, but in no event
later than the applicable Effectiveness Deadline (as defined below). Following the Effective Date, the Parent shall use its commercially
reasonable efforts to ensure the Registration Statement remains effective at all times so that a holder of Registrable Securities
can effectuate sales of such Registrable Securities pursuant to such Registration Statement and such other Registration Statement
until the date three (3) months following the date the ICA-T Note is no longer outstanding. For purposes hereof, the terms “Registrable
Securities” means (i) the shares of Parent Common Stock issuable upon (a) conversion of the ICA-T Note, and (b) conversion
of the Parent Note and/or exercise of the Parent Warrant solely to the extent such shares of Parent Common Stock are required
to be included in a Registration Statement because such shares of Parent Common Stock are not eligible for issuance and/or sale
under Rule 144 without restrictive legend(the “Other Registrable Securities”), and (ii) any capital stock of
the Parent issued or issuable with respect to the Other Registrable Securities and the shares of Parent Common Stock issuable
upon conversion of the ICA-T Note and/or the Other Registrable Securities including, without limitation, (1) as a result of any
stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock of the Parent
into which the shares of Parent Common Stock and/or are converted, exercised or exchanged and shares of capital stock of a Successor
Entity (as defined in the ICA-T Note, the Parent Note and/or the Parent Warrant, as applicable) into which the shares of Parent
Common Stock are converted or exchanged into (but with regard to the Other Registrable Securities, to the extent such Other Registrable
Securities are required to be included in a Registration Statement because they are not eligible for issuance and/or sale under
Rule 144 without restrictive legend), in each case, without regard to any limitations on conversion of the ICA-T Note the Parent
Note and/or the Parent Warrant, as applicable. “Registration Statement” means a registration statement or registration
statements of the Parent filed under the 1933 Act covering Registrable Securities. “Effectiveness Deadline”
means except as provided in Section 8(q)(v), (i) with respect to the initial Registration Statement required to be filed
pursuant to Section 8(q)(i), the date six (6) months following the closing of a Qualifying PO, , and (ii) with respect
to any additional Registration Statements that may be required to be filed by the Parent pursuant to this Section 8(q),
the earlier of (A) ninety (90) calendar days following the date on which the Parent was required to file such additional Registration
Statement (or in the event such Registration Statement receives a “full review” by the Staff (as defined below), the
one hundred twentieth (120th) day following such filing date), and (B) 2nd Business Day after the date the
Parent is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will not be reviewed
or will not be subject to further review. “Required Registration Amount” means, as of any given date, 125%
of the sum of the maximum number of Parent Conversion Shares then issuable upon conversion of the ICA-T Note (assuming for purposes
hereof that (x) the ICA-T Note is convertible at 75% the then Conversion Price (as defined in the Notes) in effect on such given
date, and (y) any such calculation shall not take into account any limitations on the conversion of the ICA-T Note set forth in
the ICA-T Note), all subject to adjustment as provided in Section 8(q)(ii) and/or Section 8(q)(v).

 

(ii)       Sufficient
Number of Registrable Securities Registered. In the event the number of Registrable Securities available under any Registration
Statement is insufficient to cover all of the Registrable Securities required to be covered by such Registration Statement, the
Parent shall amend such Registration Statement (if permissible), or file with the SEC a new Registration Statement (on the shortest
form available therefor, if applicable), or both, so as to cover at least the Required Registration Amount as of the Trading Day
immediately preceding the date of the filing of such amendment or new Registration Statement, in each case, as soon as practicable,
but in any event not later than thirty (30) days after the necessity therefor arises (but taking account of any SEC Staff (the
“Staff”) position with respect to the date on which the Staff will permit such amendment to the Registration
Statement and/or such new Registration Statement (as the case may be) to be filed with the SEC). The Parent shall use its reasonable
best efforts to cause such amendment to such Registration Statement and/or such new Registration Statement (as the case may be)
to become effective as soon as practicable following the filing thereof with the SEC, but in no event later than the applicable
Effectiveness Deadline for such Registration Statement. For purposes of the foregoing provision, the number of shares available
under a Registration Statement shall be deemed “insufficient to cover all of the shares of Parent Common Stock Registrable
Securities” if at any time the number of shares of Parent Common Stock available for resale under the applicable Registration
Statement is less than the Required Registration Amount.

 

    	 	61	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(iii)       Ineligibility
to Use Form S-3. In the event that Form S-3 is not available for the registration of the resale of Registrable Securities
hereunder, the Parent shall (i) register the resale of the Registrable Securities on Form S-1 or another appropriate form reasonably
acceptable to the Buyer and (ii) undertake to register the resale of the Registrable Securities on Form S-3 as soon as such form
is available, provided that the Parent shall maintain the effectiveness of all Registration Statements then in effect until such
time as a Registration Statement on Form S-3 covering the resale of all the Registrable Securities has been declared effective
by the SEC and the prospectus contained therein is available for use.

 

(iv)       Effect
of Failure to File and Obtain and Maintain Effectiveness of any Registration Statement. If the (a) a Registration Statement
covering the resale of all of the Registrable Securities required to be covered thereby (subject to any reduction pursuant to
Section 8(q)(v)) pursuant to this Agreement is not declared effective by the SEC on or before the Effectiveness Deadline
for such Registration Statement (an “Effectiveness Failure”), (it being understood that if on the Business
Day immediately following the Effective Date for such Registration Statement the Parent shall not have filed a “final”
prospectus for such Registration Statement with the SEC under Rule 424(b) (whether or not such a prospectus is technically required
by such rule), the Parent shall be deemed to not have satisfied this clause and such event shall be deemed to be an Effectiveness
Failure), (b) on any day after the Effective Date of a Registration Statement sales of all Registrable Securities required to
be included on such Registration Statement (disregarding any reduction pursuant to Section 8(v) of this Agreement) cannot
be made pursuant to such Registration Statement (including, without limitation, because of a failure to keep such Registration
Statement effective, a failure to disclose such information as is necessary for sales to be made pursuant to such Registration
Statement, a suspension or delisting of (or a failure to timely list) the shares of Parent Common Stock on the Principal Market
(as defined below) or any other limitations imposed by the Principal Market, or a failure to register a sufficient number of shares
of Parent Common Stock or by reason of a stop order) or the prospectus contained therein is not available for use for any reason
(a “Maintenance Failure”), or (c) if a Registration Statement is not effective for any reason or the prospectus
contained therein is not available for use for any reason and either (x) the Parent fails for any reason to satisfy the requirements
of Rule 144(c)(1), including, without limitation, the failure to satisfy the current public information requirement under Rule
144(c) or (y) the Parent has ever been an issuer described in Rule 144(i)(1)(i) or becomes such an issuer in the future, and the
Parent shall fail to satisfy any condition set forth in Rule 144(i)(2) (a “Current Public Information Failure”)
as a result of which the Buyer is unable to sell Registrable Securities without restriction under Rule 144 (including, without
limitation, volume restrictions), then, as partial relief for the damages to the Buyer by reason of any such delay in, or reduction
of, its ability to sell Registrable Securities (which remedy shall not be exclusive of any other remedies available at law or
in equity, including, without limitation, specific performance), the Parent shall pay to the Buyer of Registrable Securities an
amount in cash equal to two (2%) percent of the product of (x) the number of Registrable Securities of the Buyer required hereunder
to be included in such Registration Statement and (y) the Closing Sale Price or Closing Bid Price (as the case may be and as defined
in the ICA-T Note) as of the Trading Day immediately prior to the date a Registration Delay Payment (as defined below) is due
hereunder (1) on the date of such Effectiveness Failure, Maintenance Failure or Current Public Information Failure, as applicable,
and (2) on every thirty (30) day anniversary of (I) an Effectiveness Failure until such Effectiveness Failure is cured; (II) a
Maintenance Failure until such Maintenance Failure is cured; and (III) a Current Public Information Failure until the earlier
of (i) the date such Current Public Information Failure is cured and (ii) such time that such public information is no longer
required pursuant to Rule 144 (in each case, pro-rated for periods totaling less than thirty (30) days). The payments to which
a holder of Registrable Securities shall be entitled pursuant to this Section 8(iv) are referred to herein as “Registration
Delay Payments”, it being understood that no Registration Delay Payments shall be payable to the Buyer with respect
to each Effectiveness Failure, and/or Maintenance Failure or a Current Public Information Failure to the extent (x) such Registration
Delay Payments relate to such Registrable Securities the Buyer elects not to include in such Registration Statement or (y) the
Buyer fails to timely perform its obligations hereunder. Following the initial Registration Delay Payment for any particular event
or failure (which shall be paid on the date of such event or failure, as set forth above), without limiting the foregoing, if
an event or failure giving rise to the Registration Delay Payments is cured prior to any thirty (30) day anniversary of such event
or failure, then such Registration Delay Payment shall be made on the third (3rd) Business Day after such cure. In
the event the Parent fails to make Registration Delay Payments in a timely manner in accordance with the foregoing, such Registration
Delay Payments shall bear interest at the rate of one and one half percent (1.5%) per month (prorated for partial months) until
paid in full. “Principal Market” means the NYSE MKT, New York Stock Exchange, the NASDAQ Global Market, the
NASDAQ Global Select Market, the NASDAQ Capital Market, the OTCQB Market, the OTCQX Market, or the OTC Pink Market, or any successor
or subsequent market or exchange, which is at the time the principal trading exchange or market for the Parent Common Stock, based
upon share volume.

 

    	 	62	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(v)       Offering.
Notwithstanding anything to the contrary contained in this Agreement in the event the staff of the SEC (the “Staff”)
or the SEC seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement as constituting
an offering of securities by, or on behalf of, the Parent, or in any other manner, such that the Staff or the SEC do not permit
such Registration Statement to become effective and used for resales in a manner that does not constitute such an offering and
that permits the continuous resale at the market by the Buyer then the Parent shall reduce the number of shares to be included
in such Registration Statement by the Buyer until such time as the Staff and the SEC shall so permit such Registration Statement
to become effective as aforesaid. In addition, in the event that the Staff or the SEC requires the Buyer to be specifically identified
as an ”underwriter” in order to permit such Registration Statement to become effective, and the Buyer does not consent
to being so named as an underwriter in such Registration Statement, then, in each such case, the Parent shall reduce the total
number of Registrable Securities to be registered on behalf of the Buyer, until such time as the Staff or the SEC does not require
such identification or until the Buyer accepts such identification and the manner thereof. With regard to any reduced Registrable
Securities, upon a written request to the Parent signed by the Buyer, the Parent shall file a registration statement within twenty
(20) days of such request (subject to any restrictions imposed by Rule 415 or required by the Staff or the SEC) for resale by
the Buyer in a manner acceptable to the Buyer, and the Parent shall following such request cause to be and keep effective such
Registration Statement in the same manner as otherwise contemplated in this Agreement for other registration statements hereunder,
in each case until such time as: (i) all Registrable Securities held by the Buyer have been registered and sold pursuant to an
effective Registration Statement in a manner acceptable to the Buyer or (ii) all Registrable Securities may be resold by the Buyer
without restriction (including, without limitation, volume limitations) pursuant to Rule 144 (taking account of any Staff position
with respect to “affiliate” status) and without the need for current public information required by Rule 144(c)(1)
(or Rule 144(i)(2), if applicable) and legal counsel to the Parent provides and opinion to such effect to the Buyer in form reasonably
acceptable to the Buyer or (iii) the Buyer agrees to be named as an underwriter in any such Registration Statement in a manner
acceptable to the Buyer as to all Registrable Securities held by the Buyer and that have not theretofore been included in a Registration
Statement under this Agreement (it being understood that the special demand right under this sentence may be exercised by the
Buyer multiple times and with respect to limited amounts of Registrable Securities in order to permit the resale thereof by the
Buyer as contemplated above).

 

(vi)       Piggyback
Registrations. Without limiting any obligation of the Parent hereunder, under this Agreement and/or under the ICA-T Note,
the Parent Note and/or the Parent Warrant, if at any time following a Qualifying PO, there is not an effective Registration Statement
covering all of the Registrable Securities or the prospectus contained therein is not available for use and the Parent shall determine
to prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others
under the 1933 Act of any of its equity securities (other than on Form S-4 or Form S-8 (each as promulgated under the 1933 Act)
or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or
business or a business combination subject to Rule 145 under the 1933 Act or equity securities issuable in connection with the
Parent’s stock option or other employee benefit plans), then the Parent shall deliver to the Buyer a written notice of such
determination and, if within fifteen (15) days after the date of actual receipt of such notice, the Buyer shall so request in
writing, the Parent shall include in such registration statement all or any part of such shares of Parent Common Stock the Buyer
requests to be registered; provided, however, the Parent shall not be required to register any shares of Parent
Common Stock pursuant to this Section 8(q)(vi) that are the subject of a then-effective Registration Statement.

 

    	 	63	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(vii)       No
Inclusion of Other Securities. Except with respect to a registration statement filed under Section 8(q)(vi), the Parent shall
in no event include any securities other than Registrable Securities on any Registration Statement filed in accordance herewith
without the prior written consent of the Buyer. Until the date 90 days following the Effective Date of a Registration Statement,
the Parent shall not enter into any agreement providing any registration rights to any of its security holders other than the
Buyer, or filed a registration statement or have a previously filed registration statement declared effective by the SEC or file
a prospectus supplement to permit sales of securities pursuant to an already declared effective registration statement for any
holders of its securities, except the Buyer.

 

(viii)       If
the Buyer may be required under applicable securities law to be described in any Registration Statement as an underwriter and
the Buyer consents in writing to so being named an underwriter, upon the written request of the Buyer, the Parent shall make available
for inspection by (i) the Buyer, (ii) legal counsel for the Buyer and (iii) one (1) firm of accountants or other agents retained
by the Buyer (collectively, the “Inspectors”), all pertinent financial and other records, and pertinent corporate
documents and properties of the Parent, ICA-T and each Subsidiary (collectively, the “Records”), as shall be
reasonably deemed necessary by each Inspector, and cause the Parent’s, ICA-T’s and each Subsidiary’s officers,
directors and employees to supply all information which any Inspector may reasonably request; provided, however, each Inspector
shall agree in writing to hold in strict confidence and not to make any disclosure (except to the Buyer or its agents, representatives
and Affiliates) or use of any Record or other information which the Parent’s board of directors determines in good faith
to be confidential, and of which determination the Inspectors are so notified, unless (1) the disclosure of such Records is necessary
to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required under the 1933 Act, (2)
the release of such Records is ordered pursuant to a final, non-appealable subpoena or order from a court or government body of
competent jurisdiction, or (3) the information in such Records has been made generally available to the public other than by disclosure
in violation of this Agreement or any other Transaction Document. The Buyer agrees that it shall, upon learning that disclosure
of such Records is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt
notice to the Parent and allow the Parent, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain
a protective order for, the Records deemed confidential. Nothing herein (or in any other confidentiality agreement between the
Parent and the Buyer, if any) shall be deemed to limit the Buyer’s ability to sell Registrable Securities in a manner which
is otherwise consistent with applicable laws and regulations. If the Buyer may be required under applicable securities law to
be described in any Registration Statement as an underwriter and the Buyer consents to so being named an underwriter, at the request
of the Buyer, the Parent shall furnish to the Buyer, on the date of the effectiveness of such Registration Statement and thereafter
from time to time on such dates as the Buyer may reasonably request (i) a letter, dated such date, from the Parent’s independent
certified public accountants in form and substance as is customarily given by independent certified public accountants to underwriters
in an underwritten public offering, addressed to the Buyer, and (ii) an opinion, dated as of such date, of counsel representing
the Parent for purposes of such Registration Statement, in form, scope and substance as is customarily given in an underwritten
public offering, addressed to the Buyer.

 

    	 	64	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(ix)       In
addition, without limiting any obligation of the Parent under this Agreement, the Parent shall use its reasonable best efforts
either to (i) cause all of the Registrable Securities covered by each Registration Statement to be listed on each securities exchange
on which securities of the same class or series issued by the Parent are then listed, if any, if the listing of such Registrable
Securities is then permitted under the rules of such exchange, (ii) secure designation and quotation of all of the Registrable
Securities covered by each Registration Statement on an Eligible Market (as defined in the ICA-T Note), or (iii) if, despite the
Parent’s reasonable best efforts to satisfy the preceding clauses (i) or (ii) the Parent is unsuccessful in satisfying the
preceding clauses (i) or (ii), without limiting the generality of the foregoing, to use its best efforts to arrange for at least
two market makers to register with the Financial Industry Regulatory Authority (“FINRA”) as such with respect
to such Registrable Securities. In addition, the Parent shall cooperate with the Buyer and any broker or dealer through which
the Buyer proposes to sell its Registrable Securities in effecting a filing with FINRA pursuant to FINRA Rule 5110 as requested
by the Buyer. The Parent shall pay all fees and expenses in connection with satisfying its obligations under this Section 8(q)(ix).

 

(x)       The
obligations of the Parent under this Section 8(q), except those set forth in Section 8(q)(xi) and (xii) shall terminate
three months after the ICA-T Note (and the Parent Note if the shares of Parent Common Stock issuable upon conversion of the Parent
Note constitute Registrable Securities) is no longer outstanding or the Parent has credited to the Buyer’s account at DTC
all Registrable Securities without registration of such shares on any Registration Statement; provided that notwithstanding anything
to the contrary provided herein or elsewhere, the Buyer shall in no event be required to deliver any legal opinion removing any
legend on any Registrable Securities, which obligation to deliver a legal opinion shall be the sole responsibility and expense
of the Parent.

 

(xi)       In
addition to and not in limitation of the rights and remedies of an Indemnitee and the obligations and responsibilities of the
Parent and ICA-T set forth in Section 8(k) hereof or elsewhere, to the fullest extent permitted by law, the Parent and
ICA-T will, and each hereby does, jointly and severally, indemnify, hold harmless and defend the Buyer and each other holder of
Registrable Securities and each of its directors, officers, shareholders, members, partners, employees, agents, advisors, representatives
(and any other Person with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title
or any other title) and each Person, if any, who controls the Buyer within the meaning of the 1933 Act or the 1934 Act and each
of the directors, officers, shareholders, members, partners, employees, agents, advisors, representatives (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title)
of such controlling Persons (each, an “Indemnified Person”), against any losses, obligations, claims, damages,
liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs, reasonable
attorneys’ fees and costs of defense and investigation), amounts paid in settlement or expenses, joint or several, (collectively,
“Claims”) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation
or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or
the SEC, whether pending or threatened, whether or not an Indemnified Person is or may be a party thereto (“Indemnified
Damages”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced
or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material
fact in a Registration Statement or any post-effective amendment thereto or in any filing made in connection with the qualification
of the offering under the securities or other “blue sky” laws of any jurisdiction in which Registrable Securities
are offered (“Blue Sky Filing”), or the omission or alleged omission to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement
of a material fact contained in any preliminary prospectus if used prior to the effective date of such Registration Statement,
or contained in the final prospectus (as amended or supplemented, if the Parent files any amendment thereof or supplement thereto
with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein,
in light of the circumstances under which the statements therein were made, not misleading or (iii) any violation or alleged violation
by the Parent of the 1933 Act, the 1934 Act, any other law, including, without limitation, any state securities law, or any rule
or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to a Registration Statement or (iv)
any violation of this Agreement (the matters in the foregoing clauses (i) through (iv) being, collectively, “Violations”).
The Parent and ICA-T shall reimburse the Indemnified Persons, promptly as such expenses are incurred and are due and payable,
for any legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim.
Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 8(q)(xi):
(i) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon
and in conformity with information furnished in writing to the Parent by such Indemnified Person for such Indemnified Person expressly
for use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto,
if such prospectus was timely made available by the Parent pursuant to Section 3(d); and (ii) shall not apply to amounts
paid in settlement of any Claim if such settlement is effected without the prior written consent of the Parent and/or ICA-T, which
consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any
investigation made by or on behalf of the Indemnified Person and shall survive the transfer of any of the Registrable Securities
by the Buyer pursuant to Section 8(q)(xiii) or elsewhere.

 

    	 	65	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(xii)       To
the extent any indemnification by an Indemnifying party is prohibited or limited by law, the indemnifying party agrees to make
the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 8(q)(xi) to the
fullest extent permitted by law. In addition, as otherwise set forth in this Section 8(q)(xi), the mechanics and procedures
with respect to the rights of the Buyer and the obligations of the Parent and ICA-T under this Section 8(q)(xi) shall be
the same as those set forth in Section 8(k) of this Agreement and the provisions set forth in Section 8(k)(iii)
shall apply to the provisions of this Section 8(q), as applicable.

 

(xiii)       All
or any portion of the rights of the Buyer under this Section 8(q) shall be automatically assignable by the Buyer to any
transferee or assignee (as the case may be) of all or any portion of such Buyer’s Registrable Securities or Notes and/or
Parent Warrant if: (i) the Buyer agrees in writing with such transferee or assignee (as the case may be) to assign all or any
portion of such rights, and a copy of such agreement is furnished to the Parent within a reasonable time after such transfer or
assignment (as the case may be); (ii) the Parent is, within a reasonable time after such transfer or assignment (as the case may
be), furnished with written notice of (a) the name and address of such transferee or assignee (as the case may be), and (b) the
securities with respect to which such registration rights are being transferred or assigned (as the case may be); (iii) immediately
following such transfer or assignment (as the case may be) the further disposition of such securities by such transferee or assignee
(as the case may be) is restricted under the 1933 Act or applicable state securities laws if so required; (iv) at or before the
time the Parent receives the written notice contemplated by clause (ii) of this sentence such transferee or assignee (as the case
may be) agrees in writing with the Parent to be bound by all of the provisions contained herein; (v) such transfer or assignment
(as the case may be) shall have been made in accordance with the applicable requirements of the Securities Purchase Agreement
and the Notes and the Parent Warrant; and (vi) such transfer or assignment (as the case may be) shall have been conducted in accordance
with all applicable federal and state securities laws.

 

(xiv)       Without
limiting any other obligation of the Parent under the Securities Purchase Agreement, the Parent shall use its reasonable best
efforts (I) either to (i) cause all of the Registrable Securities covered by each Registration Statement to be listed on each
securities exchange on which securities of the same class or series issued by the Parent are then listed, if any, (ii) secure
designation and quotation of all of the Registrable Securities covered by each Registration Statement on an Eligible Market (as
defined in the Securities Purchase Agreement), or (iii) if, despite the Parent’s reasonable best efforts to satisfy the
preceding clauses (i) or (ii) the Parent is unsuccessful in satisfying the preceding clauses (i) or (ii), without limiting the
generality of the foregoing, to use its best efforts to arrange for at least two market makers to register with the Financial
Industry Regulatory Authority (“FINRA”) as such with respect to such Registrable Securities, and (II) register
and qualify, unless an exemption from registration and qualification applies, the resale by the Buyer of the Registrable Securities
covered by a Registration Statement under such other securities or “blue sky” laws of all applicable jurisdictions
in the United States, provided this provision “II” shall not require the Parent to qualify to do business in any jurisdiction
where it would not otherwise be required to qualify but for this provision “II.”

 

    	 	66	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(xv)       The
Parent shall permit Gusrae Kaplan Nusbaum PLLC, legal counsel for the Holder (“Legal Counsel”) to review and
comment upon (i) each Registration Statement at least five (5) Business Days prior to its filing with the SEC and (ii) all amendments
and supplements to each Registration Statement (including, without limitation, the prospectus contained therein) (except for Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any similar or successor reports, collectively,
the “Excluded Review Materials”) within a reasonable number of days prior to their filing with the SEC. The
Parent shall promptly furnish to Legal Counsel, without charge (i) copies of any correspondence from the SEC or the Staff to the
Company or its representatives relating to each Registration Statement, provided that such correspondence shall not contain any
material, non-public information regarding the Company or any of its Subsidiaries (as defined in the Securities Purchase Agreement),
(ii) after the same is prepared and filed with the SEC, one (1) copy of each Registration Statement and any amendment(s) and supplement(s)
thereto, including, without limitation, financial statements and schedules, all documents incorporated therein by reference, if
requested by an Investor, and all exhibits, unless such materials are publicly available via EDGAR, and (iii) upon the effectiveness
of each Registration Statement, one (1) copy of the prospectus included in such Registration Statement and all amendments and
supplements thereto.

 

(r)       The
parties agree that the Confession of Judgment relating to each respective Note shall not be filed unless a default has occurred
under such Note, which default has not been cured pursuant to the terms of such Note. Upon the occurrence of any default under
any of the Notes (which default has not been cured in accordance with the Notes), each of ICA-T and the Parent hereby consent
to the filing and enforcement by the Buyer of the Confession of Judgment relating to such Note (or Notes) that are in default.

 

[Signature
pages follow]

 

    	 	67	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

[ICA-T
AND THE PARENT SIGNATURE PAGE]

 

IN
WITNESS WHEREOF, the Buyer, ICA-T and the Parent have caused their respective signature page to this Agreement to be duly
executed as of the date first written above.

 

	 	PARENT:
	 	 	 
	 	ICAGEN,
    INC.
	 	 	 
	 	By:	/s/
Richard Cunningham
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    Chief Executive Officer
	 	 	 
	 	ICA-T:
	 	 
	 	ICAGEN-T,
    INC.
	 	 	 
	 	By:	/s/
Richard Cunningham
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    Chief Executive Officer

 

[END
OF ICA-T AND THE PARENT SIGNATURE PAGE; BUYER SIGNATURE PAGE ON NEXT PAGE]

 

    	 	S-1	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

[BUYER
SIGNATURE PAGE]

 

IN
WITNESS WHEREOF, the Buyer and ICA-T have caused their respective signature page to this Agreement to be duly executed as
of the date first written above.

 

	 	BUYER:
	 	 	 
	 	GPB
    DEBT HOLDINGS II, LLC
	 	 	 
	 	By:	/s/
David Gentile
	 	 	Name:
    David Gentile
	 	 	Title:
    Manager

  

[END
OF BUYER SIGNATURE PAGE]

 

    	 	S-1	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

LIST
OF EXHIBITS AND SCHEDULES

 

EXHIBITS

	 	 	 
		A.	Form
                                         of Note

		B.	Form
                                         of Parent Note

		C.	Form
                                         of Parent Warrant

		D.	Form
                                         of Parent Security Agreement

		E.	Form
                                         of ICA-T Security Agreement

		F.	Form
                                         of Parent Guaranty

		G.	Form
                                         of Subsidiary Guaranty

		H.	Buyer
                                         Deed of Trust

		I.	Organizational
                                         Documents of the Parent and ICA-T

		(i)	By-Laws
                                         (with amendments)

		(ii)	Certificate
                                         of Incorporation (amendments)

		J.	Form
                                         of Irrevocable Transfer Agent Instructions

		K.	Pay-Off
                                         Letter

		L.	[IP
                                         Termination Agreement ]

		M.	Confession
                                         of Judgment

 

SCHEDULES

 

Schedule
3(a) – Subsidiaries

Schedule
3(e) – Consents

Schedule
3(h) – Offerings

Schedule
3(k) – Absence of Material Changes

Schedule
3(l) – Undisclosed Events, Liabilities, Developments or Circumstances

Schedule
3(p) – Transaction with Affiliates

Schedule
3(q)(iii) – Certain Shares Information

Schedule
3(q)(iv) – Pre-emptive Rights, Securities, Etc.

Schedule
3(r) – Indebtedness, Etc.

Schedule
3(s) – Litigation, Etc.

Schedule
3(t) – Insurance

Schedule
3(u)(i) – Employee Matters, Etc.

Schedule
3(u)(iii) – Benefit Plans, Etc.

Schedule
3(u)(iv) – Exception to Benefit Plan, Etc.

Schedule
3(u)(vii) – Other exceptions to Benefit Plans

Schedule
3(v)(i) – Real Property, Etc.

Schedule
3(v)(ii) – Fixtures and Equipment

Schedule
3(w)(i) – Enforceability of Intellectual Property

Schedule
3(w)(ii) – List of IP, Etc.

Schedule
3(w)(iii) – Agreements relating to Intellectual Property

Schedule
3(w)(v) – IP Royalty Payments

Schedule
3(w)(v) – Ownership of IP

Schedule
3(w)(vii) – Works

Schedule
3(z)(ii) – Exception to payment of Taxes, Etc.

Schedule
3(z)(iii) – Tax Liens, Etc.

Schedule
3(z)(iv) – Certain Beneficial interests in other Persons

Schedule
3(aa) – Internal Accounting and Disclosure Controls

Schedule
3(jj) – Management Actions

Schedule
3(kk) – Stock option plans, Etc.

Schedule
3(nn) – Other Covered Persons and Related Matters, Remuneration

Schedule
3(rr) – Ranking of Notes

Schedule
3(ss)(i) – Customers

Schedule
3(ss)(ii) – Contracts, etc. with Major Customers

Schedule
3(ss)(iii) – Termination or possible termination of arrangements with Major Customer

Schedule
3(ww) – Liens

Schedule
3(yy) – Material Contracts

 

    	 	E/S List - 1	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Disclosure
Schedules

 

to

 

Securities
Purchase Agreement

 

Attached
to and forming a part of the Securities Purchase Agreement, dated as of May 15, 2017 (the “Purchase Agreement”),
by and among Icagen, Inc. (“Icagen”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary
of Icagen (“ICA-T”) and GPB Debt Holdings II, LLC are the disclosure schedules of Icagen and ICA-T (collectively,
the “Disclosure Schedules”). Capitalized terms used but not defined in the Disclosure Schedules have the meanings
ascribed to such terms in the Purchase Agreement. The information disclosed in these Disclosure Schedules is intended to qualify
the representations and warranties contained in the Purchase Agreement and shall not be deemed to expand in any way the scope
or effect of any of such representations and warranties on the part of the party making such representation or warranty.

 

The
inclusion of any item in these Disclosure Schedules (i) does not represent a determination that such item is material or establish
a standard of materiality; (ii) does not represent a determination that such item did not arise in the ordinary course of business;
(iii) does not represent a determination that the transactions contemplated by the Purchase Agreement require the consent of third
parties, except as specifically noted; and (iv) shall not constitute, or be deemed to be, an admission to any third party concerning
such item. No disclosure in these Disclosure Schedules relating to any possible breach or violation of any agreement or law shall
be construed as an admission or indication that any such breach or violation actually occurred. The fact that a matter has been
included in these Disclosure Schedules shall not necessarily mean that such matter must or should have been disclosed in order
that the corresponding representation or warranty be accurate, or is otherwise required to be disclosed, pursuant to the terms
and conditions of the Purchase Agreement.

 

Section
headings and numbers used in these Disclosure Schedules refer to the corresponding sections of the Purchase Agreement, and these
and other headings and numbers are for convenience only and are not to be used to interpret any provision of the Purchase Agreement
or these Disclosure Schedules. Any matters disclosed in one section of these Disclosure Schedules shall be deemed disclosed for
all purposes in all other sections of these Disclosure Schedules to the extent that such disclosure is made in such a way as to
make its relevance with respect to any such other section of these Disclosure Schedules reasonably apparent on its face. These
Disclosure Schedules (i) include matters set forth in documents referenced in these Disclosure Schedules and (ii) do not purport
to disclose any agreements, contracts or instruments that may be entered into pursuant to the terms of the Purchase Agreement.
Furthermore, these Disclosure Schedules were created for the purpose of disclosure solely to Icagen and not to any Person that
is not party to the Purchase Agreement.

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(a)

 

Subsidiaries

 

	Icagen-T,
    Inc.	Delaware
	 	 
	Caldera
    Discovery, Inc.	Delaware
	 	 
	XRpro
    Sciences, Inc.	Delaware
	 	 
	Icagen
    Corp.	Nevada

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(e)

 

Consents

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(g)

 

Placement
Agents Fees

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(h)

 

Securities
Issuance since December 31, 2015

 

Icagen,
Inc

 

		1.	Options
                                         issued on May 19, 2016 to purchase an aggregate of 302,500 shares of common stock

		2.	Issuance
                                         in June 2016 and July 2016 of (i) notes in the principal amount of $1,145,000; (ii) investor
                                         warrants to purchase 171,750 shares of common stock; and (iii) placement agent warrants
                                         to purchase 28,625 shares of common stock

		3.	Options
                                         issued on July 15, 2016 to purchase 250,000 shares of common stock

		4.	Options
                                         issued on August 22, 2016 to purchase 50,000 shares of common stock

		5.	Options
                                         issued on March 15, 2017, 2016 to purchase 120,000 shares of common stock

		6.	Issuance
                                         in April 2017 of (i) notes in the principal amount of $1,500,000; (ii) investor warrants
                                         to purchase 225,000 shares of common stock; and (iii) placement agent warrants to purchase
                                         25,000 shares of common stock

 

Icagen-T

 

Issuance
of 100 shares of common stock to Icagen, Inc.

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(j)

 

SEC
Documents: Financial Statements

 

Potential
Contingency-confession of judgement filed by SRN Dentons

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(k)

 

Absence
of Certain Changes

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(l)

 

Undisclosed
Events, Liabilities, Developments or Circumstances

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(p)

 

Transactions
With Affiliates

 

See
Schedule 3(h)

 

Timothy
Tyson

 

On
May 19, 2016, Icagen Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Tyson.

 

On
July 6, 2016, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $100,000 to Mr.
Tyson in consideration of $100,000.

 

On
July 6, 2016, Icagen, Inc. issued Mr. Tyson five year Warrants to acquire 15,000 shares of common stock exercisable at $3.50 per
share.

 

On
March 15, 2017, Icagen, Inc. issued Mr. Tyson ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

 

On
April 13, 2017, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $500,000 to
Mr. Tyson in consideration of $500,000.

 

On
April 13, 2017, Icagen, Inc. issued Mr. Tyson five year Warrants to acquire 75,000 shares of common stock exercisable at $3.50
per share. These warrants are also exchangeable, at the option of the holder, for a like number of warrants issued to any lender
in the next debt financing.

 

Michael
Taglich

 

On
May 19, 2016, Icagen Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Taglich.

 

On
June 30, 2016, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $250,000 to Mr.
Taglich in consideration of $250,000.

 

On
June 30, 2016, Icagen, Inc. issued five year Warrants to acquire 37,500 shares of common stock exercisable at $3.50 per share.

 

Icagen
Inc., retained Taglich Brothers, Inc. as the exclusive placement agent for the 2016 Bridge Note Offering. Icagen Inc., agreed
to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering ($1,145,000) and agreed to reimburse
approximately $15,000 in respect of out of pocket expenses incurred by the placement agent in connection with the Offering. Icagen
Inc., also issued the placement agent the same warrant that the investors received exercisable for an aggregate amount of 28,625
shares of Common Stock at an exercise price of $3.50 per share (the “Placement Agent Warrants”).

 

As
an employee and Principal of Taglich Brothers Inc., Mr. Taglich was issued 2016 Placement Agent Warrants to purchase 7,820 shares
of Common stock at an exercise price of $3.50 per share.

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

On
March 15, 2017, Icagen, Inc. issued Mr. Taglich ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

 

On
April 12, 2017, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $500,000 to
Mr. Taglich in consideration of $500,000.

 

On
April 12, 2017, Icagen Inc., issued five year Warrants to acquire 75,000 shares of common stock exercisable at $3.50 per share.
These warrants are also exchangeable, at the option of the holder, for a like number of warrants issued to any lender in the next
debt financing.

 

Icagen
Inc., retained Taglich Brothers, Inc. as the exclusive placement agent for the 2017 Bridge Note Offering. Icagen Inc., agreed
to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering (excluding $500,000 invested
by the Chairman of the Board of Directors, Timothy Tyson) for a total commission of $60,000. Icagen Inc., also issued the Placement
Agent the same warrant that the investors received exercisable for an aggregate amount of 25,000 shares of Common Stock at an
exercise price of $3.50 per share (the “2017 Placement Agent Warrants”). The Placement Agent has the right to exchange
the Placement Agent Warrants for a like number of warrants to be issued to the lender in the next debt financing.

 

As
an employee and Principal of Taglich Brothers Inc., Mr. Taglich was issued 2017 Placement Agent Warrants to purchase 7,500 shares
of Common stock.

 

Vincent
Palmieri

 

On
May 19, 2016, Icagen, Inc. issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Palmieri.

 

On
June 30, 2016, Icagen, Inc. issued entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $50,000
to Mr. Palmieri in consideration of $50,000.

 

On
June 30, 2016, Icagen, Inc. issued Mr. Palmieri five year Warrants to acquire 7,500 shares of common stock exercisable at $3.50
per share.

 

As
an employee of Taglich Brothers Inc., Mr. Palmieri was issued 2016 Placement Agent warrants to purchase 6,000 shares of Common
stock at an exercise price of $3.50v per share.

 

On
March 15, 2017, Icagen, Inc. issued Mr. Palmieri ten-year options exercisable for10,000 shares of common stock at $3.50 per share.

 

As
an employee of Taglich Brothers Inc., Mr. Palmieri was issued 2017 Placement Agent Warrants to purchase 6,000 shares of Common
stock at an exercise price of $3.50 per share.

 

Clive
Kabatznik

 

On
May 19, 2016, Icagen Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Kabatznik.

 

On
June 30, 2016, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $50,000 to Mr.
Kabatznik in consideration of $50,000 in cash.

 

On
June 30, 2016, Icagen, Inc. issued Mr. Kabatznik five year Warrants to acquire 7,500 shares of common stock exercisable at $3.50
per share.

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

On
March 15, 2017, Icagen, Inc. issued Mr. Kabatznik ten-year options exercisable for 10,000 shares of common stock at $3.50 per
share.

 

Edward
Roffman

 

On
May 19, 2016, Icagen Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Roffman.

 

On
June 30, 2016, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $25,000 to Mr.
Roffman in consideration of $25,000.

 

On
June 30, 2016, Icagen, Inc. issued Mr. Roffman five year Warrants to acquire 3,750 shares of common stock exercisable at $3.50
per share.

 

On
March 15, 2017, Icagen, Inc. issued Mr. Roffman ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

 

Douglas
Krafte

 

On
May 19, 2016, Icagen Inc., issued ten-year options exercisable for 100,000 shares of common stock at $3.50 per common shares to
Mr. Krafte.

 

Richard
Cunningham

 

On
March 15, 2017, Icagen, Inc. issued Mr. Cunningham ten-year options exercisable for 20,000 shares of common stock at $3.50 per
share.

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(q)(iii)

 

Valid
Issuance; Available Shares; Affiliates

 

		(A)	Icagen,
                                         Inc. -Reserved for Issuance pursuant to options and convertible Securities:

 

		1.	Options
                                         exercisable for 1,453,291 shares of common stock, of which 730,791 were issued under
                                         the 2005 Stock Option Plan and 722,500 were issued under the 2015 Stock Option Plan.

 

		2.	Warrants
                                         exercisable for 2,397,641 shares of common stock.

 

		3.	No
                                         convertible securities in issue.

 

		(B)	Icagen,
                                         Inc. Equity Held by Affiliates:

 

		1.	Richard
                                         Cunningham

 

Options
exercisable for 270,000 shares of common stock

 

		2.	Douglas
                                         Krafte

 

Options
exercisable for 100,000 shares of common stock

 

		3.	Mark
                                         Korb

 

Options
exercisable for 37,500 shares of common stock

 

Indirect
holding of 25,000 shares of common stock, via First SA Management

 

		4.	Timothy
                                         Tyson

 

142,856
shares of common stock

 

Warrants
exercisable for 125,714 shares of common stock

 

Options
exercisable for 98,500 shares of common stock

 

		5.	Clive
                                         Kabatznik

 

Indirect
holding of 25,000 shares of common stock via First SA Management

 

Warrants
exercisable for 22,500 shares of common stock

 

Option
exercisable for 60,000 shares of common stock

 

		6.	Vincent
                                         Palmieri

 

53,308
shares of common stock

 

Warrants
exercisable for 162,133 shares of common stock

 

Options
exercisable for 32,500 shares of common stock

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		7.	Edward
                                         Roffman

 

29,000
shares of common stock

 

Warrants
exercisable for 3,750 shares of common stock

 

Options
exercisable for 47,500 shares of common stock

 

		8.	Michael
                                         Taglich

 

431,885
shares of common stock, beneficially owned

 

Warrants
exercisable for 417,587 shares of common stock, beneficially owned

 

Options
exercisable for 32,500 shares of common stock.

 

		9.	Dr.
                                         Benjamin Warner

 

1,497,385
shares of common stock, beneficially owned

 

Options
exercisable for 92,500 shares of common stock

 

		10.	Robert
                                         Taglich (10% holder)

 

352,410
shares of common stock, beneficially owned

 

Warrants
exercisable for 355,030 shares of common stock, beneficially owned

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(q)(iv)

 

Icagen,
Inc.-Existing Securities; Obligations; Transfer Agent

 

 

[*****]

 

The
Series A Preferred and Series B Preferred provide for registration rights however no preferred stock is outstanding

 

The
Series A Preferred has a redemption right, however no Series A Preferred stock is outstanding.

 

The
warrants issued in the April 2017 bridge financing provide that they can be exchanged for warrants issued in the Company’s
debt financing.

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(r)

 

Indebtedness
and Other Contracts

 

Icagen,
Inc. has outstanding notes in the principal amount of $1,500,000 outstanding that were issued in April 2017

 

Icagen,
Inc. owes American Milling $333,333.34 pursuant to the terms of a settlement agreement

 

Icagen,
Inc. owes SNR Dentons $1,400,000 pursuant to the terms of a settlement agreement

 

Icagen,
Corp. has a Purchase Money lease obligation for Synchropatch Equipment supplied by Nanio0n Technologies

 

Icagen,
Corp. owes deferred purchase consideration due to Pfizer of $10,000,000 in the form of an annual royalty payment payable quarterly
commencing on May 31, 2017.

 

Agreements
with Material Adverse Effect

 

Icagen-T-MSA
and related agreements with Sanofi

 

Icagen,
Inc.-MSA and other related agreements with Pfizer

 

Secured
Obligations

 

Icagen
-T -Deed of Trust and Assignment of Rents in favor of Sanofi US Services Inc., Deed of Sale and Reverter and UCC-1 for real estate
and fixtures located at 2090 E. Innovation Park drive, Oro Valley, Arizona

 

Icagen-T-Sanofi
US Services Inc UCC-1 on assets remaining at the Tucson site that are owned by Sanofi

 

Icagen,
Inc.-MSA and other related agreements with Pfizer

 

Icagen,
Inc. -U.S. Bank Equipment Finance UCC-1

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(s)

 

Litigation

 

Icagen
Inc., SNR Dentons threatened litigation

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(t)

 

[*****]

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(u)(i)

 

[*****]

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(u)(iii)

 

[*****]

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(u)(iv)

 

Actions,
Claims, Audits, Lawsuits or Arbitrations Pending against Benefit Plans

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(u)(vii)

 

Additional
Benefits

 

Mark
Korb and Ben Warner work less than full time

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(v)(i)

 

Real
Property

 

Facility
and Real Estate located at 2090 E. Innovation Park Drive, Oro Valley, Arizona owned by Icagen-T subject to lien

 

The
Facility in Tucson is subject to a $5 million lien and certain of the equipment located on the property is subject to a lien by
Sanofi

 

Sublease
between Icagen, Inc. and Pfizer with respect to property located at 4222 Emperor Blvd., Durham, NC

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(v)(ii)

 

Fixtures
and Equipment

 

Certain
Equipment located at 2090 E. Innovation Park drive, Oro Valley, Arizona owned by Sanofi

 

[*****]

 

Icagen
Corp Purchase Money lease obligation for Synchropatch Equipment as supplied by Nanion Technologies

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(w)(i)

 

Expired
or Terminated Intellectual Property

 

Patents
due to expire within 5 years:

 

		●	US
                                         7,858,385

		●	EP
                                         1525459

		●	JP
                                         4560403

		●	SG
                                         109345

		●	US
                                         9,157,875

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(w)(ii)

 

List
of Patents and Trademarks

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-001	 	METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY	 	United States	 	09/859,701	 	2003-0027129	 	7,858,385	 	Patented
	ICA-002EP	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Europe	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002BE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Belgium	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002CH	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Switzerland	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002DE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Germany	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002DK	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Denmark	 	3748920	 	1525458	 	1525458	 	Patented

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-002ES	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Spain	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002FI	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Finland	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002FR	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	France	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002GB	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United Kingdom	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002IT	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Italy	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002SE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Sweden	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002NL	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Netherlands	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002JP	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Japan	 	2004-524531	 	2006-503268	 	4560403	 	Patented

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-002SG	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Singapore	 	200500360-3	 	109345	 	109345	 	Patented
	ICA-002C2	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United States	 	11/444,660	 	2007-0003008	 	7,519,145	 	Patented
	ICA-002C3	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United States	 	12/396,592	 	2009-0175410	 	7,929,662	 	Patented
	ICA-003EP	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Europe	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003CH	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Switzerland/ 
Liechtenstein	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003DE	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Germany	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003FR	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	France	 	4755687.3	 	1644095	 	1644095	 	Patented

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-003GB	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United Kingdom	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003IE	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Ireland	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003NL	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Netherlands	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003JP	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Japan	 	2006-520181	 	2007527524	 	4782676	 	Patented
	ICA-003SG	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Singapore	 	2005085584	 	 	 	118682	 	Patented
	ICA-003	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United States	 	10/621,825	 	2005-0011818	 	6,858,148	 	Patented
	ICA-003C1	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United States	 	10/986,519	 	2005-0095636	 	7,241,381	 	Patented
	ICA-004	 	DRUG DEVELOPMENT AND MANUFACTURING	 	United States	 	10/880,388	 	2004-0235059	 	9,157,875	 	Patented
	ICA-005EP	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Europe	 	7874491.9	 	2084519	 	2084519	 	Patented
	ICA-005CH	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Switzerland/ 
Liechtenstein	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005DE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Germany	 	60 2007 024 468.4	 	2084519	 	608007024468.4	 	Patented

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-005DK	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Denmark	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005FR1	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	France	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005GB	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	United Kingdom	 	7874491.9	 	2084519	 	2084519	 	Patented
	ICA-005HK	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Hong Kong (via EP -005EPDV)	 	13104259.3	 	1177280	 	1177280	 	Patented
	ICA-005IE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Ireland	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005IT	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Italy	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005NL	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Netherlands	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005SE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Sweden	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005EPDV	 	X-RAY MICROSCOPE	 	Europe	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005CHDV	 	X-RAY MICROSCOPE	 	Switzerland and Lichtenstein	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005DEDV	 	X-RAY MICROSCOPE	 	Germany	 	12164870.3	 	2511844	 	602007042616.2	 	Patented
	ICA-005FRDV	 	X-RAY MICROSCOPE	 	France	 	12164870.3	 	2511844	 	2511844	 	Patented

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-005GBDV	 	X-RAY MICROSCOPE	 	United Kingdom	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005HK	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Hong Kong (via EP -005EPDV)	 	2013104259.3	 	1177280	 	1177280	 	Patented
	ICA-005IEDV	 	X-RAY MICROSCOPE	 	Ireland	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005JP	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Japan	 	2009-532446	 	2010509566	 	5143841	 	Patented
	ICA-005JPDV2	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Japan	 	2014-123249	 	2014-123249	 	5913441	 	Patented
	ICA-005C1	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	United States	 	14/693,094	 	2015-0309021	 	N/A	 	Pending
	ICA-006EP	 	WELL PLATE	 	Europe	 	8798006.6	 	2183644	 	2183644	 	Patented
	ICA-006BE	 	WELL PLATE	 	Belgium	 	8798007.6	 	2183644	 	2183644	 	Patented
	ICA-006CH	 	WELL PLATE	 	Switzerland	 	8798008.6	 	2183644	 	2183644	 	Patented
	ICA-006DE	 	WELL PLATE	 	Germany	 	8798009.6	 	2183644	 	602008044640.9	 	Patented
	ICA-006DK	 	WELL PLATE	 	Denmark	 	8798010.6	 	2183644	 	2183644	 	Patented
	ICA-006ES	 	WELL PLATE	 	Spain	 	8798011.6	 	2183644	 	2183644	 	Patented
	ICA-006FI	 	WELL PLATE	 	Finland	 	8798012.6	 	2183644	 	2183644	 	Patented
	ICA-006FR	 	WELL PLATE	 	France	 	8798013.6	 	2183644	 	2183644	 	Patented
	ICA-006GB	 	WELL PLATE	 	United Kingdom	 	8798014.6	 	2183644	 	2183644	 	Patented
	ICA-006IE	 	WELL PLATE	 	Ireland	 	8798015.6	 	2183644	 	2183644	 	Patented
	ICA-006IT	 	WELL PLATE	 	Italy	 	8798016.6	 	2183644	 	2183644	 	Patented
	ICA-006 NL	 	WELL PLATE	 	Netherlands	 	8798017.6	 	2183644	 	2183644	 	Patented
	ICA-006NO	 	WELL PLATE	 	Norway	 	8798018.6	 	2183644	 	2183644	 	Patented
	ICA-006SE	 	WELL PLATE	 	Sweden	 	8798019.6	 	2183644	 	2183644	 	Patented
	ICA-006JP	 	WELL PLATE	 	Japan	 	2010-521206	 	2010537171	 	5628035	 	Patented

 

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-006JPDV	 	WELL PLATE	 	Japan	 	2013-117600	 	2013224946	 	5755682	 	Patented
	ICA-006JPDV2	 	WELL PLATE	 	Japan	 	2014-202871	 	2015004692	 	6076308	 	Patented
	ICA-006	 	WELL PLATE	 	United States	 	12/192,762	 	2009-0046832	 	8,238,515	 	Patented
	ICA-006C1	 	WELL PLATE	 	United States	 	13/567,613	 	2013-0034205	 	8,873,707	 	Patented
	ICA-006C2	 	WELL PLATE	 	United States	 	14/508,322	 	2015-0023467	 	9,476,846	 	Patented
	ICA-006C3	 	WELL PLATE	 	United States	 	15/273,767	 	2017-0010228	 	N/A	 	Pending
	ICA-007JP	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	Japan	 	2010-5272	 	2010539944	 	5743135	 	Patented
	ICA-007JPDV1	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	Japan	 	2014-221166	 	2015033386	 	N/A	 	Pending
	ICA-007C1/XR7-US2	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	United States	 	15/052,914	 	2016-0201111	 	N/A	 	Pending
	ICA-008CN	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	200980125952.3	 	102083365	 	ZL 200980125952.3	 	Patented
	ICA-008CNDV	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	201310298029.8	 	103411988	 	2077368	 	Patented

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-008CNDV2	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	201510083796.6	 	N/A	 	N/A	 	Pending
	ICA-008EP	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	Europe	 	09774467.6	 	2306897	 	N/A	 	Allowed
	ICA-008HK	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	Hong Kong	 	11112984.0	 	1158478	 	1158478	 	Patented
	ICA-008	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	12/496,532	 	2010-0003697	 	8,431,357	 	Patented
	ICA-008C1	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE	 	United States	 	13/871,697	 	2013-0236887	 	9,063,154	 	Patented
	ICA-008C2	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	14/669,923	 	2015-0198615	 	9,506,931	 	Patented
	ICA-008C3	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	15/334,854	 	2017-0045530	 	N/A	 	Pending
	ICA-009	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	13/317,341	 	2012-0093286	 	9,063,066	 	Patented
	ICA-009C1	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,206	 	2015-0276631	 	9,435,756	 	Patented

 

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-009C2	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,218	 	2015-0276632	 	9,442,085	 	Patented
	ICA-009C3	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,233	 	2015-0260664	 	9,335,284	 	Patented
	ICA-009C4	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	15/227,292	 	2016-0341678	 	N/A	 	Pending
	ICA-010PC	 	METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS	 	International	 	PCT/US17/28064	 	N/A	 	N/A	 	Pending

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

 

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(w)(iii)

 

Agreements
Relating to Intellectual Property

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(w)(iv)

 

Payments
on Intellectual Property

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(w)(v)

 

Title
to Intellectual Property Present or Former Employees

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(w)(vii)

 

Works
Created by Employees or Affiliates of the Company

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(z)(ii)

 

Tax
Status

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(z)(iii)

 

Tax
Liens

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(z)(iv)

 

Material
Beneficial Interest

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(aa)

 

Internal
Control

 

As
disclosed in Icagen, Inc’s Annual Report on Form 10-K for the year ended December 31, 2016, Icagen, Inc. has a weakness
in internal control over financial reporting and disclosure controls

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(jj)

 

Judgments
Against Management 

 

None

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(kk)

 

Stock
Option Plans

 

The
following table sets forth information about the securities of Icagen, Inc. authorized for issuance under our equity compensation
plans for the

 

	 	 	Number of securities to be issued upon exercise of outstanding options	 	 	Weighted average exercise price of outstanding options	 	 	Number of securities remaining for future issuance under equity compensation plans	 
	Equity Compensation plans approved by the stockholders	 	 	 	 	 	 	 	 	 
	2005 Stock incentive plan	 	 	730,791	 	 	$	3.67	 	 	 	-	 
	2015 stock incentive plan	 	 	722,500	 	 	$	3.50	 	 	 	77,500	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	1,453,291	 	 	$	3.59	 	 	 	77,500	 

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(nn)

 

Other
Covered Persons and Related Matters

 

Taglich
Brothers has been paid commission on prior private placements

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(rr)

 

Ranking
of Notes

 

Icagen-T-Sanofi
lien on the real estate is a senior lien

 

Icagen,
Inc.-Purchase Money lease obligation for Synchropatch equipment is a prior lien

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(ss)(i)

 

Customers
with Gross Sales over $250,000 

 

Sanofi

 

Pfizer

 

[*****]

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(ss)(ii)

 

Contracts
with Major Customers

 

Sanofi

 

Pfizer

 

[*****]

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(ss)(iii)

 

Termination
of Agreements

 

The
MSA with Sanofi and the MSA with Pfizer have reductions in services to be provided over time.

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(ww)

 

Liens

 

Icagen-T-Deed
of Trust and assignment of Rents in favor of Sanofi US Services Inc., Deed of Sale with Reverter and UCC-1 for real estate located
at 2090 E. Innovation Park drive, Oro Valley, Arizona

 

Icagen,
Inc.-U.S. Bank Equipment Finance UCC-1

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Schedule
3(yy)

 

Material
Contracts

 

	4.1	Form
    of Warrant to Purchase Common Stock (Incorporated by reference to the Registration Statement on Form S-1 filed February 14,
    2012, File No. 333-179508)
	4.2	Promissory
    Note, dated September 21, 2006, in the principal amount of $2,200,000 payable to the Incorporated County of Los Alamos (Incorporated
    by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333-179508)
	4.3	Stock
    Option Plan (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333- 179508)
	4.4	List
    of Warrant Holders (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No.
    333-179508)
	4.5	Form
    of Bridge Warrant (Incorporated by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000- 54748)
	4.6	Form
    of Bridge Note (Incorporated by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
	4.7	Promissory
    Note dated May 23, 2012 in the principal amount of $750,000 payable to Los Alamos National Bank (Incorporated by reference
    to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
	4.8	Promissory
    Note dated June 8, 2012 in the principal amount of $148,500 payable to Los Alamos National Bank (Incorporated by reference
    to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
	4.9	Promissory
    Note dated May 23, 2011 in the principal amount of $750,000 payable to Los Alamos National Bank and Commercial Loan Agreement
    dated May 23, 2011 between Los Alamos National Bank and Caldera Pharmaceuticals, Inc. (Incorporated by reference to the Annual
    report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
	4.10	Commercial
    Loan Agreement dated June 8, 2012 between Los Alamos National Bank, Caldera Pharmaceuticals, Inc. and XPRO Corp (Incorporated
    by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
	4.11	Certificate
    of designations for Series B Preferred Stocks (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013,
    File No. 000-54748)
	4.12	Form
    of Advisor Warrant (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013)
	4.13	Form
    of Placement Agent Warrant (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013, File No. 000- 54748)
	4.14	Form
    of Securities Purchase Agreement (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013, File No. 000-54748)
	4.15	Form
    of Investor Warrant (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013)
	4.16	Form
    of Investor Warrant (Incorporated by reference to Current Report on Form 8-K filed January 7, 2015 File No. 000-54748)
	4.17	Form
    of Placement Agent Warrant (Incorporated by reference to Current Report on Form 8-K filed January 7, 2015 File No. 000- 54748)
	4.18	Form
    of Bridge Exchange Warrant (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File No.
    000-54748)
	4.19	Form
    of Series B Exchange Warrant (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File
    No. 000-54748)

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	4.20	Form
    of Placement Agent Exchange Warrant (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015,
    File No. 000-54748)
	4.21	Form
    of Stock Option Agreement 2005 Incentive Stock Plan Warrant (Incorporated by reference to the Registration Statement on Form
    S-8 filed on August 17, 2017, File No. 333-213173)
	4.22	Icagen,
    Inc. Stock Incentive Plan (Incorporated by reference to Exhibit B to the Preliminary Information Statement on Schedule 14C
    filed with the Securities and Exchange Commission on December 24, 2015 and to the Current Report on Form 8-K filed on December
    29, 2015, File No. 000-54748)
	4.23	Icagen,
    Inc. Stock Option Agreement under the 2015 Stock Incentive Plan, as amended (Incorporated by reference to the Current Report
    on Form 8-K filed on December 29, 2015, File No. 000-54748)
	4.24	Form
    of Note issued to Investors (Incorporated by reference to the Current Report on Form 8-K filed on July 7, 2016, File No. 000-54748)
	4.25	Form
    of Warrant issued to investors (Incorporated by reference to the Current Report on Form 8-K filed on July 7, 2016, File No.
    000-54748)
	4.26	Form
    of note issued to Investors (Incorporated by reference to the Current Report on Form 8-K filed on April 14, 2017, File No.
    000-54748)
	4.27	Form
    of Warrant issued to investors (Incorporated by reference to the Current Report on Form 8-k filed on April 14, 2017, file
    No. 000-54748)
	10.1	Employment
    Agreement with Lori Peterson (nee Court) *(Incorporated by reference to the Registration Statement on Form S-1 filed February
    14, 2012, File No. 333-179508)
	10.2	Exclusive
    Patent License Agreement, dated September 8, 2005, by and between the Company and The Regents of the University of California
    *(Incorporated by reference to the Registration Statement on Form S-1/A filed June 14, 2012, File No. 333-179508)
	10.3	Project
    Participation Agreement, dated as of September 21, 2006, by and between the Company and the Incorporated County of Los Alamos
    (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333-179508)
	10.4	Amendment
    No. 1 to Participation Agreement, dated as of February 21, 2007, by and between the Company and the Incorporated County of
    Los Alamos (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333- 179508)
	10.5	OEM
    Agreement, dated July 5, 2011, by and between the Company and our equipment supplier (Incorporated by reference to the Registration
    Statement on Form S-1/A filed June 8, 2012, File No. 333-179508)
	10.6	Assignment
    of Exclusive License Agreement by The Regents of the University of California to Los Alamos National Security, LLC (Incorporated
    by reference to the Registration Statement on Form S-1/A filed April 20, 2012, File No. 333-179508)
	10.7	Lease
    Agreement with Reeves & Associates, LLC in connection with Suite C (Incorporated by reference to the Registration Statement
    on Form S-1/A filed April 20, 2012, File No. 333-179508)
	10.8	Lease
    Agreement with Reeves & Associates, LLC in connection with Suite D (Incorporated by reference to the Registration Statement
    on Form S-1/A filed April 20, 2012, File No. 333-179508)
	10.9	Extension
    and Modification of Lease Agreements (Incorporated by reference to the Registration Statement on Form S-1/A filed April 20,
    2012, File No. 333-179508)
	10.10	Contract
    2R44AI079935-03 with the National Institutes of Health; to develop strontium-selective therapies, contract amount: $3,000,000.00,
    operative from 08/24/2011 - 07/31/2014, $184,954.01. (Incorporated by reference to the Registration Statement on Form S-1/A
    filed April 20,2012, File No. 333-179508)
	10.11	Contract
    1R43GM090387-01 with the National Institutes of Health; to develop assays for carcinogens, contract amount: $200,000.00, operative
    from 08/06/2010 - 08/05/2012. (Incorporated by reference to the Registration Statement on Form S-1/A filed April 20, 2012,
    File No. 000-54748)
	10.12	Employment
    Agreement with Benjamin Warner dated March 15, 2013* (Incorporated by reference to the Annual Report on Form 10-K filed April
    1, 2013, File No. 000-54748)

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	10.13	Security
    Agreement dated June 8, 2012 between Los Alamos National Bank and XPRO Corp (Incorporated by reference to the Annual Report
    on Form 10-K filed April 1, 2013, File No. 000-54748)
	10.14	Guaranty
    dated June 8, 2012 by and among Los Alamos National Bank, Caldera Pharmaceuticals, Inc., XPRO Corp and Ellen K. McBee (Incorporated
    by reference to the Annual Report on Form 10-K filed April 1, 2013, File No. 000-54748)
	10.15	Settlement
    Agreement and Release between the Company and Gary Altman dated as of July 30, 2014 (Incorporated by reference to the Quarterly
    Report on Form 10-Q for quarter ended June 30, 2014 filed on August 14, 2014, File No. 000-54748)
	10.16	Employment
    Agreement with Richard Cunningham dated as of November 24, 2014* (Incorporated by reference to the Current Report on Form
    8-K filed on November 17, 2014, File No. 000-54748)
	10.17	Securities
    Purchase Agreement (Incorporated by reference to the Current Report on Form 8-K filed January 7, 2015, File No. 000- 54748)
	10.18	Form
    of Series B Preferred Stock Exchange Agreement (Incorporated by reference to the Current Report on Form 8-K filed on February
    3, 2015, File No. 000-54748)
	10.19	Form
    of Bridge Warrant Exchange Agreement (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015,
    File No. 000-54748)
	10.20	Form
    of Series B Preferred Stock and Warrant Exchange Agreement (Incorporated by reference to the Current Report on Form 8-K filed
    on February 3, 2015, File No. 000-54748)
	10.21	The
    Placement Agent Exchange Agreement (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015,
    File No. 000-54748)
	10.22	Asset
    Purchase Agreement and Collaboration Agreement dated as of June 26, 2015 between XRpro Sciences, Inc. and Icagen, Inc. (2)
    (Incorporated by reference to the Current Report on Form 8-K filed on July 2, 2015, File No. 000-54748)
	10.23	Master
    Service Agreement dated as of June 26, 2015 between XRpro Sciences and Icagen, Inc. (2)(3) (Incorporated by reference to the
    Current Report on Form 8-K filed on July 2, 2015, File No. 000-54748)
	10.24	Mutual
    Release and Settlement Agreement (Incorporated by reference to the Current Report on Form 8-K filed October 2, 2015, File
    No. 000-54748)
	10.25	Master
    Services Agreement between Icagen-T, Inc. and Sanofi US Services Inc. (Incorporated by reference to the Current Report on
    Form 8-K filed July 19, 2016 File No. 000-54748)
	10.26	Deed
    of Trust dated July 15, 2016 (Incorporated by reference to the Current Report on Form 8-K filed July 19, 2016 File No. 000-54748)
	10.27	Deed
    of Sale dated July 15, 2016 (Incorporated by reference to the Current Report on Form 8-K filed July 19, 2016 File No. 000-54748)
	10.28	Amendment
    to Asset Purchase and Collaboration Agreement between Icagen, Inc. Pfizer (Incorporated by reference to the Current Report
    on Form 8-K filed July 19, 2016 File No. 000-54748)
	10.29	Form
    of Securities Purchase Agreement between Icagen, Inc. and investors (Incorporated by reference to the Current Report on Form
    8-K filed July 7, 2016 File No. 000-54748)
	10.30	Form
    of Security and Pledge Agreement between Icagen, Inc and investors (Incorporated by reference to the Current Report on Form
    8-K filed July 7, 2016 File No. 000-54748)
	10.31	Form
    of Securities Purchase Agreement between Icagen, Inc., and investors (Incorporated by reference to the Current Report on Form
    8-K filed on April 14, 2017, File No. 000-54748)
	10.32	Form
    of Security and Pledge Agreement between Icagen, Inc., and Investors (Incorporated by reference to the Current Report on Form
    8-K filed on April 14, 2017, File No. 000-54748)Exhibit 10.2

 

Execution Version

 

SECURITY AND PLEDGE AGREEMENT
FOR OBLIGATIONS OF PARENT

 

SECURITY
AND PLEDGE AGREEMENT FOR OBLIGATIONS OF PARENT, dated as of May 15, 2017 (this “Agreement”), made by Icagen,
Inc., a Delaware corporation with offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the
“Parent”) and each of the undersigned direct and indirect Subsidiaries (as defined below) from time to time
other than Icagen-T, Inc. (together with the Parent, collectively, the “Grantors” and each a “Grantor”),
in favor of GPB Debt Holdings II, LLC (in its capacity as collateral agent for itself as purchaser of the Notes (as defined below)
and each other Person who may become a Noteholder (as defined below), the “Collateral Agent;” and in its capacity
as the purchaser of the Notes, the “Buyer”), pursuant to the Securities Purchase Agreement, dated as of May
15, 2017 (as amended, modified, supplemented, extended, renewed, restated or replaced from time to time, the “Securities
Purchase Agreement”).

 

W I T N E S S E T H:

 

WHEREAS, the
Parent, Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent (“ICA-T”) and the
Buyer are parties to the Securities Purchase Agreement, pursuant to which, among other items (i) ICA-T issued and sold an $8,000,000
aggregate principal amount senior secured convertible note of ICA-T (as such may be amended, modified, supplemented, extended,
renewed, restated or replaced from time to time (the “ICA-T Note”), and (ii) the Parent issued and sold, among
other securities, a $2,000,000 aggregate principal amount senior secured convertible note of the Parent (as such may be amended,
modified, supplemented, extended, renewed, restated or replaced from time to time (the “Parent Note” and together
with the ICA-T Note, collectively, the “Notes), to the Buyer;”

 

WHEREAS, the
Parent and certain other Grantors from time to time (each a “Guarantor” and collectively, the “Guarantors”)
may execute and deliver one or more guaranties including, but not limited to, that Guaranty of Obligations of Parent (as defined
below) in form and substance acceptable to and in favor of the Collateral Agent, for the benefit of itself as a Noteholder and
any other Noteholder with respect to all of Parent’s obligations under the Notes, the Securities Purchase Agreement and the
other Transaction Documents (as defined in the Securities Purchase Agreement);

 

WHEREAS, it is a condition precedent to the Buyer’s obligation to purchase the Notes issued pursuant
to the Securities Purchase Agreement, that the Grantors shall have executed and delivered to the Collateral Agent this Agreement
providing for the grant to the Collateral Agent, for the benefit of itself as a Noteholder and any other Noteholder, of a valid,
enforceable, and perfected security interest in all personal property of each Grantor to secure all of (i) the Parent’s and
ICA-T’s obligations under the Notes and other Transaction Documents, (ii) the Grantors’ obligations under the Guaranty
of Obligations of Parent; and (iii) the Grantors’ obligations under the Guaranty of Obligations of ICA-T (as defined below);
and

 

WHEREAS, each
Grantor has determined that the execution, delivery and performance of this Agreement directly and/or indirectly benefits, and
is in the best interest of, such Grantor;

 

     

     

    

 

NOW, THEREFORE,
in consideration of the premises and the agreements herein and such other consideration which the parties hereto recognize and
acknowledge the sufficiency of and in order to induce the Buyer to perform its obligations under the Securities Purchase Agreement,
each Grantor agrees with the Collateral Agent, for the benefit of the Collateral Agent and the Noteholders, as follows:

 

SECTION
1. Definitions.

 

(a)       Reference
is hereby made to the Securities Purchase Agreement and the Notes for a statement of the terms thereof. All terms used in this
Agreement and the recitals hereto which are defined in the Securities Purchase Agreement, the Notes or in the Code (as defined
below), and which are not otherwise defined herein shall have the same meanings herein as set forth therein; provided that
terms used herein which are defined in the Code on the date hereof shall continue to have the same meaning notwithstanding any
replacement or amendment of the Code except as the Collateral Agent may otherwise determine.

 

(b)       The
following terms shall have the respective meanings provided for in the Code: “Accounts” “Account Debtor”,
“Cash Proceeds”, “Certificate of Title”, “Chattel Paper”, “Commercial Tort Claim”,
“Commodity Account”, “Commodity Contracts”, “Deposit Account”, “Documents”, “Electronic
Chattel Paper”, “Equipment”, “Fixtures”, “General Intangibles”, “Goods”,
“Instruments”, “Inventory”, “Investment Property”, “Letter-of-Credit Rights”,
“Payment Intangibles”, “Proceeds”, “Promissory Notes”, “Security”, “Record”,
“Security Account”, “Software”, and “Supporting Obligations”.

 

(c)       As
used in this Agreement, the following terms shall have the respective meanings indicated below, such meanings to be applicable
equally to both the singular and plural forms of such terms:

 

“Affiliate”
of any Person means any other Person which, directly or indirectly, controls or is controlled by or is under common control with
such Person and any officer or director of such Person. A Person shall be deemed to be “controlled by” any other Person
if such Person possesses, directly or indirectly, power to vote 10% or more of the securities (on a fully diluted basis) having
ordinary voting power for the election of directors or managers or power to direct or cause the direction of the management and
policies of such Person, whether by contract or otherwise.

 

“Bankruptcy
Code” means Chapter 11 of Title 11 of the United States Code, 11 U.S.C §§ 101 et seq. (or other applicable
bankruptcy, insolvency or similar laws).

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in New York City are authorized
or required by law to remain closed.

 

“Buyer”
shall have the meaning set forth in the recitals hereto.

 

“Capital
Stock” means (i) with respect to any Person that is a corporation, any and all shares, interests, participations or
other equivalents (however designated and whether or not voting) of corporate stock (including, without limitation, any warrants,
options, rights or other securities exercisable or convertible into equity interests or securities of such Person), and (ii) with
respect to any Person that is not a corporation, any and all partnership, membership or other equity interests of such Person.

 

    	 	2	 

     

    

 

“Closing
Date” means the date of the sale by (i) ICA-T of the ICA-T Note, and (ii) the Parent of the Parent Note and the Parent
Warrant to the Buyer pursuant to the terms of the Securities Purchase Agreement.

 

“Code”
means Articles 8 or 9 of the Uniform Commercial Code as in effect from time to time in the State of New York; provided
that, if perfection or the effect of perfection or non-perfection or the priority of any security interest in any Collateral is
governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, “Code” means
the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating
to such perfection, effect of perfection or non-perfection or priority.

 

“Collateral”
shall have the meaning set forth in Section 2(a) of this Agreement.

 

“Collateral
Agent” shall have the meaning set forth in the preamble hereto.

 

“Controlled
Account Agreement” means a deposit account control agreement or securities account control agreement with respect to
a Pledged Account, in form and substance satisfactory to the Collateral Agent, as the same may be amended, modified, supplemented,
extended, renewed, restated or replaced from time to time.

 

“Controlled
Accounts” means the Deposit Accounts, Commodity Accounts, Securities Accounts, and/or Foreign Currency Controlled Account
of the Grantors listed on Schedule I attached hereto.

 

“Copyright
Licenses” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensee
or licensor and providing for the grant of any right to use or sell any works covered by any Copyright (including, without limitation,
all Copyright Licenses set forth in Schedule II hereto).

 

“Copyrights”
means all domestic and foreign copyrights, whether registered or not, including, without limitation, all copyright rights throughout
the universe (whether now or hereafter arising) in any and all media (whether now or hereafter developed), in and to all original
works of authorship fixed in any tangible medium of expression, acquired or used by any Grantor (including, without limitation,
all copyrights described in Schedule II hereto), all applications, registrations and recordings thereof (including, without
limitation, applications, registrations and recordings in the United States Copyright Office or in any similar office or agency
of the United States or any other country or any political subdivision thereof), and all reissues, divisions, continuations, continuations
in part and extensions or renewals thereof.

 

“Domestic
Subsidiary” means any Subsidiary other than a Foreign Subsidiary.

 

“Event
of Default” shall have the meaning set forth in Section 4(a) of each of the Notes.

 

    	 	3	 

     

    

 

“Excluded
Collateral” means (A) the voting Capital Stock of any Foreign Subsidiary to the extent that (i) such Capital Stock represents
more than 65% of the issued and outstanding voting Capital Stock of such Foreign Subsidiary and (ii) to the extent the pledge
thereof is prohibited by the laws of such Foreign Subsidiary’s Organization or pledging more than 65% of the total outstanding
voting Capital Stock of such Foreign Subsidiary would result in a material adverse tax consequence to a Grantor, (B) accounts
receivable and/or Inventory of each Grantor, but only if and to the extent as of any time of determination any such Grantor’s
accounts receivable and/or Inventory is being factored pursuant to an existing accounts receivable and/or Inventory financing
arrangement between the provider of such financing and such Grantor, provided at all times commencing on the Closing Date (as
defined in the Securities Purchase Agreement) that a Grantor’s accounts receivable and/or Inventory does not constitute
Excluded Collateral pursuant to (B) of this definition of Excluded Collateral, such shall constitute Collateral and the Collateral
Agent for the benefit of itself as a Noteholder and any other Noteholders shall have a senior secured security interest in and
a valid, enforceable perfected senior priority Lien on such Grantor’s accounts receivable and/or Inventory and the Parent
and each Grantor shall take at any time and from time to time any and all action necessary and/or as reasonably requested by the
Collateral Agent to effectuate the same including, but not limited to, providing an opinion of legal counsel to the Parent relating
to the above in form and substance satisfactory to the Collateral Agent, and (C) the Capital Stock of ICA-T; provided, the Capital
Stock of ICA-T shall not be considered Excluded Collateral and shall constitute Collateral and “Pledged Equity”
and ICA-T shall be a Pledged Entity commencing on the first calendar day following the date that the Master Services Agreement
dated July 15, 2016 by and between Sanofi US Services, Inc. (“Sanofi”) and ICA-T (as amended, restated and/or
otherwise modified, the “MSA”) shall not prohibit the Capital Stock of ICA-T from being pledged as Collateral
(the “Restriction End Date”) and in connection therewith, ICA-T and the Parent shall take any and all such
actions necessary and/or requested by the Collateral Agent to satisfy the Collateral Agent that such and the following has been
effectuated and that the Collateral Agent for the benefit of itself as a Noteholder and any other Noteholders has a senior secured
security interest in and a perfected senior priority Lien on the Capital Stock of ICA-T and that the Capital Stock of ICA-T is
not directly and/or indirectly subject to any security interest and/or Lien of Sanofi and/or any other Person (except the Collateral
Agent for the benefit of itself as a Noteholder and the holder of the Parent Note and any other Noteholder and/or other holder
of a Parent Note) including, but not limited to, providing an opinion of legal counsel to the Parent relating to the above in
form and substance satisfactory to the Collateral Agent (the “ICA-T Capital Stock Actions”).

 

“Foreign
Currency Controlled Accounts” means any Controlled Account of the Parent or its Subsidiaries holding non-United States
dollar deposits.

 

“Foreign
Subsidiary” means any Subsidiary of a Grantor organized under the laws of a jurisdiction other than the United States,
any of the states thereof, Puerto Rico or the District of Columbia.

 

“GAAP”
means U.S. generally accepted accounting principles consistently applied.

 

“Governmental
Authority” means any nation or government, any Federal, state, city, town, municipality, county, local, foreign or other
political subdivision thereof or thereto and any department, commission, board, bureau, instrumentality, agency or other entity
exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.

 

    	 	4	 

     

    

 

“Guaranteed
Obligations of Parent” shall have the meaning set forth in Section 2 of the Guaranty of Obligations of Parent.

 

“Guaranteed
Obligations of ICA-T” shall have the meaning set forth in Section 2 of the Guaranty of Obligations of ICA-T.

 

“Guarantor”
or “Guarantors” shall have the meaning set forth in the recitals hereto.

 

“Guaranty”
or “Guaranties” shall mean any additional guaranties required to be entered into pursuant to the Transaction
Documents.

 

“Guaranty
of Obligations of ICA-T” shall mean that Guaranty of Obligations of ICA-T dated the date hereof made by the Grantors
and any future grantors.

 

“Guaranty
of Obligations of Parent” shall mean that Guaranty of Obligations of Parent dated the date hereof made by the Grantors
and any future grantors.

 

“ICA-T
Note” shall have the meaning set forth in the recitals hereto.

 

“Insolvency
Proceeding” means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code or under
any other bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions,
or extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

 

“Intellectual
Property” means, collectively, the Copyrights, Trademarks and Patents.

 

“Intellectual
Property Security Agreement” means the Intellectual Property Security Agreement required to be delivered pursuant to
Section 5(h)(i) of this Agreement, in the form attached hereto as Exhibit A.

 

“Licenses”
means, collectively, the Copyright Licenses, the Trademark Licenses and the Patent Licenses, provided any such License does not
contain a provision expressly prohibiting the pledge of such License.

 

“Lien”
means any mortgage, lien, pledge, charge, security interest, adverse claim or other encumbrance upon or in any property or assets.

 

“Noteholder”
means, at any time, the holders of all or any portion of the Notes at such time.

 

“Obligations”
shall have the meaning set forth in Section 3 of this Agreement.

 

“Paid in Full” or “Payment in Full” means the indefeasible payment
in full (including by way of redemption) of all Obligations in cash (and/or through the issuance of shares of Parent Common Stock
(as defined in the Parent Note), by ICA-T, Parent or a Subsidiary but only if and to the extent permitted by each of the Notes
and the other Transaction Documents).

 

“Parent”
shall have the meaning set forth in the preamble hereto.

 

    	 	5	 

     

    

 

“Patent
Licenses” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensee
or licensor and providing for the grant of any right to manufacture, use or sell any invention covered by any Patent (including,
without limitation, all Patent Licenses set forth in Schedule III hereto).

 

“Patents”
means all domestic and foreign letters patent, design patents, utility patents, industrial designs, inventions, trade secrets,
ideas, concepts, methods, techniques, processes, proprietary information, technology, know-how, formulae, rights of publicity
and other general intangibles of like nature, now existing or hereafter acquired (including, without limitation, all domestic
and foreign letters patent, design patents, utility patents, industrial designs, inventions, trade secrets, ideas, concepts, methods,
techniques, processes, proprietary information, technology, know-how and formulae described in Schedule III hereto), all
applications, registrations and recordings thereof (including, without limitation, applications, registrations and recordings
in the United States Patent and Trademark Office, or in any similar office or agency of the United States or any other country
or any political subdivision thereof), and all reissues, reexaminations, divisions, continuations, continuations in part and extensions
or renewals thereof.

 

“Perfection
Requirement” or “Perfection Requirements” shall have the meaning set forth in Section 4(j) of this
Agreement.

 

“Person”
means an individual, corporation, limited liability Parent, partnership, association, joint-stock Parent, trust, unincorporated
organization, joint venture or other enterprise or entity or Governmental Authority.

 

“Pledged
Accounts” means all of each Grantor’s right, title and interest in all of its Deposit Accounts, Commodity Accounts
and Securities Accounts (in all cases, including, without limitation, all Controlled Accounts and Foreign Currency Control Accounts).

 

“Pledged
Entity” means, each Person listed from time to time on Schedule IV hereto as a “Pledged Entity,”
together with each other Person, any right in or interest in or to all or a portion of whose Capital Stock is acquired or otherwise
owned by a Grantor after the date hereof.

 

“Pledged
Equity” means all of each Grantor’s right, title and interest in and to all of the Securities and Capital Stock
now or hereafter owned by such Grantor, regardless of class or designation, including all substitutions therefor and replacements
thereof, all proceeds thereof and all rights relating thereto, also including any certificates representing the Securities and/or
Capital Stock, the right to receive any certificates representing any of the Securities and/or Capital Stock, all warrants, options,
share appreciation rights and other rights, contractual or otherwise, in respect thereof, and the right to receive dividends,
distributions of income, profits, surplus, or other compensation by way of income or liquidating distributions, in cash or in
kind, and cash, instruments, and other property from time to time received, receivable, or otherwise distributed in respect of
or in addition to, in substitution of, on account of, or in exchange for any or all of the foregoing; provided, however,
that the term Pledged Equity shall include all ICA-T Capital Stock commencing on the Restriction End Date and the Parent, ICA-T
and each other Grantor shall take all ICA-T Capital Stock Actions.

 

    	 	6	 

     

    

 

“Pledged
Operating Agreements” means all of each Grantor’s rights, powers and remedies under the limited liability Parent
operating agreements of each of the Pledged Entities that are limited liability companies, as may be amended, modified, supplemented,
extended, renewed, restated or replaced from time to time.

 

“Pledged
Partnership Agreements” means all of each Grantor’s rights, powers, and remedies under the partnership agreements
of each of the Pledged Entities that are partnerships, as may be amended, modified, supplemented, extended, renewed, restated
or replaced from time to time.

 

“Securities
Purchase Agreement” shall have the meaning set forth in the recitals hereto.

 

“Subsidiary”
means any Person in which a Grantor directly or indirectly (i) owns a majority of the outstanding Capital Stock, voting stock
or holds a majority of any equity or similar interest of such Person or (ii) controls or operates a substantial portion of the
business, operations or administration of such Person, and all of the foregoing, collectively, “Subsidiaries”.

 

“Trademark
Licenses” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensor
or licensee and providing for the grant of any right concerning any Trademark, together with any goodwill connected with and symbolized
by any such licenses, contracts or agreements and the right to prepare for sale or lease and sell or lease any and all Inventory
now or hereafter owned by any Grantor and now or hereafter covered by such licenses, contracts or agreements (including, without
limitation, all Trademark Licenses described in Schedule V hereto).

 

“Trademarks”
means all domestic and foreign trademarks, service marks, collective marks, certification marks, trade names, business names,
d/b/a’s, assumed names, Internet domain names, trade styles, designs, logos and other source or business identifiers and
all general intangibles of like nature, now or hereafter owned, adopted, acquired or used by any Grantor (including, without limitation,
all domestic and foreign trademarks, service marks, collective marks, certification marks, trade names, business names, d/b/a’s,
assumed names, Internet domain names, trade styles, designs, logos and other source or business identifiers described in Schedule
V(a) hereto), all applications, registrations and recordings thereof (including, without limitation, applications, registrations
and recordings in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state
thereof or any other country or any political subdivision thereof), and all reissues, extensions or renewals thereof, together
with all goodwill of the business symbolized by such marks and all customer lists, formulae and other Records of any Grantor relating
to the distribution of products and services in connection with which any of such marks are used.

 

SECTION 2. Grant
of Security Interest.

 

(a)       As
collateral security for the due and punctual payment and performance of all of the Obligations, as and when due, each Grantor
hereby pledges, assigns and grants to the Collateral Agent, for the benefit of itself as a Noteholder itself and for the benefit
of any other Noteholders, a continuing security interest in, all personal property and assets of such Grantor, wherever located
and whether now or hereafter existing and whether now owned or hereafter acquired, of every kind, nature and description, whether
tangible or intangible (collectively, the “Collateral”), including, without limitation, the following:

 

(i)       
All Accounts (but with regard to accounts receivable, subject to the provisions of Section (B) of the definition of Excluded Collateral);

 

    	 	7	 

     

    

 

(ii)       all
Chattel Paper (whether tangible or Electronic Chattel Paper) having a value in excess of $25,000;

 

(iii)      all
Commercial Tort Claims having a value in excess of $25,000, including, without limitation, those specified on Schedule VI
hereto;

 

(iv)      all
Documents;

 

(v)       all
Equipment;

 

(vi)      all
Fixtures;

 

(vii)     all
General Intangibles (including, without limitation, all Payment Intangibles);

 

(viii)     all
Goods;

 

(ix)       all
Inventory (subject to the provisions of Section (B) of the definition of Excluded Collateral);

 

(x)        all
Instruments (including, without limitation, all Promissory Notes and each certificated Security);

 

(xi)       all
Investment Property (and, regardless of whether classified as Investment Property under the Code, all Pledged Equity, Pledged
Operating Agreements and Pledged Partnership Agreements);

 

(xii)      all
Intellectual Property and Licenses;

 

(xiii)     all
Letters of Credit and Letter-of-Credit Rights;

 

(xiv)     all
Pledged Accounts, all cash and other property from time to time deposited therein, and all monies and property in the possession
or under the control of the Collateral Agent or any Noteholder or any Affiliate, representative, agent or correspondent of the
Collateral Agent or any such Noteholder;

 

(xv)      all
Supporting Obligations;

 

    	 	8	 

     

    

 

(xvi)     all other tangible and intangible personal property of each Grantor (whether or not subject to the Code),
including, without limitation, all those relating to all compound libraries owned by the Grantors pursuant to which a security
interest can be granted upon, all  cell line and plasmid repositories owned by the Grantors and related items, all Deposit
and other accounts and all cash and all investments therein, all proceeds, products, offspring, accessions, rents, profits, income,
benefits, substitutions and replacements of and to any of the property of any Grantor described in the preceding clauses of this
Section 2(a) (including, without limitation, any proceeds of insurance thereon and all causes of action, claims and warranties
now or hereafter held by each Grantor in respect of any of the items listed above), and all books, correspondence, files and other
Records, including, without limitation, all tapes, desks, cards, Software, data and computer programs in the possession or under
the control of any Grantor or any other Person from time to time acting for any Grantor, in each case, to the extent of such Grantor’s
rights therein, that at any time evidence or contain information relating to any of the property described in the preceding clauses
of this Section 2(a) or are otherwise necessary or helpful in the collection or realization thereof; and

 

(xvii)    all
Proceeds, including all Cash Proceeds and Noncash Proceeds, and products of any and all of the foregoing Collateral;

 

in each case howsoever any Grantor’s
interest therein may arise or appear (whether by ownership, security interest, claim or otherwise).

 

(b)       Notwithstanding
anything herein to the contrary, the term “Collateral” shall not include any Excluded Collateral.

 

(c)       Except
for Permitted Liens, each Grantor agrees not to further encumber, or permit any other Lien to exist that encumbers, any of its
Copyrights, Copyright applications, Copyright registrations and like protections in each work of authorship and derivative work,
whether published or unpublished, any Licenses other than by the parties to the License, Patents, Patent applications and like
protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the
same, Trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered
or not, and the goodwill of the business of such Grantor connected with and symbolized thereby, know-how, operating manuals, trade
secret rights, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement
of any of the foregoing, in each case without the Collateral Agent’s prior written consent (which consent may be withheld
or given in the Collateral Agent’s sole discretion).

 

(d)       The
Grantors agree that the pledge of the shares of Capital Stock acquired by a Grantor of any and all Persons now or hereafter existing
who is a Foreign Subsidiary may be supplemented by one or more separate pledge agreements, deeds of pledge, share charges or other
similar agreements or instruments, executed and delivered by the relevant Grantors in favor of the Collateral Agent, which pledge
agreements will provide for the pledge of such shares of Capital Stock in accordance with the laws of the applicable foreign jurisdiction
but in no event shall Excluded Collateral be pledged. With respect to such shares of Capital Stock, the Collateral Agent may,
at any time and from time to time, in its sole discretion, take such actions in such foreign jurisdictions that will result in
the perfection of the Lien created in such shares of Capital Stock.

 

(e)       In
addition, to secure the prompt and complete payment, performance and observance of the Obligations and in order to induce the
Buyer as aforesaid, each Grantor hereby grants to the Collateral Agent, for itself and for the ratable benefit of the Noteholders,
a right of set-off against the property of such Grantor held by the Collateral Agent, for itself and for the ratable benefit of
the Noteholders, consisting of property described above in Section 2(a) now or hereafter in the possession or custody of
or in transit to the Collateral Agent, for any purpose, including safekeeping, collection or pledge, for the account of such Grantor,
or as to which such Grantor may have any right or power; provided that such right shall only to be exercised after an Event of
Default has occurred and is continuing.

 

    	 	9	 

     

    

 

SECTION 3. Security
for Obligations. The security interest created hereby in the Collateral constitutes continuing collateral security for all
of the following obligations, whether direct or indirect, absolute or contingent, and whether now existing or hereafter incurred
(collectively, the “Obligations”):

 

(a)       (i)
all payments by the Parent as and when due and payable (by scheduled maturity, required prepayment, redemption,
acceleration, demand or otherwise), of all amounts from time to time owing by it in respect of the Securities Purchase Agreement,
this Agreement, the Parent Note, the ICA-T Note and the other Transaction Documents, and (ii) in the case of the Guarantors, the
payment by such Guarantors, as and when due and payable of all (x) Guaranteed Obligations of Parent under the Guaranty of Obligations
of Parent and (y) Guaranteed Obligations of ICA-T under the Guaranty of Obligations of ICA-T, including, without limitation, in
all cases set forth in (i) – (ii) above, (A) all principal of, interest, redemption amounts, Late Charges (as defined in
the Notes) and other amounts on the Notes and the other Transaction Documents (including, without limitation, all interest, redemption
amounts, Late Charges and other amounts that accrue after the commencement of any Insolvency Proceeding of any Grantor, whether
or not the payment of such interest is enforceable or is allowable in such Insolvency Proceeding), and (B) all fees (including
legal fees), interest, Late Charges, premiums, penalties, contract causes of action, costs, commissions, expense reimbursements,
indemnifications and all other amounts due or to become due under this Agreement or any of the Transaction Documents; and

 

(b)       the
due performance and observance by each Grantor of all of its other obligations from time to time existing in respect of any of
the Transaction Documents, including without limitation, with respect to any conversion or redemption rights of the Noteholders
under the Notes.

 

SECTION 4. Representations
and Warranties. Each Grantor represents and warrants as follows:

 

(a)       Schedule
VII hereto sets forth (i) the exact legal name of each Grantor, and (ii) the state of incorporation, organization or formation
and the organizational identification number of each Grantor in such state. The information set forth in Schedule VII hereto
with respect to such Grantor is true and accurate in all respects. Such Grantor has not previously changed its name (or operated
under any other name), jurisdiction of organization or organizational identification number from those set forth in Schedule
VII hereto except as disclosed in Schedule VII hereto.

 

    	 	10	 

     

    

 

(b)       There
is no pending or, to its knowledge, written notice threatening any action, suit, proceeding or claim affecting any Grantor before
any Governmental Authority or any arbitrator, or any order, judgment or award issued by any Governmental Authority or arbitrator,
in each case, that may adversely affect the grant by any Grantor, or the perfection, of the security interest purported to be
created hereby in the Collateral, or the exercise by the Collateral Agent of any of its rights or remedies hereunder.

 

(c)       All
Federal, state and local tax returns and other reports required by applicable law to be filed by any Grantor have been filed,
or extensions have been obtained, and all taxes, assessments and other governmental charges imposed upon any Grantor or any property
of any Grantor (including, without limitation, all federal income and social security taxes on employees’ wages) and which
have become due and payable on or prior to the date hereof have been paid, except to the extent contested in good faith by proper
proceedings which stay the imposition of any penalty, fine or Lien resulting from the non-payment thereof and with respect to
which adequate reserves have been set aside for the payment thereof in accordance with GAAP.

 

(d)       All
Equipment, Fixtures, Goods and Inventory of each Grantor now existing are, and all Equipment, Fixtures, Goods and Inventory of
each Grantor hereafter existing will be, located and/or based at the addresses specified therefor in Schedule VIII hereto,
except that each Grantor will give the Collateral Agent written notice of any change in the location of any such Collateral within
20 days of such change, other than to locations set forth on Schedule VIII hereto (and with respect to which the Collateral
Agent has filed financing statements and otherwise fully perfected its Liens thereon). Each Grantor’s principal place of
business and chief executive office, the place where each Grantor keeps its Records concerning the Collateral and all located
at the addresses specified therefor in Schedule VIII hereto. None of the Accounts is or will be evidenced by Promissory
Notes or other Instruments.

 

(e)       Set
forth in Schedule IX hereto is a complete and accurate list, as of the date of this Agreement, of (i) each Promissory Note,
Security and other Instrument owned by each Grantor, (ii) each Pledged Account of each Grantor, together with the name and address
of each institution at which each such Pledged Account is maintained, the account number for each such Pledged Account and a description
of the purpose of each such Pledged Account and (iii) the name of each Foreign Currency Controlled Account, together with the
name and address of each institution at which each such Foreign Currency Controlled Account is maintained and the amount of cash
or cash equivalents held in each such Foreign Currency Controlled Account. Set forth in Schedule IX hereto is a complete
and correct list of each trade name used by each Grantor and the name of, and each trade name used by, each Person from which
each Grantor has acquired any substantial part of the Collateral.

 

    	 	11	 

     

    

 

(f)       Each
Grantor has delivered to the Collateral Agent complete and correct copies of each License described in Schedule X hereto,
including all schedules and exhibits thereto, which represent all of the Licenses of the Grantors existing on the date of this
Agreement. Each such License sets forth the entire agreement and understanding of the parties thereto relating to the subject
matter thereof, and there are no other agreements, arrangements or understandings, written or oral, relating to the matters covered
thereby or the rights of such Grantor or any of its Affiliates in respect thereof. Each material License now existing is, and
any material License entered into in the future will be, the legal, valid and binding obligation of the parties thereto, enforceable
against such parties in accordance with its terms except as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, and similar laws of general application relating to or affecting the rights and remedies of creditors and by general
principles of equity. No default under any material License by any such party has occurred, nor does any defense, offset, deduction
or counterclaim exist thereunder in favor of any such party.

 

(g)       Each
Grantor owns and controls, or otherwise possesses adequate rights to use, all of its Intellectual Property. Schedule XI
hereto sets forth a true and complete list of all Intellectual Property and Licenses owned or used by each Grantor as of the date
hereof, and applications for grant or registration of Intellectual Property. To the knowledge of each Grantor, all such Intellectual
Property of such Grantor is subsisting and in full force and effect, has not been adjudged invalid or unenforceable, and has not
been abandoned in whole or in part. Except as set forth in Schedule XI, no such Intellectual Property is the subject of
any licensing or franchising agreement. Except as set forth in Schedule XI, no Grantor has any knowledge of any infringement
upon or conflict with the Patent, Trademark, Copyright, trade secret rights of others and, each Grantor is not now knowingly infringing
or knowingly in conflict with any Patent, Trademark, Copyright, trade secret or similar rights of others, and to the knowledge
of each Grantor, no other Person is now infringing or in conflict in any material respect with any such properties, assets and
rights owned or used by each Grantor. No Grantor has received any notice that it is violating or has violated the Trademarks,
Patents, Copyrights, inventions, trade secrets, proprietary information and technology, know-how, formulae, rights of publicity
or other intellectual property rights of any third party.

 

(h)       Each
Grantor is and will be at all times the sole and exclusive owner of the Collateral pledged by such Grantor hereunder free and
clear of any Liens, except for Permitted Liens thereon. No effective financing statement or other instrument similar in effect
covering all or any part of the Collateral is on file in any recording or filing office except such as (i) may have been filed
in favor of the Collateral Agent and/or the Noteholders relating to this Agreement or the other Transaction Documents, and (ii)
are securing Permitted Liens as of the date hereof and disclosed on Schedule XII hereto.

 

(i)        The
exercise by the Collateral Agent of any of its rights and remedies hereunder will not contravene any law or any contractual restriction
binding on or otherwise affecting each Grantor or any of its properties and will not result in or require the creation of any
Lien, upon or with respect to any of its properties.

 

    	 	12	 

     

    

 

(j)       No
authorization or approval or other action by, and no notice to or filing with, any Governmental Authority, is required for (i)
the grant by each Grantor, or the perfection, of the security interest purported to be created hereby in the Collateral, or (ii)
the exercise by the Collateral Agent of any of its rights and remedies hereunder, except for (A) the filing under the Code as
in effect in the applicable jurisdiction of the financing statements described in Schedule XII hereto, all of which financing
statements have been duly filed and are in full force and effect, (B) with respect to all Pledged Accounts, and all cash and other
property from time to time deposited therein, the execution of a Controlled Account Agreement with the depository or other institution
with which the applicable Pledged Accounts are maintained, as provided in Section 5(h)(i), (C) with respect to Commodity
Contracts, the execution of a control agreement with the commodity intermediary with which such Commodity Contract is carried,
as provided in Section 5(h)(i), (D) with respect to the perfection of the security interest created hereby in the United
States Intellectual Property and Licenses, the recording of the appropriate Intellectual Property Security Agreement in the United
States Patent and Trademark Office or the United States Copyright Office, as applicable (E) with respect to the perfection of
the security interest created hereby in any Letter-of-Credit Rights, the consent of the issuer of the applicable letter of credit
to the assignment of proceeds as provided in the Code as in effect in the applicable jurisdiction, (G) with respect to Investment
Property constituting uncertificated securities, the applicable Grantor causing the issuer thereof either (i) to register the
Collateral Agent as the registered owner of such securities or (ii) to agree in an authenticated record with such Grantor and
the Collateral Agent that such issuer will comply with instructions with respect to such securities originated by the Collateral
Agent without further consent of such Grantor, such authenticated record to be in form and substance satisfactory to the Collateral
Agent, (H) with respect to Investment Property constituting certificated securities or instruments, such items to be delivered
to and held by or on behalf of the Collateral Agent pursuant hereto in suitable form for transfer by delivery or accompanied by
duly executed instruments of transfer or assignment in blank, all in form and substance satisfactory to the Collateral Agent,
(I) with respect to any action that may be necessary to obtain control of Collateral constituting Commodity Contracts, Electronic
Chattel Paper or Letter of Credit Rights, the taking of such actions, and (J) the Collateral Agent having possession of all Documents,
Chattel Paper, Instruments and cash constituting Collateral (subclauses (A) through (J) each a “Perfection Requirement”
and collectively, the “Perfection Requirements”).

 

(k)       This
Agreement creates in favor of the Collateral Agent a legal, valid and enforceable security interest in the Collateral, as security
for the Obligations. The performance of the Perfection Requirements results in the perfection of such security interest in the
Collateral. Such security interest is (or in the case of Collateral in which each Grantor obtains rights after the date hereof,
will be), subject only to Permitted Liens and the Perfection Requirements, a first priority, valid, enforceable and perfected
security interests in all personal property of each Grantor (other than Excluded Collateral). Such recordings and filings and
all other action necessary to perfect and protect such security interest have been duly taken (and, in the case of Collateral
in which any Grantor obtains rights after the date hereof, will be duly taken), except for the Collateral Agent’s having
possession of all Documents, Chattel Paper, Instruments and cash constituting Collateral after the date hereof and the other actions,
filings and recordations described above, including the Perfection Requirements.

 

(l)        As
of the date hereof, no Grantor holds any Commercial Tort Claims or has knowledge of any pending Commercial Tort Claims, except
for the Commercial Tort Claims described in Schedule VI.

 

    	 	13	 

     

    

 

(m)      All
of the Pledged Equity is presently owned by the applicable Grantor as set forth in Schedule XV, and is presently represented
by the certificates listed on Schedule XV hereto (if applicable). As of the date hereof, there are no existing options,
warrants, calls or commitments of any character whatsoever relating to the Pledged Equity other than as contemplated and permitted
by the Transaction Documents. Each Grantor is the sole holder of record and the sole beneficial owner of the Pledged Equity, as
applicable. None of the Pledged Equity has been issued or transferred in violation of the securities registration, securities
disclosure or similar laws of any jurisdiction to which such issuance or transfer may be subject. The Pledged Equity constitutes
100% or such other percentage as set forth on Schedule XV of the issued and outstanding shares of Capital Stock of the
applicable Pledged Entity.

 

(n)       Such
Grantor (i) is a corporation, limited liability company or limited partnership, as applicable, duly organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation, organization or formation, (ii) has all requisite
corporate, limited liability company or limited partnership power and authority to conduct its business as now conducted and as
presently contemplated and to execute and deliver this Agreement and each other Transaction Document to which such Grantor is
a party, and to consummate the transactions contemplated hereby and thereby and (iii) is duly qualified to do business and is
in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction
of its business makes such qualification necessary, except where the failure to be so qualified would not result in a Material
Adverse Effect.

 

(o)       The
execution, delivery and performance by each Grantor of this Agreement and each other Transaction Document to which such Grantor
is a party (i) have been duly authorized by all necessary corporate, limited liability company or limited partnership action,
(ii) do not and will not contravene its charter or by-laws, limited liability company or operating agreement, certificate of partnership
or partnership agreement, as applicable, or any applicable law or any contractual restriction binding on such Grantor or its properties,
(iii) do not and will not result in or require the creation of any Lien (other than pursuant to any Transaction Document) upon
or with respect to any of its assets or properties, and (iv) do not and will not result in any default, noncompliance, suspension,
revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to it or
its operations or any of its assets or properties.

 

(p)       This
Agreement and each of the other Transaction Documents to which any Grantor is or will be a party, when delivered, will be, a legal,
valid and binding obligation of such Grantor, enforceable against such Grantor in accordance with its terms, except as may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, suretyship or other similar laws
and equitable principles (regardless of whether enforcement is sought in equity or at law).

 

(q)       There
are no conditions precedent to the effectiveness of this Agreement that have not been satisfied or waived.

 

    	 	14	 

     

    

 

SECTION 5. Covenants
as to the Collateral. So long as any of the Obligations shall remain outstanding, unless the Collateral Agent shall otherwise
consent in writing:

 

(a)       Further
Assurances. Each Grantor will, at its expense, at any time and from time to time, promptly execute and deliver all further
instruments and documents and take all further action that the Collateral Agent may reasonably request in order to: (i) perfect
and protect the security interest of the Collateral Agent created hereby; (ii) enable the Collateral Agent to exercise and enforce
its rights and remedies hereunder in respect of the Collateral, including, without limitation, the Controlled Accounts; or (iii)
otherwise effect the purposes of this Agreement, including, without limitation: (A) marking conspicuously all Chattel Paper and
each License and, at the request of the Collateral Agent, each of its Records pertaining to the Collateral with a legend, in form
and substance satisfactory to the Collateral Agent, indicating that such Chattel Paper, License or Collateral is subject to the
security interest created hereby, (B) delivering and pledging to the Collateral Agent each Promissory Note, Security (subject
to the limitations set forth in Section 2), Chattel Paper or other Instrument, now or hereafter owned by any Grantor, duly
endorsed and accompanied by executed instruments of transfer or assignment, all in form and substance satisfactory to the Collateral
Agent, (C) executing and filing (to the extent, if any, that any Grantor’s signature is required thereon) or authenticating
the filing of, such financing or continuation statements, or amendments thereto, as may be necessary or that the Collateral Agent
may reasonably request in order to perfect and preserve the security interest created hereby, (D) furnishing to the Collateral
Agent from time to time statements and schedules further identifying and describing the Collateral and such other reports in connection
with the Collateral in each case as the Collateral Agent may reasonably request, all in reasonable detail, (E) if any Collateral
shall be in the possession of a third party, notifying such Person of the Collateral Agent’s security interest created hereby
and obtaining a written acknowledgment from such Person, in form and substance reasonably satisfactory to the Collateral Agent,
that such Person holds possession of the Collateral for the benefit of the Collateral Agent (for the benefit the Noteholders),
(F) if at any time after the date hereof, any Grantor acquires or holds any Commercial Tort Claim, promptly notifying the Collateral
Agent in a writing signed by such Grantor setting forth a brief description of such Commercial Tort Claim and granting to the
Collateral Agent a security interest therein and in the proceeds thereof, which writing shall incorporate the provisions hereof
and shall be in form and substance satisfactory to the Collateral Agent, (G) upon the acquisition after the date hereof by any
Grantor of any motor vehicle or other Equipment subject to a certificate of title or ownership (other than a motor vehicle or
Equipment that is subject to a purchase money security interest), causing the Collateral Agent to be listed as the lienholder
on such certificate of title or ownership and delivering evidence of the same to the Collateral Agent in accordance with Section
5(j) hereof; and (H) taking all actions required by the Code or by other law, as applicable, in any relevant Code jurisdiction,
or by other law as applicable in any foreign jurisdiction.

 

(b)       Location
of Collateral. Each Grantor will keep the Collateral (i) at the locations specified therefor on Schedule XVI hereto,
or (ii) at such other locations set forth on Schedule XVI and with respect to which the Collateral Agent has filed financing
statements and otherwise fully perfected its Liens thereon, or (iii) at such other locations in the United States , provided that
30 days prior to any change in the location of any Collateral to such other location, or upon the acquisition of any Collateral
to be kept at such other locations, the Grantors shall give the Collateral Agent written notice thereof and deliver to the Collateral
Agent a new Schedule XVI indicating such new locations and such other written statements and schedules as the Collateral
Agent may require.

 

(c)       Condition
of Equipment. Each Grantor will maintain or cause to be maintained and preserved in good condition, repair and working order,
ordinary wear and tear excepted, the Equipment (necessary or useful to its business) and will forthwith, or in the case of any
loss or damage to any Equipment of any Grantor within a commercially reasonable time after the occurrence thereof, make or cause
to be made all repairs, replacements and other improvements in connection therewith which are necessary or desirable, consistent
with past practice, or which the Collateral Agent may request to such end. Any Grantor will promptly furnish to the Collateral
Agent a statement describing in reasonable detail any such loss or damage in excess of $50,000 per occurrence to any Equipment.

 

    	 	15	 

     

    

 

(d)       Taxes,
Etc. Each Grantor agrees to pay promptly when due all property and other taxes, assessments and governmental charges or levies
imposed upon, and all claims (including claims for labor, materials and supplies) against, the Equipment and Inventory, except
to the extent the validity thereof is being contested in good faith by proper proceedings which stay the imposition of any penalty,
fine or Lien resulting from the non-payment thereof and with respect to which adequate reserves in accordance with GAAP have been
set aside for the payment thereof.

 

(e)       Insurance.

 

(i)       Each
Grantor will, at its own expense, maintain insurance (including, without limitation, comprehensive general liability, hazard,
rent and business interruption insurance) with respect to its properties (including all real properties leased or owned by it)
and business, in such amounts and covering such risks, in such form and with responsible and reputable insurance companies or
associations as is required by any Governmental Authority having jurisdiction with respect thereto or as is carried generally
in accordance with sound business practice by companies in similar businesses similarly situated and in any event, in amount,
adequacy and scope reasonably satisfactory to the Collateral Agent.

 

(ii)      To
the extent requested by the Collateral Agent at any time and from time to time, each such policy for liability insurance shall
provide for all losses to be paid on behalf of the Collateral Agent and any Grantor as their respective interests may appear,
and each policy for property damage insurance shall provide for all losses to be adjusted with, and paid directly to, the Collateral
Agent. In addition to and without limiting the foregoing, to the extent requested by the Collateral Agent at any time and from
time to time, each such policy shall in addition (A) name the Collateral Agent as an additional insured party and/or loss payee,
as applicable, thereunder (without any representation or warranty by or obligation upon the Collateral Agent) as its interests
may appear, (B) contain an agreement by the insurer that any loss thereunder shall be payable to the Collateral Agent on its own
account notwithstanding any action, inaction or breach of representation or warranty by any Grantor, (C) provide that there shall
be no recourse against the Collateral Agent for payment of premiums or other amounts with respect thereto, and (D) provide that
at least 30 days’ prior written notice of cancellation, lapse, expiration or other adverse change shall be given to the
Collateral Agent by the insurer. Any Grantor will, if so requested by the Collateral Agent, deliver to the Collateral Agent original
or duplicate policies of such insurance (including certificates demonstrating compliance with this Section 5(e)) and, as often
as the Collateral Agent may reasonably request, a report of a reputable insurance broker with respect to such insurance. Any Grantor
will also, at the request of the Collateral Agent, execute and deliver instruments of assignment of such insurance policies and
cause the respective insurers to acknowledge notice of such assignment.

 

    	 	16	 

     

    

 

(iii)      Reimbursement
under any liability insurance maintained by any Grantor pursuant to this Section 5(e) may be paid directly to the Person
who shall have incurred liability covered by such insurance. In the case of any loss involving damage to Equipment or Inventory,
to the extent paragraph (iv) of this Section 5(e) is not applicable, any proceeds of insurance involving such damage shall
be paid to the Collateral Agent, and any Grantor will make or cause to be made the necessary repairs to or replacements of such
Equipment or Inventory, and any proceeds of insurance maintained by any Grantor pursuant to this Section 5(e) (except as
otherwise provided in paragraph (iv) in this Section 5(e)) shall be paid by the Collateral Agent to any Grantor as reimbursement
for the reasonable costs of such repairs or replacements.

 

(iv)      Notwithstanding
anything to the contrary in subsection 5(e)(iii) above, following and during the continuance of an Event of Default (as defined
in the Securities Purchase Agreement and the Notes), all insurance payments in respect of each Grantor’s properties
and business shall be paid to the Collateral Agent and applied as specified in Section 7(b) hereof.

 

(f)       Provisions
Concerning the Accounts and the Licenses.

 

(i)        Each
Grantor will (A) give the Collateral Agent at least 30 days’ prior written notice of any change in such Grantor’s
name, identity or organizational structure, (B) maintain its jurisdiction of incorporation, organization or formation as set forth
in Schedule VII hereto, (C) immediately notify the Collateral Agent upon obtaining an organizational identification number,
if on the date hereof such Grantor did not have such identification number, and (D) keep adequate records concerning the Collateral
and permit representatives of the Collateral Agent during normal business hours on reasonable notice to such Grantor, to inspect
and make abstracts from such records.

 

    	 	17	 

     

    

 

(ii)      
Each Grantor will (except as otherwise provided in this subsection (f)), continue to collect, at its own expense, all amounts
due or to become due under the Accounts. In connection with such collections, any Grantor may (and, at the Collateral Agent’s
direction, will) take such action as any Grantor or the Collateral Agent may deem necessary or advisable to enforce collection
or performance of the Accounts that are not Excluded Collateral; provided, however, that the Collateral Agent shall
have the right at any time following the occurrence and during the continuance of an Event of Default to notify the Account Debtors
or obligors under any Accounts that are not Excluded Collateral of the assignment of such Accounts to the Collateral Agent and
to direct such Account Debtors or obligors to make payment of all amounts due or to become due to any Grantor thereunder directly
to the Collateral Agent or its designated agent and, upon such notification and at the expense of any Grantor and to the extent
permitted by applicable law, to enforce collection of any such Accounts and to adjust, settle or compromise the amount or payment
thereof, in the same manner and to the same extent as any Grantor might have done. After receipt by any Grantor of a notice from
the Collateral Agent that the Collateral Agent has notified, intends to notify, or has enforced or intends to enforce any Grantor’s
rights against the Account Debtors or obligors under any Accounts as referred to in the proviso to the immediately preceding sentence,
(A) all amounts and proceeds (including Instruments) received by any Grantor in respect of the Accounts shall be received in trust
for the benefit of the Collateral Agent hereunder (for the benefit the Noteholders), shall be segregated from other funds of any
Grantor and shall be forthwith paid over to the Collateral Agent in the same form as so received (with any necessary endorsement)
to be applied as specified in Section 7(b) hereof, and (B) no Grantor will adjust, settle or compromise the amount or payment
of any Account or release wholly or partly any Account Debtor or obligor thereof or allow any credit or discount thereon. In addition,
upon the occurrence and during the continuance of an Event of Default, the Collateral Agent may (in its sole and absolute discretion)
direct any or all of the banks and financial institutions with which any Grantor either maintains a Deposit Account or a lockbox
(including, without limitation, any Controlled Account) or deposits the proceeds of any Accounts to send immediately to the Collateral
Agent by wire transfer (to such deposit account as the Collateral Agent shall specify, or in such other manner as the Collateral
Agent shall direct) all or a portion of such securities, cash, investments and other items held by such institution. Any such
securities, cash, investments and other items so received by the Collateral Agent shall be applied as specified in accordance
with Section 7(b) hereof.

 

(iii)      
Upon the occurrence and during the continuance of any breach or default under any material License referred to in Schedule
XVII hereto by any party thereto other than any Grantor, each Grantor party thereto will, promptly after obtaining knowledge
thereof, give the Collateral Agent written notice of the nature and duration thereof, specifying what action, if any, it has taken
and proposes to take with respect thereto and thereafter will take reasonable steps to protect and preserve its rights and remedies
in respect of such breach or default, or will obtain or acquire an appropriate substitute License.

 

(iv)      
Each Grantor will, at its expense, promptly deliver to the Collateral Agent a copy of each notice or other communication received
by it by which any other party to any material License referred to in Schedule XVIII hereto purports to exercise any of
its rights or affect any of its obligations thereunder, together with a copy of any reply by such Grantor thereto.

 

(v)        Each
Grantor will exercise promptly and diligently each and every right which it may have under each material License (other than any
right of termination) and will duly perform and observe in all respects all of its obligations under each material License and
will take all action reasonably necessary to maintain such Licenses in full force and effect. No Grantor will, without the prior
written consent of the Collateral Agent, cancel, terminate, amend or otherwise modify in any respect, or waive any provision of,
any material License referred to in Schedule XIX hereto.

 

    	 	18	 

     

    

 

(g)       Transfers
and Other Liens.

 

(i)       Except
as otherwise expressly permitted in the other Transaction Documents, no Grantor shall, directly or indirectly, sell, lease, license,
assign, transfer, spin-off, split-off, close, convey or otherwise dispose of any Collateral whether in a single transaction or
a series of related transactions, other than (A) sales, leases, licenses, assignments, transfers, conveyances and other dispositions
of such assets or rights by such Grantor for value in the ordinary course of business consistent with past practices; and (B)
sales of Inventory and product in the ordinary course of business.

 

(ii)      Except
if expressly permitted under Section 14(e) of the Notes, no Grantor shall, directly or indirectly, redeem, repurchase or
declare or pay any cash dividend or distribution on any of its Capital Stock.

 

(iii)     No
Grantor shall, directly or indirectly, without the prior written consent of the Required Holders issue any securities that would
cause a breach or default under the Notes, the Securities Purchase Agreement and/or any other Transaction Document.

 

(iv)     Except
for payments to Taglich Brothers, Inc. or an Affiliate thereof for fundraising services they provide (but no payments shall be
made to any such parties related to any financing provided to any Grantor by the Buyer), no Grantor shall enter into, renew, extend
or be a party to, any transaction or series of related transactions (including, without limitation, the purchase, sale, lease,
transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate, except in
the ordinary course of business in a manner and to an extent consistent with past practice and necessary or desirable for the
prudent operation of its business, for fair consideration and on terms no less favorable to it than would be obtainable in a comparable
arm’s length transaction with a Person that is not an Affiliate thereof.

 

(v)       No
Grantor will create, suffer to exist or grant any Lien upon or with respect to any Collateral other than a Permitted Lien.

 

    	 	19	 

     

    

 

(h)       Intellectual
Property.

 

(i)       If
applicable, each Grantor shall duly execute and deliver the applicable Intellectual Property Security Agreement. Each Grantor
(either itself or through licensees) will, and will cause each licensee thereof to, take all action reasonably necessary and/or
requested by the Collateral Agent to maintain all of the Intellectual Property in full force and effect, including, without limitation,
using the proper statutory notices, numbers and markings (relating to patent, trademark and copyright rights) and using the Trademarks
on each applicable trademark class of goods in order to so maintain the Trademarks in full force and free from any claim of abandonment
for non-use, and each Grantor will not (nor permit any licensee thereof to) do any act or knowingly omit to do any act whereby
any Intellectual Property may become abandoned, cancelled or invalidated; provided, however, that so long as no
Event of Default has occurred and is continuing, no Grantor shall have an obligation to use or to maintain any Intellectual Property
(A) that relates solely to any product or work, that is no longer necessary or material and has been, or is in the process of
being, discontinued, abandoned or terminated in the ordinary course of business and consistent with the exercise of reasonable
business judgment, (B) that is being replaced with Intellectual Property substantially similar to the Intellectual Property that
may be abandoned or otherwise become invalid, so long as the failure to use or maintain such Intellectual Property does not materially
adversely affect the validity of such replacement Intellectual Property and so long as such replacement Intellectual Property
is subject to the Lien created by this Agreement and does not have a Material Adverse Effect on the business of any Grantor or
(C) that is substantially the same as another Intellectual Property that is in full force, so long the failure to use or maintain
such Intellectual Property does not materially adversely affect the validity of such replacement Intellectual Property and so
long as such other Intellectual Property is subject to the Lien and security interest created by this Agreement and does not have
a material adverse effect on the business of any Grantor. Each Grantor will cause to be taken all necessary steps in any proceeding
before the United States Patent and Trademark Office and the United States Copyright Office or any similar office or agency in
any other country or political subdivision thereof to maintain each registration of the Intellectual Property and application
for registration of Intellectual Property (other than the Intellectual Property described in the proviso to the immediately preceding
sentence), including, without limitation, filing of renewals, affidavits of use, affidavits of incontestability and opposition,
interference and cancellation proceedings and payment of maintenance fees, filing fees, taxes or other governmental fees. If any
Intellectual Property (other than Intellectual Property described in the proviso to the second sentence of subsection (i) of this
clause (h)) is infringed, misappropriated, diluted or otherwise violated in any material respect by a third party, each Grantor
shall (x) upon learning of such infringement, misappropriation, dilution or other violation, promptly (but in no event more than
five (5) business days after learning of such) notify the Collateral Agent and (y) if reasonably requested by the Collateral Agent
promptly sue for infringement, misappropriation, dilution or other violation, seek injunctive relief where appropriate and recover
any and all damages for such infringement, misappropriation, dilution or other violation, or take such other actions as such Grantor
shall deem appropriate under the circumstances to protect such Intellectual Property. Each Grantor shall furnish to the Collateral
Agent from time to time upon its request statements and schedules further identifying and describing the Intellectual Property
and Licenses and such other reports in connection with the Intellectual Property and Licenses as the Collateral Agent may reasonably
request, all in reasonable detail and promptly upon request of the Collateral Agent, following receipt by the Collateral Agent
of any such statements, schedules or reports, each Grantor shall modify this Agreement by amending Schedules II, III and IV
and any other applicable Schedule hereto, as the case may be, to include any Intellectual Property and License, as the case
may be, which is or hereafter becomes part of the Collateral under this Agreement and shall execute and authenticate such documents
and do such acts as shall be necessary or, in the reasonable judgment of the Collateral Agent, desirable to subject such Intellectual
Property and Licenses to the Lien and security interest created by this Agreement. Notwithstanding anything herein to the contrary,
upon the occurrence and during the continuance of an Event of Default, no Grantor may abandon, surrender or otherwise permit any
Intellectual Property to become abandoned, cancelled or invalid without the prior written consent of the Collateral Agent, and
if any Intellectual Property is infringed, misappropriated, diluted or otherwise violated in any material respect by a third party,
each Grantor will take such reasonable action as the Collateral Agent shall deem appropriate under the circumstances to protect
such Intellectual Property.

 

    	 	20	 

     

    

 

(ii)       In
the event that any Grantor, either itself or through any agent, employee, licensee or designee, files an application for the registration
of any Patent, Trademark or Copyright or the United States Copyright Office or the United States Patent and Trademark Office,
as applicable, or in any similar office or agency of the United States or any country or any political subdivision thereof, it
shall give the Collateral Agent prompt written notice thereof (but in no event more than one (1) business day after the initial
filing of application). Upon request of the Collateral Agent, any Grantor shall execute, authenticate and deliver any and all
assignments, agreements, instruments, documents and papers as the Collateral Agent may reasonably request to evidence the Collateral
Agent’s security interest hereunder in such Intellectual Property and the General Intangibles of any Grantor relating thereto
or represented thereby, and each Grantor hereby appoints the Collateral Agent its attorney-in-fact to execute and/or authenticate
and file all such writings for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed, and such
power (being coupled with an interest) shall be irrevocable until all Obligations are Paid in Full.

 

(i)       Pledged
Accounts.

 

(A)       Each
Grantor shall use its reasonable best efforts to, as soon as practical following the Closing Date, but in no event more than
(60)  sixty calendar days following the Closing Date (the “CAB Period”) cause each bank and other
financial institution which maintains a Controlled Account (each a “Controlled Account Bank”) to execute
and deliver to the Collateral Agent, in form and substance satisfactory to the Collateral Agent, a Controlled Account
Agreement with respect to such Controlled Account, duly executed by each Grantor and such Controlled Account Bank, pursuant
to which such Controlled Account Bank among other things shall irrevocably agree, with respect to such Controlled Account,
that (i) at any time after any Grantor, the Collateral Agent or the Buyer shall have notified such Controlled Account Bank
that an Event of Default has occurred or is continuing, such Controlled Account Bank will comply with any and all
instructions originated by the Collateral Agent directing the disposition of the funds in such Controlled Account without
further consent by such Grantor, (ii) such Controlled Account Bank shall waive, subordinate or agree not to exercise any
rights of setoff or recoupment or any other claim against the applicable Controlled Account other than for payment of its
service fees and other charges directly related to the administration of such Controlled Account and for returned checks or
other items of payment, (iii) at any time after any Grantor, the Collateral Agent or the Buyer shall have notified such
Controlled Account Bank that an Event of Default has occurred or is continuing, with respect to each such Controlled Account,
such Controlled Account Bank shall not comply with any instructions, directions or orders of any form with respect to such
Controlled Accounts other than instructions, directions or orders originated by the Collateral Agent, (iv) all funds
deposited by any Grantor with such Controlled Account Bank shall be subject to a perfected, first priority security interest
in favor of the Collateral Agent, and (v) upon receipt of written notice from the Collateral Agent during the continuance of
an Event of Default, such Controlled Account Bank shall immediately send to the Collateral Agent by wire transfer (to such
account as the Collateral Agent shall specify, or in such other manner as the Collateral Agent shall direct) all such funds
and other items held by it.] No Grantor shall create or maintain any Pledged Account without the prior written consent of the
Collateral Agent and complying with the terms of this Agreement.

 

    	 	21	 

     

    

 

(B)       If
at any time after the expiration of the CAB Period, the average daily balance of any Account that is not subject to a Controlled
Account Agreement exceeds $100,000 during any calendar month (including the calendar month in which the Closing Date occurs),
the Parent shall, either (x) within two (2) Business Days following such date, transfer to a Controlled Account an amount sufficient
to reduce the total aggregate amount of the cash in such Account to an amount not in excess of $100,000 or (y) within twenty-one
(21) calendar days following the last day of such calendar month, deliver to the Collateral Agent a Controlled Account Agreement
with respect to such Account, duly executed by such Grantor and the depositary bank in which such Account is maintained.

 

(C)       Notwithstanding
anything to the contrary contained in Section 5(i)(B) above, and without limiting any of the foregoing, if at any time
after the expiration of the CAB Period, the total aggregate amount of the cash of the Parent and any of its Subsidiaries, in the
aggregate, that is not held in a Controlled Account exceeds $150,000 (the “Maximum Free Cash Amount”), the
Parent shall within twenty one (21) Business Days following such date, either (x) transfer to a Controlled Account an amount sufficient
to reduce the total aggregate amount of the cash that is not held in a Controlled Account to an amount not in excess of the Maximum
Free Cash Amount or (y) deliver to the Collateral Agent a Controlled Account Agreement with respect to such Account (or Accounts),
duly executed by such Grantor and the depositary bank in which such Account (or Accounts) is maintained, as necessary to reduce
the total aggregate amount of the cash that is not held in a Controlled Account to an amount not in excess of the Maximum Free
Cash Amount.

 

(j)       Control.
Each Grantor hereby agrees to take any or all action that may be necessary or that the Collateral Agent may reasonably request
in order for the Collateral Agent to obtain “control” in accordance with Sections 9-105 through 9-107 of the Code
with respect to the following Collateral: (i) Electronic Chattel Paper, (ii) Investment Property, and (iii) Letter-of-Credit Rights.

 

    	 	22	 

     

    

 

(k)       Inspection
and Reporting. Each Grantor shall permit the Collateral Agent, or any agent or representatives thereof or such professionals
or other Persons as the Collateral Agent may designate at Grantors’ sole cost and expense no more than once per quarter
(the “Quarterly Limitations”), unless an Event of Default exists and/or with the passage of time, the occurrence
of an event or the giving of notice an Event of Default would exist, in which event there shall be no limitations including, but
not limited to, the Quarterly Limitations (i) to examine and make copies of and abstracts from any Grantor’s records and
books of account, (ii) to visit and inspect its properties, (iii) to verify materials, leases, Instruments, Accounts, Inventory
and other assets of any Grantor from time to time, and (iv) to conduct audits, physical counts, appraisals and/or valuations,
examinations at the locations of any Grantor. Each Grantor shall also permit the Collateral Agent, or any agent or representatives
thereof or such attorneys, accountants or other professionals or other Persons as the Collateral Agent may designate to discuss
such Grantor’s affairs, finances and accounts with any of its directors, officers, members, managers managerial employees,
independent accountants or any of its other representatives. Without limiting the foregoing, the Collateral Agent may, at any
time, in the Collateral Agent’s own name, in the name of a nominee of the Collateral Agent, or in the name of any Grantor
communicate (by mail, telephone, facsimile or otherwise) with the Account Debtors of such Grantor, parties to contracts with such
Grantor and/or obligors in respect of Instruments of such Grantor to verify with such Persons, to the Collateral Agent’s
satisfaction, the existence, amount, terms of, and any other matter relating to, Accounts, Instruments, Chattel Paper, payment
intangibles and/or other receivables.

 

(l)       Future
Subsidiaries. If any Grantor hereafter creates or acquires any Subsidiary, simultaneously with the creation or acquisition
of such Subsidiary, such Grantor shall (i) if such Subsidiary is a Domestic Subsidiary, cause such Subsidiary to become a party
to this Agreement as an additional “Grantor” hereunder, (ii) deliver to the Collateral Agent updated Schedules to
this Agreement, as appropriate (including, without limitation, an updated Schedule IV to reflect the grant by such Grantor
of a Lien on all Pledged Equity now or hereafter owned by such Grantor), (iii) if such Subsidiary is a Domestic Subsidiary, cause
such Subsidiary to duly execute and deliver a guaranty of the Obligations in favor of the Collateral Agent in form and substance
acceptable to the Collateral Agent, (iv) if such Subsidiary is a (a) Domestic Subsidiary, deliver to the Collateral Agent the
stock certificates representing all, and (b) so long as permitted by applicable law, Foreign Subsidiary, deliver to the Collateral
Agent the stock certificates representing 65%, of the Capital Stock of such Subsidiary, along with undated stock powers for each
such certificates, executed in blank (or, if any such shares of Capital Stock are uncertificated, confirmation and evidence reasonably
satisfactory to the Collateral Agent that the security interest in such uncertificated securities has been transferred to and
perfected by the Collateral Agent, in accordance with Sections 8-313, 8-321 and 9-115 of the Code or any other similar or local
or foreign law that may be applicable), and (v) duly execute and/or cause to be delivered to the Collateral Agent, in form and
substance acceptable to the Collateral Agent, such opinions of counsel and other documents as the Collateral Agent shall request
with respect thereto; provided, however, that no Grantor shall be required to pledge any Excluded Collateral. Each
Grantor hereby authorizes the Collateral Agent to attach such updated Schedules to this Agreement and agrees that all Pledged
Equity listed on any updated Schedule delivered to the Collateral Agent shall for all purposes hereunder be considered Collateral.
The Grantors agree that the pledge of the shares of Capital Stock acquired by a Grantor of Foreign Subsidiary may be supplemented
by one or more separate pledge agreements, deeds of pledge, share charges, or other similar agreements or instruments, executed
and delivered by the relevant Grantor in favor of the Collateral Agent, which pledge agreements will provide for the pledge of
such shares of Capital Stock in accordance with the laws of the applicable foreign jurisdiction. With respect to such shares of
Capital Stock, the Collateral Agent may, at any time and from time to time, in its sole discretion, take actions in such foreign
jurisdictions that will result in the perfection of the Lien created in such shares of Capital Stock other than Excluded Collateral.

 

    	 	23	 

     

    

 

SECTION 6. Additional
Provisions Concerning the Collateral.

 

(a)       To
the maximum extent permitted by applicable law, and for the purpose of taking any action that the Collateral Agent may deem necessary
or advisable to accomplish the purposes of this Agreement, each Grantor hereby (i) authorizes the Collateral Agent to execute
any such agreements, instruments or other documents in such Grantor’s name and to file such agreements, instruments or other
documents in such Grantor’s name and in any appropriate filing office, (ii) authorizes the Collateral Agent at any time
and from time to time to file, one or more financing or continuation statements, and amendments thereto, relating to the Collateral
(including, without limitation, any such financing statements that (A) describe the Collateral as “all assets” or
“all personal property” (or words of similar effect) other than Excluded Collateral or that describe or identify the
Collateral by type or in any other manner as the Collateral Agent may determine regardless of whether any particular asset of
such Grantor falls within the scope of Article 9 of the Code or whether any particular asset of such Grantor constitutes part
of the Collateral, and (B) contain any other information required by Part 5 of Article 9 of the Code for the sufficiency or filing
office acceptance of any financing statement, continuation statement or amendment, including, without limitation, whether such
Grantor is an organization, the type of organization and any organizational identification number issued to such Grantor) and
(iii) ratifies such authorization to the extent that the Collateral Agent has filed any such financing or continuation statements,
or amendments thereto, prior to the date hereof. A photocopy or other reproduction of this Agreement or any financing statement
covering the Collateral or any part thereof shall be sufficient as a financing statement where permitted by law.

 

(b)       Each
Grantor hereby irrevocably appoints (but Collateral Agent shall not use such power until an Event of Default occurs) the Collateral
Agent as its attorney-in-fact and proxy, with full authority in the place and stead of such Grantor and in the name of such Grantor
or otherwise, from time to time in the Collateral Agent’s discretion to take any action and to execute any instrument which
the Collateral Agent may deem necessary or advisable to accomplish the purposes of this Agreement, including, without limitation,
(i) to obtain and adjust insurance required to be paid to the Collateral Agent pursuant to Section 5(e) hereof, (ii) to
ask, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for moneys due and to become due under
or in respect of any Collateral, (iii) to receive, endorse, and collect any drafts or other instruments, documents and chattel
paper in connection with clause (i) or (ii) above, (iv) to file any claims or take any action or institute any proceedings which
the Collateral Agent may deem necessary or desirable for the collection of any Collateral or otherwise to enforce the rights of
the Collateral Agent and the Noteholders with respect to any Collateral, (v) to execute assignments, licenses and other documents
to enforce the rights of the Collateral Agent and the Noteholders with respect to any Collateral, and (vi) to verify any and all
information with respect to any and all Accounts. This power is coupled with an interest and is irrevocable until all of the Obligations
are Paid in Full.

 

    	 	24	 

     

    

 

(c)       For
the purpose of enabling the Collateral Agent to exercise rights and remedies hereunder, at such time as the Collateral Agent shall
be lawfully entitled to exercise such rights and remedies, and for no other purpose, each Grantor hereby grants to the Collateral
Agent, to the extent assignable, an irrevocable, non-exclusive license (exercisable without payment of royalty or other compensation
to any Grantor) to use, assign, license or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor,
wherever the same may be located, including in such license reasonable access to all media in which any of the licensed items
may be recorded or stored and to all computer programs used for the compilation or printout thereof. Notwithstanding anything
contained herein to the contrary, but subject to the provisions of the Securities Purchase Agreement that limit the right of any
Grantor to dispose of its property, and Section 5(g) and Section 5(h) hereof, so long as no Event of Default shall
have occurred and be continuing, any Grantor may exploit, use, enjoy, protect, license, sublicense, assign, sell, dispose of or
take other actions with respect to the Intellectual Property in the ordinary course of its business and as otherwise expressly
permitted by any of the other Transaction Documents. In furtherance of the foregoing, unless an Event of Default shall have occurred
and be continuing, the Collateral Agent shall from time to time, upon the request of any Grantor, execute and deliver any instruments,
certificates or other documents, in the form so requested, which such Grantor shall have certified are appropriate (in such Grantor’s
judgment) to allow it to take any action permitted above (including relinquishment of the license provided pursuant to this clause
(c) as to any Intellectual Property). Further, upon the Payment in Full of all of the Obligations, the Collateral Agent (subject
to Section 10(e) hereof) shall release and reassign to any Grantor all of the Collateral Agent’s right, title and
interest in and to the Collateral, including the Intellectual Property, and the Licenses, all without recourse, representation
or warranty whatsoever. The exercise of rights and remedies hereunder by the Collateral Agent shall not terminate the rights of
the holders of any licenses or sublicenses theretofore granted by each Grantor in accordance with the second sentence of this
clause (c). Each Grantor hereby releases the Collateral Agent from any claims, causes of action and demands at any time arising
out of or with respect to any actions taken or omitted to be taken by the Collateral Agent under the powers of attorney granted
herein other than actions taken or omitted to be taken through the Collateral Agent’s gross negligence or willful misconduct,
as determined by a final determination of a court of competent jurisdiction.

 

(d)       If
any Grantor fails to perform any agreement or obligation contained herein, upon an Event of Default, the Collateral Agent may
itself perform, or cause performance of, such agreement or obligation, in the name of such Grantor or the Collateral Agent, and
the expenses of the Collateral Agent incurred in connection therewith shall be payable by such Grantor pursuant to Section
8 hereof and shall be secured by the Collateral.

 

    	 	25	 

     

    

 

(e)       The
powers conferred on the Collateral Agent hereunder are solely to protect its interest in the Collateral and shall not impose any
duty upon it to exercise any such powers. Except for the safe custody of any Collateral in its possession and the accounting for
moneys actually received by it hereunder, the Collateral Agent shall have no duty as to any Collateral or as to the taking of
any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral.

 

(f)       Anything
herein to the contrary notwithstanding (i) each Grantor shall remain liable under the Licenses and otherwise with respect to any
of the Collateral to the extent set forth therein to perform all of its obligations thereunder to the same extent as if this Agreement
had not been executed, (ii) the exercise by the Collateral Agent of any of its rights hereunder shall not release any Grantor
from any of its obligations under the Licenses or otherwise in respect of the Collateral, and (iii) the Collateral Agent shall
not have any obligation or liability by reason of this Agreement under the Licenses or with respect to any of the other Collateral,
nor shall the Collateral Agent be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any
action to collect or enforce any claim for payment assigned hereunder.

 

(g)       As
long as no Event of Default (as defined under the Notes) shall have occurred and be continuing and until written notice shall
be given to the applicable Grantor:

 

(i)       Each
Grantor shall have the right, from time to time, to vote and give consents with respect to the Pledged Equity, or any part thereof
for all purposes not inconsistent with the provisions of this Agreement, the Securities Purchase Agreement or any other Transaction
Document; provided, however, that no vote shall be cast, and no consent shall be given or action taken, which would
have the effect of impairing the position or interest of the Collateral Agent in respect of the Pledged Equity or which would
authorize, effect or consent to (unless and to the extent expressly permitted by the Securities Purchase Agreement):

 

(A)       the
dissolution or liquidation, in whole or in part, of a Pledged Entity;

 

(B)       the
consolidation or merger of a Pledged Entity with any other Person;

 

(C)       the
sale, disposition or encumbrance of all or substantially all of the assets of a Pledged Entity, except for Liens in favor of the
Collateral Agent;

 

(D)       any
change in the authorized number of shares, the stated capital or the authorized share capital of a Pledged Entity or the issuance
of any additional shares of its Capital Stock; or

 

(E)       the
alteration of the voting rights with respect to the Capital Stock of a Pledged Entity.

 

    	 	26	 

     

    

 

(ii)       Each
Grantor shall be entitled, from time to time, to collect and receive for its own use all cash dividends and interest paid in respect
of the Pledged Equity to the extent not in violation of the Securities Purchase Agreement other than any and all: (A) dividends
and interest paid or payable other than in cash in respect of any Pledged Equity, and instruments and other property received,
receivable or otherwise distributed in respect of, or in exchange for, any Pledged Equity; (B) dividends and other distributions
paid or payable in cash in respect of any Pledged Equity in connection with a partial or total liquidation or dissolution or in
connection with a reduction of capital, capital surplus or paid-in capital of a Pledged Entity; and (C) cash paid, payable or
otherwise distributed, in respect of principal of, or in redemption of, or in exchange for, any Pledged Equity; provided,
however, that until actually paid all rights to such distributions shall remain subject to the Lien created by this Agreement;
and

 

(iii)       all
dividends and interest (other than such cash dividends and interest as are permitted to be paid to any Grantor in accordance with
clause (i) above) and all other distributions in respect of any of the Pledged Equity, whenever paid or made, shall be delivered
to the Collateral Agent to hold as Pledged Equity and shall, if received by any Grantor, be received in trust for the benefit
of the Collateral Agent (for the benefit of the Noteholders), be segregated from the other property or funds of such Grantor,
and be forthwith delivered to the Collateral Agent as Pledged Equity in the same form as so received (with any necessary endorsement).

 

SECTION 7. Remedies
Upon Event of Default; Application of Proceeds. If any Event of Default shall have occurred and be continuing:

 

(a)       The
Collateral Agent may exercise in respect of the Collateral, in addition to any other rights and remedies provided for herein,
in any other Transaction Document or otherwise available to it, all of the rights and remedies of a secured party upon default
under the Code (whether or not the Code applies to the affected Collateral), and also may (i) take absolute control of the Collateral,
including, without limitation, transfer into the Collateral Agent’s name or into the name of its nominee or nominees (to
the extent the Collateral Agent has not theretofore done so) and thereafter receive, for the benefit of the Noteholders, all payments
made thereon, give all consents, waivers and ratifications in respect thereof and otherwise act with respect thereto as though
it were the outright owner thereof, (ii) require each Grantor to, and each Grantor hereby agrees that it will at its expense and
upon request of the Collateral Agent forthwith, assemble all or part of its respective Collateral as directed by the Collateral
Agent and make it available to the Collateral Agent at a place or places to be designated by the Collateral Agent that is reasonably
convenient to both parties, and the Collateral Agent may enter into and occupy any premises owned or leased by any Grantor where
the Collateral or any part thereof is located or assembled for a reasonable period in order to effectuate the Collateral Agent’s
rights and remedies hereunder or under law, without obligation to any Grantor in respect of such occupation, and (iii) without
notice except as specified below and without any obligation to prepare or process the Collateral for sale, (A) sell the Collateral
or any part thereof in one or more parcels at public or private sale (including, without limitation, by credit bid), at any of
the Collateral Agent’s offices or elsewhere, for cash, on credit or for future delivery, and at such price or prices and
upon such other terms as the Collateral Agent may deem commercially reasonable and/or (B) lease, license or dispose of the Collateral
or any part thereof upon such terms as the Collateral Agent may deem commercially reasonable. Each Grantor agrees that, to the
extent notice of sale or any other disposition of its respective Collateral shall be required by law, at least ten (10) days’
notice to any Grantor of the time and place of any public sale or the time after which any private sale or other disposition of
its respective Collateral is to be made shall constitute reasonable notification. The Collateral Agent shall not be obligated
to make any sale or other disposition of any Collateral regardless of notice of sale having been given. The Collateral Agent may
adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may,
without further notice, be made at the time and place to which it was so adjourned. Each Grantor hereby waives any claims against
the Collateral Agent and the Noteholders arising by reason of the fact that the price at which its respective Collateral may have
been sold at a private sale was less than the price which might have been obtained at a public sale or was less than the aggregate
amount of the Obligations, even if the Collateral Agent accepts the first offer received and does not offer such Collateral to
more than one offeree, and waives all rights that any Grantor may have to require that all or any part of such Collateral be marshaled
upon any sale (public or private) thereof. Each Grantor hereby acknowledges that (i) any such sale of its respective Collateral
by the Collateral Agent shall be made without warranty, (ii) the Collateral Agent may specifically disclaim any warranties of
title, possession, quiet enjoyment or the like, and (iii) such actions set forth in clauses (i) and (ii) above shall not adversely
affect the commercial reasonableness of any such sale of Collateral. In addition to the foregoing, (1) upon written notice to
any Grantor from the Collateral Agent after and during the continuance of an Event of Default, such Grantor shall cease any use
of the Intellectual Property or any trademark, patent or copyright similar thereto for any purpose described in such notice; (2)
the Collateral Agent may, at any time and from time to time after and during the continuance of an Event of Default, upon 5 days’
prior notice to such Grantor, license, whether general, special or otherwise, and whether on an exclusive or non-exclusive basis,
any of the Intellectual Property, throughout the universe for such term or terms, on such conditions, and in such manner, as the
Collateral Agent shall in its sole discretion determine; and (3) the Collateral Agent may, at any time, pursuant to the authority
granted in Section 6 hereof or otherwise (such authority being effective upon the occurrence and during the continuance
of an Event of Default), execute and deliver on behalf of such Grantor, one or more instruments of assignment of the Intellectual
Property (or any application or registration thereof), in form suitable for filing, recording or registration in any country.

 

    	 	27	 

     

    

 

(b)       Any
cash held by the Collateral Agent as Collateral and all Cash Proceeds received by the Collateral Agent in respect of any sale
or disposition of or collection from, or other realization upon, all or any part of the Collateral shall be applied as follows
(subject to the provisions of the Securities Purchase Agreement): first, to pay any fees, indemnities or expense reimbursements
then due to the Collateral Agent (including those described in Section 8 hereof); second, to pay any fees, indemnities
or expense reimbursements then due to the Noteholders, on a pro rata basis; third to pay interest due under the Notes
owing to the Noteholders, on a pro rata basis; fourth, to pay or prepay principal in respect of the Note, whether
or not then due, owing to the Noteholders, on a pro rata basis; fifth, to pay or prepay any other Obligations, whether
or not then due, in such order and manner as the Collateral Agent shall elect, consistent with the provisions of the Securities
Purchase Agreement and any other Transaction Document. Any surplus of such cash or Cash Proceeds held by the Collateral Agent
and remaining after the Payment in Full of all of the Obligations shall be paid over to whomsoever shall be lawfully entitled
to receive the same or as a court of competent jurisdiction shall direct.

 

(c)       In
the event that the proceeds of any such sale, disposition, collection or realization are insufficient to pay all amounts to which
the Collateral Agent and the Noteholders are legally entitled, each Grantor shall be, jointly and severally, liable for the deficiency,
together with interest thereon at the highest rate specified in the Notes for interest on overdue principal thereof or such
other rate as shall be fixed by applicable law, together with the costs of collection and the fees, costs, expenses and other
charges of any attorneys employed by the Collateral Agent to collect such deficiency.

 

(d)       To
the extent that applicable law imposes duties on the Collateral Agent to exercise remedies in a commercially reasonable manner,
each Grantor acknowledges and agrees that it is commercially reasonable for the Collateral Agent (i) to fail to incur expenses
deemed significant by the Collateral Agent to prepare Collateral for disposition or otherwise to transform raw material or work
in process into finished goods or other finished products for disposition, (ii) to fail to obtain third party consents for access
to Collateral to be disposed of, or to obtain or, if not required by other law, to fail to obtain governmental or third party
consents for the collection or disposition of Collateral to be collected or disposed of, (iii) to fail to exercise collection
remedies against Account Debtors or other Persons obligated on Collateral or to remove Liens on or any adverse claims against
Collateral, (iv) to exercise collection remedies against Account Debtors and other Persons obligated on Collateral directly or
through the use of collection agencies and other collection specialists, (v) to advertise dispositions of Collateral through publications
or media of general circulation, whether or not the Collateral is of a specialized nature, (vi) to contact other Persons, whether
or not in the same business as any Grantor, for expressions of interest in acquiring all or any portion of such Collateral, (vii)
to hire one or more professional auctioneers to assist in the disposition of Collateral, whether or not the Collateral is of a
specialized nature, (viii) to dispose of Collateral by utilizing internet sites that provide for the auction of assets of the
types included in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets,
(ix) to dispose of assets in wholesale rather than retail markets, (x) to disclaim disposition warranties, such as title, possession
or quiet enjoyment, (xi) to purchase insurance or credit enhancements to insure the Collateral Agent against risks of loss, collection
or disposition of Collateral or to provide to the Collateral Agent a guaranteed return from the collection or disposition of Collateral,
or (xii) to the extent deemed appropriate by the Collateral Agent, to obtain the services of brokers, investment bankers, consultants,
attorneys and other professionals to assist the Collateral Agent in the collection or disposition of any of the Collateral. Each
Grantor acknowledges that the purpose of this section is to provide non-exhaustive indications of what actions or omissions by
the Collateral Agent would be commercially reasonable in the Collateral Agent’s exercise of remedies against the Collateral
and that other actions or omissions by the Collateral Agent shall not be deemed commercially unreasonable solely on account of
not being indicated in this section. Without limitation upon the foregoing, nothing contained in this section shall be construed
to grant any rights to any Grantor or to impose any duties on the Collateral Agent that would not have been granted or imposed
by this Agreement or by applicable law in the absence of this section.

 

    	 	28	 

     

    

 

(e)       The
Collateral Agent shall not be required to marshal any present or future collateral security (including, but not limited to, this
Agreement and the Collateral) for, or other assurances of payment of, the Obligations or any of them or to resort to such collateral
security or other assurances of payment in any particular order, and all of the Collateral Agent’s rights hereunder and
in respect of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights,
however existing or arising. To the extent that any Grantor lawfully may, each Grantor hereby agrees that it will not invoke any
law relating to the marshaling of collateral which might cause delay in or impede the enforcement of the Collateral Agent’s
rights under this Agreement or under any other instrument creating or evidencing any of the Obligations or under which any of
the Obligations is outstanding or by which any of the Obligations is secured or payment thereof is otherwise assured, and, to
the extent that it lawfully may, each Grantor hereby irrevocably waives the benefits of all such laws.

 

SECTION 8. Indemnity
and Expenses.

 

(a)       Each
Grantor agrees, jointly and severally, to defend, protect, indemnify and hold the Collateral Agent and each of the Noteholders
harmless from and against any and all claims, damages, losses, liabilities, obligations, penalties, fees, costs and expenses (including,
without limitation, legal fees, costs, expenses, and disbursements of such Person’s counsel) to the extent that they arise
out of or otherwise result from this Agreement (including, without limitation, enforcement of this Agreement), except to the extent
resulting from such Person’s gross negligence or willful misconduct, as determined by a final judgment of a court of competent
jurisdiction no longer subject to appeal.

 

(b)       Each
Grantor agrees, jointly and severally, to pay to the Collateral Agent upon demand the amount of any and all costs and expenses,
including the reasonable fees, costs, expenses and disbursements of counsel for the Collateral Agent and of any experts and agents
(including, without limitation, any collateral trustee which may act as agent of the Collateral Agent), which the Collateral Agent
may incur in connection with (i) the preparation, negotiation, execution, delivery, recordation, administration, amendment, waiver
or other modification or termination of this Agreement, (ii) the custody, preservation, use or operation of, or the sale of, collection
from, or other realization upon, any Collateral, (iii) the exercise or enforcement of any of the rights of the Collateral Agent
hereunder, or (iv) the failure by any Grantor to perform or observe any of the provisions hereof.

 

SECTION 9. Notices,
Etc. All notices and other communications provided for hereunder shall be in writing and shall be mailed (by certified mail,
first-class postage prepaid and return receipt requested), telecopied, e-mailed or delivered, if to any Grantor, to the Parent’s
address, if to Parent, to Parent’s address or if to the Collateral Agent or any Noteholder, to it at its respective address,
each as set forth in Section 9(f) of the Securities Purchase Agreement; or as to any such Person, at such other address as shall
be designated by such Person in a written notice to all other parties hereto complying as to delivery with the terms of this Section
9. All such notices and other communications shall be effective (a) if sent by certified mail, return receipt requested, when
received or three (3) Business Days after deposited in the mails, whichever occurs first, (b) if telecopied or e-mailed, when
transmitted (during normal business hours) and confirmation is received, and otherwise, the day after the notice or communication
was transmitted and confirmation is received, or (c) if delivered in person, upon delivery. For the avoidance of doubt, all Foreign
Subsidiaries, as Grantors, hereby appoint the Parent as its agent for receipt of service of process and all notices and other
communications in the United States at the address specified below.

 

    	 	29	 

     

    

 

SECTION 10. Miscellaneous.

 

(a)       No
amendment of any provision of this Agreement shall be effective unless it is in writing and signed by each Grantor and the Collateral
Agent (and approved by the Required Holders), and no waiver of any provision of this Agreement, and no consent to any departure
by each Grantor therefrom, shall be effective unless it is in writing and signed by each Grantor and the Collateral Agent (and
approved by the Required Holders), and then such waiver or consent shall be effective only in the specific instance and for the
specific purpose for which given.

 

(b)       No
failure on the part of the Collateral Agent to exercise, and no delay in exercising, any right reasonably hereunder or under any
of the other Transaction Documents shall operate as a waiver thereof; nor shall any single or partial exercise of any such right
reasonably preclude any other or further exercise thereof or the exercise of any other right. The rights and remedies of the Collateral
Agent or any Noteholder provided herein and in the other Transaction Documents are cumulative and are in addition to, and not
exclusive of, any rights or remedies provided by law. The rights of the Collateral Agent or any Noteholder under any of the other
Transaction Documents against any party thereto are not conditional or contingent on any attempt by such Person to exercise any
of its rights under any of the other Transaction Documents against such party or against any other Person, including but not limited
to, any Grantor.

 

(c)       If
any provision of this Agreement or any Transaction Document is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred
upon the parties.  The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable
provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s).

 

(d)       This
Agreement shall create a continuing security interest in the Collateral and shall (i) remain in full force and effect until Payment
in Full of the Obligations, and (ii) be binding on each Grantor and all other Persons who become bound as debtor to this Agreement
in accordance with Section 9-203(d) of the Code and shall inure, together with all rights and remedies of the Collateral Agent
and the Noteholders hereunder, to the benefit of the Collateral Agent and the Noteholders and their respective permitted successors,
transferees and assigns. Without limiting the generality of clause (ii) of the immediately preceding sentence, without notice
to any Grantor, the Collateral Agent and the Noteholders may assign or otherwise transfer their rights and obligations under this
Agreement and any of the other Transaction Documents, to any other Person and such other Person shall thereupon become vested
with all of the benefits in respect thereof granted to the Collateral Agent and the Noteholders herein or otherwise. Upon any
such assignment or transfer, all references in this Agreement to the Collateral Agent or any such Noteholder shall mean the assignee
of the Collateral Agent or such Noteholder. None of the rights or obligations of any Grantor hereunder may be assigned or otherwise
transferred without the prior written consent of the Collateral Agent, and any such assignment or transfer without such consent
of the Collateral Agent shall be null and void.

 

    	 	30	 

     

    

 

(e)       Upon
the Payment in Full of the Obligations, (i) this Agreement and the security interests created hereby shall terminate and all rights
to the Collateral shall revert to the respective Grantor that granted such security interests hereunder, and (ii) the Collateral
Agent will, upon any Grantor’s request and at such Grantor’s expense, (A) return to such Grantor such of the Collateral
as shall not have been sold or otherwise disposed of or applied pursuant to the terms hereof and (B) execute and deliver to such
Grantor such documents as such Grantor shall reasonably request to evidence such termination, all without any representation,
warranty or recourse whatsoever.

 

(f)       Governing
Law; Jurisdiction; Jury Trial.

 

(i)       All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed exclusively
by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York.

 

(ii)      Each
Grantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction
Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim, defense or objection that it is not personally subject to the jurisdiction of any such
court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding
is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of
the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Noteholders from bringing suit or
taking other legal action against any Grantor in any other jurisdiction to collect on a Grantor’s obligations or to enforce
a judgment or other court ruling in favor of the Collateral Agent or a Noteholder.

 

    	 	31	 

     

    

 

(iii)       WAIVER
OF JURY TRIAL, ETC. EACH GRANTOR IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR
THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS
AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

(iv)       Each
Grantor irrevocably and unconditionally waives any right it may have to claim or recover in any legal action, suit or proceeding
referred to in this Section any special, exemplary, indirect, incidental, punitive or consequential damages.

 

(g)       Section
headings herein are included for convenience of reference only and shall not constitute a part of this Agreement for any other
purpose.

 

(h)       This
Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which
shall be deemed to be an original, but all of which taken together constitute one and the same Agreement. Delivery of any executed
counterpart of a signature page of this Agreement by pdf, facsimile or other electronic transmission shall be effective as delivery
of a manually executed counterpart of this Agreement.

 

(i)       This
Agreement shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any of the Obligations
is rescinded or must otherwise be returned by the Collateral Agent, any Noteholder or any other Person (upon (i) the occurrence
of any Insolvency Proceeding of any of the Parent or any Grantor or (ii) otherwise, in all cases as though such payment had not
been made).

 

SECTION 11. Material
Non-Public Information. Upon receipt or delivery by the Parent of any notice in accordance with the terms of this Agreement, unless
the Parent has in good faith determined that the matters relating to such notice do not constitute material, non-public information
relating to the Parent or any of its Subsidiaries, the Parent shall within two (2) Business Days after any such receipt or delivery
publicly disclose such material, non-public information on a Current Report on Form 8-K or otherwise. In the event that the Parent
believes that a notice contains material, non-public information relating to the Parent or any of its Subsidiaries, the Parent
so shall indicate to the Collateral Agent and any applicable Noteholder contemporaneously with delivery of such notice, and in
the absence of any such indication, the Collateral Agent and each Noteholder shall be allowed to presume that all matters relating
to such notice do not constitute material, non-public information relating to the Parent or its Subsidiaries. Nothing contained
in this Section 11 shall limit any obligations of the Parent, or any rights of the Collateral Agent or any Noteholder, under
Section 4(i) of the Securities Purchase Agreement.

 

[REMAINDER OF THIS PAGE INTENTIONALLY
LEFT BLANK]

 

    	 	32	 

     

    

 

IN WITNESS WHEREOF,
each Grantor has caused this Agreement to be executed and delivered by its officer thereunto duly authorized, as of the date first
above written.

 

	 	GRANTORS:
	 	 	 
	 	ICAGEN,
    INC.,
	 	a
    Delaware corporation
	 	 	 
	 	By:	/s/ Richard Cunningham
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    President and CEO
	 	 	 
	 	ICAGEN
    CORP (FORMERLY KNOWN AS XRPRO CORP.)., a Nevada corporation
	 	 	 
	 	By:	/s/ Richard
    Cunningham
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    President and CEO

 

	 	CALDERA
    DISCOVERY, INC, a Delaware corporation
	 	 	 
	 	By:	/s/ Richard
    Cunningham
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    President and CEO
	 	 	 
	 	XRPRO
    SCIENCES, INC., a Delaware corporation
	 	 	 
	 	By:	/s/ Richard
    Cunningham
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    President and CEO

 

	ACCEPTED
    BY:	 
	 	 	 
	GPB
    Debt Holdings II, LLC,	 
	as
    Collateral Agent	 
		

         
	 
	By: 	/s/ David Gentile	 
	 	Name: David
    Gentile	 
	 	Title:
    Manager	 

 

    	 	33	 

     

    

 

LIST OF EXHIBITS AND SCHEDULES
TO SECURITY AND PLEDGE AGREEMENT

 

A. EXHIBITS

 

Exhibit A – IP Security Agreement

 

B. SCHEDULES

 

Schedule I – Controlled Accounts Etc.

 

Schedule II – Copyrights, Etc.

 

Schedule III – Patents, Etc.

 

Schedule IV – Pledged Entities

 

Schedule V – Trademark Licenses

 

Schedule V(a) – Trademarks, Etc.

 

Schedule VI – Commercial Tort Claims

 

Schedule VII – Legal Names, Organizational Identification
Numbers; States or Jurisdiction of Organization

 

Schedule VIII – Locations

 

Schedule IX – Securities Etc. of each Grantor

 

Schedule X – Licenses, Etc.

 

Schedule XI – All Intellectual Property and Licenses
of Grantors

 

Schedule XII – Pledged Collateral

 

Schedule XIII – [RESERVED]

 

Schedule XIV – [RESERVED]

 

Schedule XV - Pledged Equity

 

Schedule XVI – Locations of Collateral

 

Schedule XVII – Licenses, Etc.

 

Schedule XVIII – Notices. Etc., Re: Exercise of
Rights by certain parties under Licenses

 

Schedule XIX – No Termination Etc. of Licenses

 

     

     

    

 

EXHIBIT A

 

FORM OF INTELLECTUAL PROPERTY
SECURITY AGREEMENT 

 

INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

This INTELLECTUAL
PROPERTY SECURITY AGREEMENT (as amended, modified, supplemented, renewed, restated or replaced from time to time, this “IP
Security Agreement”), dated May 15, 2017, is made by the Persons listed on the signature pages hereof (collectively,
the “Grantors”) in favor of GPB Debt Holdings II, LLC, in its capacity as collateral agent (the “Collateral
Agent”) for itself as a Noteholder and any other Noteholders. All capitalized terms not otherwise defined herein (or
as indicated herein as being defined in another document, agreement and/or instrument) shall have the meanings respectively ascribed
thereto in the Security Agreement (as defined below).

 

WHEREAS, Icagen,
Inc., a Delaware corporation with offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703
(the “Parent”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent with offices
located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“ICA-T”) and GPB Debt Holdings II, LLC,
as investor (the “Buyer”) are parties to that certain Securities Purchase Agreement, dated May 15, 2017, pursuant
to which ICA-T and the Parent shall be required to sell, and the Buyer shall purchase or have the right to purchase, the ICA-T
Note (as defined therein) and the Parent Note and Parent Warrant (both terms as defined therein) from ICA-T and the Parent, respectively;

 

WHEREAS, it is
a condition precedent to the purchase of the Notes and the Parent Note and Parent Warrants under the Securities Purchase
Agreement that each Grantor has executed and delivered that certain Security and Pledge Agreement, dated May 15, 2017, made by
the Grantors to the Collateral Agent (as amended, modified, supplemented, renewed, restated or replaced from time to time, the
“Security Agreement”); and

 

WHEREAS, under
the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Noteholders, a
security interest in, among other property, certain intellectual property and Licenses of the Grantors, and have agreed as a condition
thereof to execute this IP Security Agreement for recording with the U.S. Patent and Trademark Office and the United States Copyright
Office; and

 

WHEREAS, the
Grantors have determined that the execution, delivery and performance of this IP Security Agreement directly benefits, and is
in the best interest of, the Grantors.

 

NOW, THEREFORE,
in consideration of the premises and the agreements herein and for such other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, and in order to induce the Buyer to perform under the Securities Purchase Agreement,
each Grantor agrees with the Collateral Agent, for the benefit of the Noteholders, as follows

 

SECTION 1. Grant
of Security. Each Grantor hereby grants to the Collateral Agent for the benefit of the Collateral Agent as a Noteholder and
any other Noteholders a security interest in all of such Grantor’s right, title and interest in and to the following (the
“Collateral”):

 

(i)       the
United States Patents and Patent applications set forth in Schedule A hereto;

 

     

     

    

 

(ii)       the
United States Trademarks and service mark registrations and applications set forth in Schedule B hereto (provided that
no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during
the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use
trademark applications under applicable federal law), together with the goodwill symbolized thereby;

 

(iii)      all
United States Copyrights, whether registered or unregistered, now owned or hereafter acquired by such Grantor, including, without
limitation, the copyright registrations and applications and exclusive copyright licenses set forth in Schedule C hereto;

 

(iv)      all
reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all
rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world
and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

 

(v)       any
and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation,
misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise
recover, such damages; and

 

(vi)       any
and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and
supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing.

 

SECTION 2. Security
for Obligations. The grant of a security interest in, the Collateral under this IP Security Agreement by each Grantor)
secures the payment of all Obligations of each Grantor now or hereafter existing under or in respect of the Notes and the
other Transaction Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement
obligations, interest, redemption payments, premiums, penalties, fees, indemnifications, contract causes of action, costs,
expenses or otherwise.

 

SECTION 3. Recordation.
Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks
and any other applicable government officer record this IP Security Agreement.

 

SECTION 4. Execution
in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed
shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

 

SECTION 5. Grants,
Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement.
Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies
of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions
of which are incorporated herein by reference as if fully set forth herein.

 

    	 	2	 

     

    

 

SECTION
6. Governing Law; Jurisdiction; Jury Trial.

 

(i)       All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal
laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the
State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the
State of New York.

 

(ii)       Each
Grantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction
Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim, defense or objection that it is not personally subject to the jurisdiction of any such
court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding
is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of
the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Noteholders from bringing suit or
taking other legal action against any Grantor in any other jurisdiction to collect on a Grantor’s obligations or to enforce
a judgment or other court ruling in favor of the Collateral Agent or a Noteholder.

 

(iii)      WAIVER
OF JURY TRIAL, ETC. EACH GRANTOR IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR
THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS
AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

(iv)      Each
Grantor irrevocably and unconditionally waives any right it may have to claim or recover in any legal action, suit or proceeding
referred to in this Section any special, exemplary, indirect, incidental, punitive or consequential damages.

 

[The remainder of the page is intentionally
left blank]

 

    	 	3	 

     

    

 

IN WITNESS WHEREOF,
each Grantor has caused this Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date
first above written.

 

	 	GRANTORS:
	 	 	 
	 	ICAGEN,
    INC.,
	 	a
    Delaware corporation
	 	 	 
	 	By:	
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    President and CEO
	 	 	 
	 	ICAGEN
    CORP. (FORMERLY KNOWN AS XRPRO CORP., FORMERLY KNOWN AS CALDERA
    PHARMACEUTICALS, INC.),
    a Nevada corporation
	 	 	 
	 	By:	
	 	 	Name: Richard Cunningham
	 	 	Title: President and
    CEO

 

	 	CALDERA
    DISCOVERY, INC, a Delaware corporation
	 	 	 
	 	By:	
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    President and CEO
	 	 	 
	 	XRPRO
    SCIENCES, INC., a Delaware corporation
	 	 	 
	 	By:	
	 	 	Name:
    Richard Cunningham
	 	 	Title:
    President and CEO

 

    	 	4	 

     

    

 

SCHEDULE I

 

Controlled Accounts Etc.

 

	 	Icagen Inc.	 
	 	 	 
	 	#####	#####	 
	 	 	 	 
	 	Icagen Corp.	 
	 	 	 
	 	#####	#####	 
	 	 	 	 

  

Accounts to be closed within 90
days of conclusion of Agreement:

 

Icagen Inc.

 

	 	#####	#####	 
	 	 	 	 
	 	#####	#####	 
	 	 	 	 
	 	#####	#####	 
	 	 	 	 
	 	#####	#####	 
	 	 	 	 
	 	#####	#####	 

 

     

     

    

 

SCHEDULE II

 

Copyrights, Etc.

 

None

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

SCHEDULE III

 

Patents, Etc.

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-001	 	METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY	 	United States	 	09/859,701	 	2003-0027129	 	7,858,385	 	Patented
	ICA-002EP	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Europe	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002BE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Belgium	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002CH	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Switzerland	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002DE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Germany	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002DK	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Denmark	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002ES	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Spain	 	3748920	 	1525458	 	1525458	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-002FI	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Finland	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002FR	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	France	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002GB	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United Kingdom	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002IT	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Italy	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002SE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Sweden	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002NL	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Netherlands	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002JP	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Japan	 	2004-524531	 	2006-503268	 	4560403	 	Patented
	ICA-002SG	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Singapore	 	200500360-3	 	109345	 	109345	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-002C2	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United States	 	11/444,660	 	2007-0003008	 	7,519,145	 	Patented
	ICA-002C3	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United States	 	12/396,592	 	2009-0175410	 	7,929,662	 	Patented
	ICA-003EP	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Europe	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003CH	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Switzerland/ 
Liechtenstein	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003DE	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Germany	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003FR	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	France	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003GB	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United Kingdom	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003IE	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Ireland	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003NL	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Netherlands	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003JP	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Japan	 	2006-520181	 	2007527524	 	4782676	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-003SG	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Singapore	 	2005085584	 	 	 	118682	 	Patented
	ICA-003	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United States	 	10/621,825	 	2005-0011818	 	6,858,148	 	Patented
	ICA-003C1	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United States	 	10/986,519	 	2005-0095636	 	7,241,381	 	Patented
	ICA-004	 	DRUG DEVELOPMENT AND MANUFACTURING	 	United States	 	10/880,388	 	2004-0235059	 	9,157,875	 	Patented
	ICA-005EP	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Europe	 	7874491.9	 	2084519	 	2084519	 	Patented
	ICA-005CH	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Switzerland/ 
Liechtenstein	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005DE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Germany	 	60 2007 024 468.4	 	2084519	 	608007024468.4	 	Patented
	ICA-005DK	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Denmark	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005FR1	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	France	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005GB	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	United Kingdom	 	7874491.9	 	2084519	 	2084519	 	Patented
	ICA-005HK	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Hong Kong (via EP -005EPDV)	 	13104259.3	 	1177280	 	1177280	 	Patented
	ICA-005IE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Ireland	 	7874491.9	 	1177280	 	2084519	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-005IT	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Italy	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005NL	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Netherlands	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005SE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Sweden	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005EPDV	 	X-RAY MICROSCOPE	 	Europe	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005CHDV	 	X-RAY MICROSCOPE	 	Switzerland and Lichtenstein	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005DEDV	 	X-RAY MICROSCOPE	 	Germany	 	12164870.3	 	2511844	 	602007042616.2	 	Patented
	ICA-005FRDV	 	X-RAY MICROSCOPE	 	France	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005GBDV	 	X-RAY MICROSCOPE	 	United Kingdom	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005HK	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Hong Kong (via EP -005EPDV)	 	2013104259.3	 	1177280	 	1177280	 	Patented
	ICA-005IEDV	 	X-RAY MICROSCOPE	 	Ireland	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005JP	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Japan	 	2009-532446	 	2010509566	 	5143841	 	Patented
	ICA-005JPDV2	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Japan	 	2014-123249	 	2014-123249	 	5913441	 	Patented
	ICA-005C1	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	United States	 	14/693,094	 	2015-0309021	 	N/A	 	Pending

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-006EP	 	WELL PLATE	 	Europe	 	8798006.6	 	2183644	 	2183644	 	Patented
	ICA-006BE	 	WELL PLATE	 	Belgium	 	8798007.6	 	2183644	 	2183644	 	Patented
	ICA-006CH	 	WELL PLATE	 	Switzerland	 	8798008.6	 	2183644	 	2183644	 	Patented
	ICA-006DE	 	WELL PLATE	 	Germany	 	8798009.6	 	2183644	 	602008044640.9	 	Patented
	ICA-006DK	 	WELL PLATE	 	Denmark	 	8798010.6	 	2183644	 	2183644	 	Patented
	ICA-006ES	 	WELL PLATE	 	Spain	 	8798011.6	 	2183644	 	2183644	 	Patented
	ICA-006FI	 	WELL PLATE	 	Finland	 	8798012.6	 	2183644	 	2183644	 	Patented
	ICA-006FR	 	WELL PLATE	 	France	 	8798013.6	 	2183644	 	2183644	 	Patented
	ICA-006GB	 	WELL PLATE	 	United Kingdom	 	8798014.6	 	2183644	 	2183644	 	Patented
	ICA-006IE	 	WELL PLATE	 	Ireland	 	8798015.6	 	2183644	 	2183644	 	Patented
	ICA-006IT	 	WELL PLATE	 	Italy	 	8798016.6	 	2183644	 	2183644	 	Patented
	ICA-006 NL	 	WELL PLATE	 	Netherlands	 	8798017.6	 	2183644	 	2183644	 	Patented
	ICA-006NO	 	WELL PLATE	 	Norway	 	8798018.6	 	2183644	 	2183644	 	Patented
	ICA-006SE	 	WELL PLATE	 	Sweden	 	8798019.6	 	2183644	 	2183644	 	Patented
	ICA-006JP	 	WELL PLATE	 	Japan	 	2010-521206	 	2010537171	 	5628035	 	Patented
	ICA-006JPDV	 	WELL PLATE	 	Japan	 	2013-117600	 	2013224946	 	5755682	 	Patented
	ICA-006JPDV2	 	WELL PLATE	 	Japan	 	2014-202871	 	2015004692	 	6076308	 	Patented
	ICA-006	 	WELL PLATE	 	United States	 	12/192,762	 	2009-0046832	 	8,238,515	 	Patented
	ICA-006C1	 	WELL PLATE	 	United States	 	13/567,613	 	2013-0034205	 	8,873,707	 	Patented
	ICA-006C2	 	WELL PLATE	 	United States	 	14/508,322	 	2015-0023467	 	9,476,846	 	Patented
	ICA-006C3	 	WELL PLATE	 	United States	 	15/273,767	 	2017-0010228	 	N/A	 	Pending
	ICA-007JP	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	Japan	 	2010-5272	 	2010539944	 	5743135	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-007JPDV1	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	Japan	 	2014-221166	 	2015033386	 	N/A	 	Pending
	ICA-007C1/XR7-US2	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	United States	 	15/052,914	 	2016-0201111	 	N/A	 	Pending
	ICA-008CN	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	200980125952.3	 	102083365	 	ZL 200980125952.3	 	Patented
	ICA-008CNDV	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	201310298029.8	 	103411988	 	2077368	 	Patented
	ICA-008CNDV2	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	201510083796.6	 	N/A	 	N/A	 	Pending
	ICA-008EP	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	Europe	 	09774467.6	 	2306897	 	N/A	 	Allowed
	ICA-008HK	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	Hong Kong	 	11112984.0	 	1158478	 	1158478	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-008	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	12/496,532	 	2010-0003697	 	8,431,357	 	Patented
	ICA-008C1	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE	 	United States	 	13/871,697	 	2013-0236887	 	9,063,154	 	Patented
	ICA-008C2	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	14/669,923	 	2015-0198615	 	9,506,931	 	Patented
	ICA-008C3	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	15/334,854	 	2017-0045530	 	N/A	 	Pending
	ICA-009	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	13/317,341	 	2012-0093286	 	9,063,066	 	Patented
	ICA-009C1	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,206	 	2015-0276631	 	9,435,756	 	Patented
	ICA-009C2	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,218	 	2015-0276632	 	9,442,085	 	Patented
	ICA-009C3	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,233	 	2015-0260664	 	9,335,284	 	Patented
	ICA-009C4	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	15/227,292	 	2016-0341678	 	N/A	 	Pending
	ICA-010PC	 	METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS	 	International	 	PCT/US17/28064	 	N/A	 	N/A	 	Pending

 

     

     

    

 

SCHEDULE IV

 

Pledged Entities

 

Icagen Corp.

 

XRpro Sciences, Inc.

 

Caldera Discovery, Inc.

 

 

 

 

 

 

 

 

 

 

     

     

    

 

SCHEDULE V

 

Trademark Licenses

 

None

 

 

 

 

 

 

 

 

 

     

     

    

 

SCHEDULE V(a)

 

Trademarks, Etc.

 

 

     

     

    

 

 

 

     

     

    

 

 

     

     

    

 

SCHEDULE VI

 

Commercial Tort Claims

 

None

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

SCHEDULE VII

 

Legal Names, Organizational
Identification Numbers; States or Jurisdiction of Organization

 

	Grantor’s Name	 	State of Organization	 	Federal Employer I.D.	 	Organizational I.D.
	Icagen, Inc. (formerly known as; Caldera Pharmaceuticals, Inc.; and XRpro Sciences, Inc.	 	Delaware North Carolina	 	#####	 	3723366
	Icagen Corp. (formerly known as XRpro Corp.)	 	Nevada North Carolina   	 	#####	 	NV20101523783
	Caldera Discovery, Inc.	 	Delaware 	 	#####	 	5717856
	XRpro Sciences, Inc.	 	Delaware 	 	#####	 	5904530

 

     

     

    

 

SCHEDULE VIII

 

Locations

 

Icagen Corp.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

Icagen-T, Inc.

2090 E. Innovation Park Drive

Tucson, AZ 85755

 

 

 

 

 

 

     

     

    

 

SCHEDULE IX

 

Securities Etc. of each Grantor

 

Securities

 

	Grantor	 	Name of Issuer / Pledged Entity	 	Number
    of Shares	 	Class	 	Certificate
    No.(s)
	Icagen, Inc.	 	Icagen Corp.	 	100,000	 	Common	 	C01
	Icagen, Inc.	 	Caldera Discovery, Inc.	 	100	 	Common	 	C-01
	Icagen, Inc.	 	XRpro Sciences, Inc	 	100	 	Common	 	C-01

 

Deposit Accounts, Securities
Accounts and Commodities Accounts

 

	Grantor	 	Name and Address of Institution	 	Purpose of the Account	 	Account No.
	Icagen Inc.	 	 #####	 	 #####	 	 #####
	 	 	 	 	 	 	 
	Icagen Inc.	 	 #####	 	 #####	 	 #####
	 	 	 	 	 	 	 
	Icagen Inc.	 	 #####	 	 #####	 	 #####
	 	 	 	 	 	 	 
	Icagen Corp.	 	 #####	 	 #####	 	 #####

 

Foreign Currency Controlled
Accounts

 

None

 

     

     

    

 

SCHEDULE X

 

Licenses, Etc.

 

Hazardous Materials License

 

 

 

 

 

 

 

 

     

     

    

 

SCHEDULE XI

 

All Intellectual Property
of Grantors

 

See Schedule 5(a) and 10

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-001	 	METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY	 	United States	 	09/859,701	 	2003-0027129	 	7,858,385	 	Patented
	ICA-002EP	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Europe	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002BE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Belgium	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002CH	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Switzerland	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002DE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Germany	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002DK	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Denmark	 	3748920	 	1525458	 	1525458	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-002ES	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Spain	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002FI	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Finland	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002FR	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	France	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002GB	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United Kingdom	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002IT	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Italy	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002SE	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Sweden	 	3748920	 	1525458	 	1525458	 	Patented
	ICA-002NL	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Netherlands	 	3748920	 	1525458	 	1525458	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-002JP	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Japan	 	2004-524531	 	2006-503268	 	4560403	 	Patented
	ICA-002SG	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	Singapore	 	200500360-3	 	109345	 	109345	 	Patented
	ICA-002C2	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United States	 	11/444,660	 	2007-0003008	 	7,519,145	 	Patented
	ICA-002C3	 	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	 	United States	 	12/396,592	 	2009-0175410	 	7,929,662	 	Patented
	ICA-003EP	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Europe	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003CH	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Switzerland/ 
Liechtenstein	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003DE	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Germany	 	4755687.3	 	1644095	 	1644095	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-003FR	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	France	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003GB	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United Kingdom	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003IE	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Ireland	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003NL	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Netherlands	 	4755687.3	 	1644095	 	1644095	 	Patented
	ICA-003JP	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Japan	 	2006-520181	 	2007527524	 	4782676	 	Patented
	ICA-003SG	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	Singapore	 	2005085584	 	 	 	118682	 	Patented
	ICA-003	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United States	 	10/621,825	 	2005-0011818	 	6,858,148	 	Patented
	ICA-003C1	 	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	 	United States	 	10/986,519	 	2005-0095636	 	7,241,381	 	Patented
	ICA-004	 	DRUG DEVELOPMENT AND MANUFACTURING	 	United States	 	10/880,388	 	2004-0235059	 	9,157,875	 	Patented
	ICA-005EP	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Europe	 	7874491.9	 	2084519	 	2084519	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-005CH	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Switzerland/ 
Liechtenstein	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005DE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Germany	 	60 2007 024 468.4	 	2084519	 	608007024468.4	 	Patented
	ICA-005DK	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Denmark	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005FR1	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	France	 	07 874 491.9	 	2084519	 	2084519	 	Patented
	ICA-005GB	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	United Kingdom	 	7874491.9	 	2084519	 	2084519	 	Patented
	ICA-005HK	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Hong Kong (via EP -005EPDV)	 	13104259.3	 	1177280	 	1177280	 	Patented
	ICA-005IE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Ireland	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005IT	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Italy	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005NL	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Netherlands	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005SE	 	X-RAY FLUORESCENCE ANALYSIS METHOD	 	Sweden	 	7874491.9	 	1177280	 	2084519	 	Patented
	ICA-005EPDV	 	X-RAY MICROSCOPE	 	Europe	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005CHDV	 	X-RAY MICROSCOPE	 	Switzerland and Lichtenstein	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005DEDV	 	X-RAY MICROSCOPE	 	Germany	 	12164870.3	 	2511844	 	602007042616.2	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-005FRDV	 	X-RAY MICROSCOPE	 	France	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005GBDV	 	X-RAY MICROSCOPE	 	United Kingdom	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005HK	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Hong Kong (via EP -005EPDV)	 	2013104259.3	 	1177280	 	1177280	 	Patented
	ICA-005IEDV	 	X-RAY MICROSCOPE	 	Ireland	 	12164870.3	 	2511844	 	2511844	 	Patented
	ICA-005JP	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Japan	 	2009-532446	 	2010509566	 	5143841	 	Patented
	ICA-005JPDV2	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	Japan	 	2014-123249	 	2014-123249	 	5913441	 	Patented
	ICA-005C1	 	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	 	United States	 	14/693,094	 	2015-0309021	 	N/A	 	Pending
	ICA-006EP	 	WELL PLATE	 	Europe	 	8798006.6	 	2183644	 	2183644	 	Patented
	ICA-006BE	 	WELL PLATE	 	Belgium	 	8798007.6	 	2183644	 	2183644	 	Patented
	ICA-006CH	 	WELL PLATE	 	Switzerland	 	8798008.6	 	2183644	 	2183644	 	Patented
	ICA-006DE	 	WELL PLATE	 	Germany	 	8798009.6	 	2183644	 	602008044640.9	 	Patented
	ICA-006DK	 	WELL PLATE	 	Denmark	 	8798010.6	 	2183644	 	2183644	 	Patented
	ICA-006ES	 	WELL PLATE	 	Spain	 	8798011.6	 	2183644	 	2183644	 	Patented
	ICA-006FI	 	WELL PLATE	 	Finland	 	8798012.6	 	2183644	 	2183644	 	Patented
	ICA-006FR	 	WELL PLATE	 	France	 	8798013.6	 	2183644	 	2183644	 	Patented
	ICA-006GB	 	WELL PLATE	 	United Kingdom	 	8798014.6	 	2183644	 	2183644	 	Patented
	ICA-006IE	 	WELL PLATE	 	Ireland	 	8798015.6	 	2183644	 	2183644	 	Patented
	ICA-006IT	 	WELL PLATE	 	Italy	 	8798016.6	 	2183644	 	2183644	 	Patented
	ICA-006 NL	 	WELL PLATE	 	Netherlands	 	8798017.6	 	2183644	 	2183644	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-006NO	 	WELL PLATE	 	Norway	 	8798018.6	 	2183644	 	2183644	 	Patented
	ICA-006SE	 	WELL PLATE	 	Sweden	 	8798019.6	 	2183644	 	2183644	 	Patented
	ICA-006JP	 	WELL PLATE	 	Japan	 	2010-521206	 	2010537171	 	5628035	 	Patented
	ICA-006JPDV	 	WELL PLATE	 	Japan	 	2013-117600	 	2013224946	 	5755682	 	Patented
	ICA-006JPDV2	 	WELL PLATE	 	Japan	 	2014-202871	 	2015004692	 	6076308	 	Patented
	ICA-006	 	WELL PLATE	 	United States	 	12/192,762	 	2009-0046832	 	8,238,515	 	Patented
	ICA-006C1	 	WELL PLATE	 	United States	 	13/567,613	 	2013-0034205	 	8,873,707	 	Patented
	ICA-006C2	 	WELL PLATE	 	United States	 	14/508,322	 	2015-0023467	 	9,476,846	 	Patented
	ICA-006C3	 	WELL PLATE	 	United States	 	15/273,767	 	2017-0010228	 	N/A	 	Pending
	ICA-007JP	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	Japan	 	2010-5272	 	2010539944	 	5743135	 	Patented
	ICA-007JPDV1	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	Japan	 	2014-221166	 	2015033386	 	N/A	 	Pending
	ICA-007C1/XR7-US2	 	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	 	United States	 	15/052,914	 	2016-0201111	 	N/A	 	Pending

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-008CN	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	200980125952.3	 	102083365	 	ZL 200980125952.3	 	Patented
	ICA-008CNDV	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	201310298029.8	 	103411988	 	2077368	 	Patented
	ICA-008CNDV2	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	China	 	201510083796.6	 	N/A	 	N/A	 	Pending
	ICA-008EP	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	Europe	 	09774467.6	 	2306897	 	N/A	 	Allowed
	ICA-008HK	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	 	Hong Kong	 	11112984.0	 	1158478	 	1158478	 	Patented
	ICA-008	 	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	12/496,532	 	2010-0003697	 	8,431,357	 	Patented
	ICA-008C1	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE	 	United States	 	13/871,697	 	2013-0236887	 	9,063,154	 	Patented

 

     

     

    

 

	Reference	 	Title	 	Country	 	Application No.	 	Pub. No.	 	Patent No.	 	Status
	ICA-008C2	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	14/669,923	 	2015-0198615	 	9,506,931	 	Patented
	ICA-008C3	 	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	 	United States	 	15/334,854	 	2017-0045530	 	N/A	 	Pending
	ICA-009	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	13/317,341	 	2012-0093286	 	9,063,066	 	Patented
	ICA-009C1	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,206	 	2015-0276631	 	9,435,756	 	Patented
	ICA-009C2	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,218	 	2015-0276632	 	9,442,085	 	Patented
	ICA-009C3	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	14/715,233	 	2015-0260664	 	9,335,284	 	Patented
	ICA-009C4	 	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	 	United States	 	15/227,292	 	2016-0341678	 	N/A	 	Pending
	ICA-010PC	 	METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS	 	International	 	PCT/US17/28064	 	N/A	 	N/A	 	Pending

 

     

     

    

 

SCHEDULE XII

 

Pledged Collateral

 

	Icagen,
    Inc.	Delaware
    Secretary of State - U.S. Bank Equipment Finance-Equipment

 

     

     

    

 

SCHEDULE XIII

 

[RESERVED]

 

 

 

 

 

 

 

 

 

     

     

    

 

SCHEDULE XIV

 

[RESERVED]

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

SCHEDULE XV

 

Pledged Equity

 

	Icagen Inc.	Icagen Corp.	100,000 common shares	C01
	 	 	 	 
	 	XRpro Sciences, Inc.	1,000 common shares	C-01
	 	 	 	 
	 	Caldera Discovery, Inc.	100 common shares	C-01

 

 

     

     

    

 

SCHEDULE XVI

 

Locations of Collateral 

 

Icagen Inc.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

Icagen Corp.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

 

     

     

    

 

SCHEDULE XVII

 

Licenses, Etc.

 

Hazardous Materials License

 

     

     

    

 

Schedule XVIII

 

Notices. Etc. Re: Exercise
of Rights by certain parties under Licenses

 

None

 

 

 

     

     

    

 

SCHEDULE XIX

 

No Termination Etc. of Licenses

 

None

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]